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General Introduction
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Cancer
 
 Cancer is one of the most prevalent diseases in the Western world 
including the Netherlands and a leading cause of mortality and morbidity 
worldwide (1-3). It is estimated that the incidence of cancer worldwide will 
increase from 13 million new cases in 2008 to 22 million new cases in 2030, 
which is due to a growing world population, steadily increased life expectan-
cy and increased exposure to risk factors (e.g. smoking, sunlight, obesity). 
Cancer is not one disease, but the collective term for a group of diseases that 
originate from several cell types / tissues, sharing several characteristics 
such as uncontrolled cell division and metastasis that disrupt normal tissue 
anatomy / function. Cancer is considered a disease of our genes in which 
mutations, gross chromosomal rearrangements or epigenetic alterations 
abrogate tumour-suppressor genes or activate oncogenes, which both drive 
carcinogenesis. This multistep process is predominantly driven by a combi-
nation of genome instability that abrogates or erroneously activates gene 
function and subsequent clonal selection of the best surviving and growing 
cells. The complexity of carcinogenesis is even greater and several other 
processes have to be altered for a tumour (cell) to survive and proliferate 
(Fig. 1A). These features are regarded the ‘hallmarks’ of cancer and repre-
sent acquired capabilities present in most, if not all, human tumours (4, 5). 
 Of the aforementioned cancer hallmarks, genome instability is consi-
dered the driving force behind carcinogenesis as the spontaneous mutation 
frequency of normal cells in too low to account for all mutations / chromoso-
mal aberration found in cancer cells and required for mutating relevant com-
binations of tumour suppressors and oncogenes. Genome instability is often 
the result of repeated exposure to exogenous DNA-damaging agents (e.g. 
UV light from the sun, cigarette smoke) or defects in DNA damage repair 
and/or signalling, collectively designated the DNA damage response (DDR), 
molecules as one of the first steps in carcinogenesis. Indeed, many heredi-
tary cancer syndromes have germ line mutations in a DDR gene. In additi-
on, most, if not all spontaneous cancers have at least one defect in the DDR.
 Uncontrolled cell proliferation is mainly the result of mutations in ge-
nes that control cell proliferation and makes a cell grow independent from 
growth factors. Another important aspect of cancer cells is immortality. 
During each round of cell division, telomere length is shortened. Critical-
ly short or absent telomeres due to repeated cell divisions induce cellu-
lar senescence (permanent cell cycle arrest) or apoptosis. Telomere length 
is thus limiting the number of cell divisions, which have to be overcome 
by a pre-cancer cell to progress into more malignant states. Therefore, 
telomere length is maintained by reactivation of the enzyme telomerase, 
which prolongs telomere length and allows cells to replicate infinitively. 
 Besides telomere immortalization, cancer cells have acquired re-
sistance to apoptosis to maintain viability. Many mechanisms to evade 
apoptosis have been discovered that prevent proper induction or execution 
of apoptosis. One of them is a cancer hallmark on its own, i.e. deregu-
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lated metabolism. Cancer cells favour glycolysis over mitochondrial res-
piration to produce ATP. This effect is known as the Warburg effect and 
inhibits mitochondrial-dependent apoptosis. The ATP output from glycoly-
sis however, is lower than mitochondrial respiration, therefore most can-
cer cells have increased expression of membrane-bound glucose transpor-
ters to enhance glucose uptake from their environment. Tumour growth 
is often limited due to lack of nutrients. To propagate cell growth and 
maintenance of the inner tumour mass, angiogenesis is initiated by the 
overproduction of vascular growth factors such as VGEF, PDEGF and FGF, 
leading to migration of endothelial cells into the tumour and formation 
of capillaries to supply the inner tumour cells with nutrients and oxygen. 
 In addition to self-sustained proliferation, tumour cells have to avoid 
clearance by the immune system. Ironically, it is thought that the immu-
ne system itself selects for less immunogenic cancer cells by taking out 
the most highly immunogenic cancer cells thereby allowing less immu-
nogenic cancer cells to survive. Furthermore, pro-inflammatory cytoki-
nes secreted by tumour infiltrating immune cells and senescent cells in 
the tumour stroma enhance tumour maintenance and growth. In additi-
on, a pro-inflammatory environment can induce epithelial-to-mesenchy-
mal transition (EMT) of tumour cells, which is a key process in metastasis. 
Cancer therapy
 
 Cancer therapy usually consists of several steps; each designed to 
reduce the chance of relapse. First-line treatment of non-metastasized so-
lid tumours is surgery to physically remove the tumour from the patient’s 
body. Subsequently, the patient is often treated with radiotherapy, chemo-
∞ 
Immortality 
Deregulation 
cellular 
metabolism 
Genome 
instability 
Insensitive 
to growth 
suppressors 
Angiogenesis 
Metastasis 
& tissue 
invasion 
Continuous 
proliferation 
signalling 
Avoiding 
apoptosis 
Prevention 
activation 
immune system 
Pro-
inflammatory 
environment  
CANCER 
A B
∞ 
Telomerase  
inhibitors 
Inhibitors 
aerobic 
glycolysis 
Ionizing 
radiation/
Chemotherapy 
EGF signalling 
inhibitors/
Mitotic spindle 
inhibitors 
VGEF 
signalling 
inhibitors 
HGF/c-Met 
inhibitors 
Cyclin-
dependent 
kinase 
inhibitors 
Pro-
apoptotic 
BH3 
mimetics 
Immunotherapy 
Anti-
inflammatory 
drugs 
TREATMENT 
Figure 1: The hallmarks of cancer and treatment targets. A) Cancer cells acquire different hall-
marks during carcinogenesis. Often a combination of these hallmarks is found in cancer cells. However, 
the order in which they are acquired and how many are minimally necessary to induce malignancy are 
unknown. B) The hallmarks are also used as targets for drug development. Most drugs developed at 
the moment target one of the hallmarks specifically. Adapted from D. Hanahan and R.A. Weinberg (5).
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therapy, targeted therapy and/or immune therapy. First line treatment of 
primary tumours that cannot be resected or metastasized tumours is often 
radiotherapy or chemotherapy to offer patients palliation and prolonging 
of life. Although several interventions are targeting one of the aforementi-
oned cancer hallmarks (Fig 1B), genotoxic/cytotoxic cancer therapies are 
still the mainstay in medicinal cancer treatment by inducing DNA damage 
followed by subsequent programmed cell death. Their proven success im-
plies that cancer cells are more sensitive to DNA damage than normal proli-
ferating cells. This increased specific sensitivity of cancer cells is thought 
to be largely due to intrinsic defects in DNA damage repair and response 
genes in combination with high cell proliferation in the absence of cell cycle 
checkpoints, which are so called “proliferation brakes” that arrest the cell 
cycle in case of DNA damage to allow the cell time to repair the damage. 
 Currently, three types of genotoxic cancer therapies are being used 
in the clinic, i.e. radiotherapy, chemotherapy, and targeted therapy. Ra-
diotherapy by ionizing radiation (IR) induces several DNA lesions, but 
mainly relies on the induction of toxic double strand DNA breaks (DSBs) 
(6). IR can be applied by i) external beam radiotherapy (EBRT), ii) brac-
hytherapy in which a radioactive source is implanted in or close to the 
tumour, or iii) radionuclide therapy, a systemic treatment with a radionu-
clide coupled to a ligand of a highly expressed receptor on the tumour. 
 A plethora of chemotherapeutic genotoxic/cytotoxic cancer treat-
ments has been developed and is regularly used in the clinic with diffe-
rent modes of action. Examples are platinum-bassed compounds that 
induce inter- and intrastrand crosslinks, agents that alkylate DNA, com-
pounds that induce DSBs (e.g. bleomycin), etc.  Other well-known che-
motherapeutic drugs are anthracyclines, which inhibit DNA topoisome-
rases thereby interfering with DNA and RNA synthesis and preventing 
relaxation of supercoiled DNA leading to inhibition of DNA replication and 
transcription, and taxanes that inhibit mitotic spindle formation (7, 8).
 Lately, targeted therapies have been developed to primarily target 
cancer cells with a specific defect in a DNA repair gene. Currently, one tar-
geted therapy is available in the clinic that relies on poly(ADP) ribose poly-
merase (PARP) inhibition. The effectiveness of PARP inhibition is based on a 
synthetic lethal interaction with defects in homologous recombination (HR), 
mainly with BRCA1 and BRCA2. On their own inhibition of PARP or defective 
BRCA1/BRCA2 are not lethal in cells. Originally it was thought that PARP 
inhibition leads to spontaneous single strand breaks that result in collapsed 
replication forks and double strand breaks, which are then repaired via HR. 
However, when repair requiring BRCA1/BRCA2 is deficient due to mutations, 
replication induced double-strand breaks are not repaired and the cells go 
into apoptosis. Recent findings however, indicate that PARP inhibitors exert 
their function by ‘trapping’ PARP to the DNA, forming complexes on the DNA 
that can only be resolved via HR and are therefore cytotoxic (9-11). Interes-
tingly, this mechanism relies on the presence of PARP since the effect PARP 
inhibition is abrogated when PARP is genetically removed. Treatment with 
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PARP inhibitors is therefore especially effective in hereditary breast and ova-
rian cancer in which BRCA1 and BRCA2 are mutated (12-14), although a frac-
tion of several other tumours may also be amenable to this treatment (15).
 Since many conventional cancer therapy treatments, including radio-
therapy, rely on the induction of DNA damage and most, if not all, tumours have 
at least one defect in the DDR, it is evident that the status of the DDR is one 
of the important aspects of determining whether a treatment is successful. 
The DNA damage response 
 
 DNA is an intrinsic instable molecule and therefore vulnerable to che-
mical modifications (16, 17). Each day, every cell in the human body may 
encounter up to 100,000 DNA lesions (18) induced by various endogenous 
and exogenous sources. For example, endogenous sources include reactive 
metabolic by-products or spontaneous reactions (mostly hydrolysis). Exo-
genous sources are e.g. cigarette smoke, UV-light from the sun, or che-
micals in food, contaminated water or air (16), but also numerous cancer 
therapies. Error-prone repair of DNA damage leads to mutations, insertions, 
deletions and chromosomal aberrations, which all drive carcinogenesis. Per-
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Figure 2: DNA damage, DNA repair pathways and genes involved. Different types of DNA dama-
ges are induced via endogenous of exogenous sources. Specific pathways are present to repair these 
damages, each having specific gene and protein expression. Adapted from J.H.J. Hoeijmakers (21).
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sistent DNA damage accumulating throughout life is thought to be a causal 
driver of the aging process. To counteract the harmful consequences of DNA 
damage, cells contain various DNA repair systems to correct the damage 
and DNA damage checkpoints that arrest the cell cycle to allow the cell time 
to repair the damage, or, in case of damage beyond repair, induce apopto-
sis or cellular senescence. In addition, several other cellular processes are 
implicated in the cellular response to DNA damage. The collective cellular 
response to DNA damage is designated the DNA damage response (DDR). 
DNA damage repair
 
 DNA damage comes in many different forms, each being corrected 
by a different repair pathway (Fig. 2). Radiotherapy induces predominantly 
single-strand breaks (SSBs) and double-strand breaks (DSBs), which in-
dicate that the SSB and DSB repair systems are most important for the 
effectiveness of radiotherapy. There are however, additional DNA repair sys-
tems. Helix-distorting bulky lesions interfere with base pairing and block 
transcription and replication in which the consequence is replication fork 
stalling and collapse, leading to DSBs in S-phase. Another consequence 
of unrepaired bulky DNA lesions is blocked transcription, which in essen-
ce stochastically alters gene expression. These bulky lesions are repaired 
via nucleotide excision repair (NER). Small chemical modifications of DNA 
bases, such as oxidation, alkylation damage and deamination, can result 
in non-canonical base pairing which in turn can lead to incorporation of an 
incorrect base during S-phase (19), enhancing mutagenesis. These small 
base damages are repaired by short and long patch base excision repair 
(BER). The proofreading function of the replication machinery attempts 
to prevent incorporation of incorrect DNA bases. However when this fails, 
mismatch repair (MMR) is able to deal with these incorrectly incorpora-
ted DNA bases (20). When the DNA replication machinery is blocked by 
an interstrand crosslink, the covalent binding of the two opposite strands 
of the DNA helix, the replication fork is stalled and can eventually col-
lapse. Interstrand crosslinks are repaired by interstrand crosslink repair.
 As mentioned above radiotherapy mainly induces SSBs and DSBs. 
Single-strand break repair (SSBR) repairs SSBs via either direct ligation, 
short patch or long patch BER. SSBs are recognized by PARP and polynu-
Figure 3: DNA damage repair, signalling and factors involved in resistance upon treat-
ment with DNA-damaging agents. This is a simplified schematic representation of the DNA 
damage response. Different sensor proteins, like MRE11, RAD51 and NBS1, which recruit trans-
ducer proteins ATM, ATR and DNApK, detect DNA damage. Dependent on the cell cycle dif-
ferent DNA repair factors are recruited and at the same time other effector proteins, such as 
CHK1 and CHK2 are phosphorylated. This leads to cellular response that, depending on the se-
verity of the damage, leads to cell cycle arrest, apoptosis, DNA repair and/or senescence. Pro-
teins that are increased in expression during IR resistance are in red. In green are proteins 
that are decreased in expression during IR resistance. Proteins indicated in white are impor-
tant players in one or more of these processes, but have not yet been linked to IR resistance. 
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cleotide kinase (PNK). DNA polymerase δ/ε together with proliferating cell 
nuclear antigen (PCNA) adds ±2-8 nucleotides more into the DNA gap, 
generating a 5’-flap of replaced nucleotides. These nucleotides are then re-
moved by FEN1 (19, 22) and DNA ligase I seals the break. If the SSB is not 
repaired via BER it will result in a DSB during DNA replication in S-phase.
 The two main pathways that repair DSBs are homologous recombi-
nation (HR) and non-homologous end joining (NHEJ). HR requires an intact 
sister chromatid and is therefore only active during the S- and G2-phase 
of the cell cycle, while NHEJ repairs DSBs during all phases of the cell cycle 
(23, 24). In HR, a DSB is recognized by the MRN complex (MRE11, RAD50 
and NBS1), which recruits CtIP, BRCA1 and other nucleases to generate a 
3’-ssDNA overhang at both sides of the DSB, which is bound and covered by 
replication protein A (RPA). Subsequently, RPA is replaced by RAD51 with 
the help of BRCA2, thereby forming nucleoprotein filaments. These filaments 
invade the sister chromatid at the homologous sequence and by using the 
intact sister chromatid as a template, the DNA is extended. The other end of 
the DSB is captured and repaired after the junctions are resolved, resulting 
in a repaired DSB (25). HR is the most accurate DSB repair mechanism. 
 NHEJ on the other hand is more error-prone. NHEJ is not dependent 
on cell cycle and does not require a template. The end-joining reaction is 
initiated by the KU70-KU80 heterodimer that binds to the ends of the DSB 
and recruits DNA-dependent protein kinase (DNA-PK). If there are no com-
patible ends, DSB ends are processed by nucleases such as Artemis. Finally, 
the ligation complex, consisting of DNA ligase IV, XRCC4, XLF and PAXX, li-
gates the two DNA ends (26, 27). Since NHEJ repairs breaks without homo-
logy or template, it is very well possible that small mutations of indels occur. 
 NHEJ as described above is often referred to canonical NHEJ 
(c-NHEJ) however; in c-NHEJ disabled systems there is still residual NHEJ 
present (28). The residual NHEJ is referred to as alternative NHEJ (alt-
NHEJ) and functions independent from DNA-PK (29, 30). In alt-NHEJ 
small stretches of nucleotides serve as a template for micro homology, 
which is mediated by PARP1. Subsequently, DNA ligase I or DNA ligase 
III together with XRCC1 repair the break. Although micro homology is 
used in alt-NHEJ, still mutagenesis and small rearrangements can occur. 
DNA damage signalling
 
 DNA repair mechanisms are the first line of defence in the DDR. In 
addition to DNA repair activation, the cell activates elaborate DNA damage 
signalling pathways, which are usually referred to as DNA damage/cell cycle 
checkpoints, since they block transition from G1 to S-phase or G2 to M-phase 
(31, 32). DNA damage checkpoints halt cell proliferation thereby allowing cell 
additional time to repair the damage. These DNA damage checkpoints can 
also induce apoptosis or senescence when damage is beyond repair (Fig. 3).
 In order to activate the signalling cascade so-called sensor proteins 
of which the MRN complex is well known detect DNA damage, especially 
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DSBs. Upon DNA damage detection transducer proteins, such as ATM, ATR 
and DNA-PK, are recruited to the site of damage. ATM mainly regulates the 
response to DSBs (33); whereas ATR primarily regulated the response to 
SSBs (34). ATM and ATR regulate a broad range of downstream responses, 
DNA-PK on the other hand directly promotes DSB repair via NHEJ (7, 34). 
Together, ATM and ATR phosphorylate a plethora of downstream media-
tor and effector proteins, with each their own specific set of targets (35). 
 In the DDR ATM kinase activity is activated by MRN and leads to the 
phosphorylation of mediator protein H2AX (γH2AX). H2AX phosphorylation 
spreads several kilo bases away from the DSB; subsequently γH2AX recruits 
other DDR factors and thereby enhances the signalling cascade. Formation 
of γH2AX foci is important for sustaining the DDR, but γH2AX is not essential 
for the initial localization of DDR factors such as BCRA1 and 53BP1 (36). Upon 
phosphorylation of mediator proteins, such as γH2AX, effector proteins are 
recruited and activated by phosphorylation. However, ATM can also directly 
phosphorylate effector proteins like CHK2 and p53. Phosphorylation of CHK2 
results in an S and G2/M arrest, whereas ATM stabilizes p53 by phosphory-
lation, leading to increased p21 expression and subsequent G1 arrest (37). 
 In SSB repair one of the main sensors of DNA damage is RPA that is re-
cruited to ssDNA regions that were generated during DNA replication and DNA 
repair (34, 38). ATR, which is in complex with ATRIP, recognizes RPA, howe-
ver ssDNA bound RPA is not sufficient to activate ATR. ATR signalling depends 
on the 9-1-1 complex (a complex formed by RAD9, RAD1 and HUS1) that re-
cruits TOPBP1. TOPBP1 activates the ATR kinase activity, resulting in the ATR 
signalling cascade and finally CHK1 phosphorylation. CHK1 phosphorylation 
eventually results in an S and G2/M arrest (37). Failure of the DDR can have 
detrimental effects on the cell (16, 17), however for cancer cells DDR failure 
could be an advantage in order to survive treatment and become resistant.
Cancer therapy resistance
 
 Most tumours display initial sensitivity to aforementioned treatments, 
but unfortunately also develop resistance that limits therapy effectiveness. 
Regrettably, therapy resistance is not driven by a single process. Although 
various cellular resistance mechanisms have been elucidated, these cannot 
explain all resistance events by far. We can discriminate two main types 
of resistance to therapy, i.e. intrinsic and acquired resistance. Intrinsic re-
sistance is already present in the tumour before treatment. Intrinsic re-
sistance is usually the result of the cancer cell’s specific mutational profile 
that renders it insensitive to therapy a priori. Acquired resistance is a form 
of therapy resistance that develops during the course of treatment (39). 
Here, the tumour is initially sensitive to the treatment, but acquires therapy 
resistance in the course of treatment often as a result of the therapy itself. A 
simple explanation could be that genotoxic therapies induce mutations that 
result in therapy resistance. It has been shown however, that acquired re-
sistance is also induced upon non-genotoxic therapies and often has a tran-
1Chapter 1
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sient nature, suggesting that active processes are on going to maintain cell 
viability. Several mechanisms of chemotherapy resistance have been des-
cribed, e.g. alterations of the drug target or increased drug efflux (8, 39). 
 Since DNA damage induction is the mode of action of genotoxic/cyto-
toxic therapies including radiotherapy (RT), it is likely that alteration in the 
DDR could play a role in both intrinsic and acquired resistance. These alte-
rations however, are poorly understood. Here we summarize the role of the 
DDR in RT-resistance in solid tumours from prostate, lung, head and neck, 
breast and glioblastoma (GBM) in which RT is often applied as treatment. In 
addition, we classified studies based on intrinsic or acquired resistance. We 
published that DNA repair protein expression can be almost absent in hu-
man cancer without functionally altering DNA repair capacity (40). Meaning 
that even small amounts of functional protein are sufficient for efficient and 
functional DNA repair. Therefore, we added a second classification in which 
we indicated whether functional DDR data was present: often only a correla-
tion between DDR gene expression/protein level and resistance was publis-
hed as evidence for the implication of DDR alterations in therapy resistance. 
The role of DNA repair in intrinsic RT-resistance
 
 Intrinsic RT-resistance encompasses changes in both HR and NHEJ. 
Several studies address the role of HR status in RT-resistance. Both BRCA1 
and RAD51 are up regulated after IR in the RT-resistant prostate cancer 
cell line PC3, but down regulated in the IR-sensitive LNCaP prostate cancer 
cell line, suggesting that HR status plays a role in RT -sensitivity/-resistan-
ce (41). Indeed, siRNA-mediated knockdown of RAD51 in CD133+ lung 
cancer stem cells or overexpression of miR-155, which targets RAD51, in 
the MCF7 breast cancer cell line, increased IR sensitivity (42, 43). Conver-
sely, BRCA1-defective breast cancer cells are highly radiosensitive. Resto-
ring critical mutated regions of BRCA1 in these cells induced RT-resistan-
ce (44, 45). A similar observation was made in BRCA2-deficient Capan-1 
pancreatic cancer cells, in which BRCA2 restoration led to RT-resistance 
(46). DSBs are recognized by the MRN complex, which is involved in both 
DSB repair via HR and DSB signalling (47). High expression of MRE11 in 
breast cancer patients is associated with resistance to chemotherapy and 
RT and decreased disease free and patient survival (48). In line with the-
se results, head and neck squamous cell carcinoma (HNSCC) cells with 
non-functional RAD50 formed smaller tumours in mice when compared to 
the control cells after IR treatment (49). In addition, L1CAM expressing 
gliobastoma multiforme (GBM) stem cells, which are RT-resistant, have 
increased NBS1 expression and increased phosphorylation of ATM and 
CHK2 that act downstream in the DNA damage signalling cascade (50). 
 Several lines of evidence also indicate a role for NHEJ in intrinsic 
RT-resistance. Restoration of mutant P53 in epidermal carcinoma and lung 
cancer led to IR sensitivity, which correlated with attenuated DNA repair 
and lower expression of NHEJ proteins KU70, XRCC4 and DNA-PK (51). In 
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addition, positive cofactor 4 (PC4), an activator of NHEJ (52), was iden-
tified as a regulator of NHEJ in RT-resistance (53). PC4 is up regulated 
in oesophageal cancer and its knockdown led to IR sensitization in vitro 
and in vivo by suppression of NHEJ via XLF down regulation (53). In ad-
dition, increased expression of KU80 was observed in HPV-negative HN-
SCC patients, which correlated with loco-regional failure (tumour recur-
rence at the same site) and mortality after IR (54). Another hint that 
NHEJ is involved in resistance to IR was derived from studies in colorectal 
cancer (CRC). Differentiation of colon stem cells is under the control of 
Wnt/β-catenin signalling, which is often mutated in human colon cancer 
(55, 56). LIG4, which mediates the final step in NHEJ, is a direct tran-
scriptional target of β-catenin (57). Hyper activation of β-catenin led to 
increased expression of LIG4 in CRC cells and induced RT-resistance, which 
was abolished by down regulation of LIG4 or targeting of β-catenin (57). 
 IR does not only induce DSBs but also 8-oxoguanine and SSBs. SSBs 
indirectly induce DSBs by collapsing replication forks (58, 59). Both types 
of lesions are repaired via BER. Cervical cancer and germ cell tumours with 
high APE1 expression, which functions in BER, correlated with resistant to 
radiotherapy (60, 61). RAD9 is another factor in BER, but functions in other 
DNA repair pathways and in damage signalling as well (62). In the prosta-
te cancer cell lines PC3 and Du145 RAD9 knockdown sensitized these cells 
to RT (63), suggesting a role for BER in RT-resistance. Thus, the cellular 
status of both DSB repair pathways HR and NHEJ, but possibly BER that 
repairs IR-induced lesions as well, can determine intrinsic RT-resistance.
The role of DNA damage signalling in intrinsic RT-resistance
 
 DNA repair is not the only line of defence when a cell encounters DNA 
damage. Cell cycle checkpoints arrest cell proliferation at the G1/S or G2/M 
transition. Cancer cells often lack a functional G1/S checkpoint, leading to an 
arrest in the S/G2 phase of the cell cycle. In most cancers the G2/M checkpoint 
is intact. Cancer cells often rely on the G2/M checkpoint to avoid cell death after 
DNA damage: DSBs are particularly harmful during mitosis, leading to loss or 
gain of parts of chromosomes (64, 65). Intrinsic RT-resistance in relation to 
DNA damage signalling appears to centre on the ATM-CHK1/2-P53 DNA da-
mage signalling axis and downstream alterations in cell cycle control proteins. 
 Oro-pharyngeal squamous cell carcinoma cells deficient for ATM, due 
to an 11q copy number loss, require ATR-dependent CHK1 phosphorylation 
to control the cell cycle and are thus RT-resistant. This is in contrast to AT 
cells that, without a functional ATM protein, are highly sensitive to IR (66). 
In the case of an 11q deletion, still some ATM expression is retained, which 
is sufficient for the cells to survive RT treatment. Therefore, inhibition of 
CHK1 sensitized these cells to RT (67). DDB2 is a DNA repair protein mainly 
known for its role in NER (68, 69). DDB has several functions outside NER 
(70-75) of which one is linked to RT-resistance in non-small cell lung cancer 
(NSCLC) (76). DDB2 expression promoted RT-resistance by phosphorylati-
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on of CHK1, resulting in a G2 cell cycle arrest and increased HR that contri-
buted to RT-resistance in lung cancer cells (77). P53 is a central component 
of the DDR downstream of CHK1 and CHK2, which is mutated in all cancer 
types ranging from 5% in cervical cancer to almost 50% in ovarian cancer 
(78), and activates the G1/S cell cycle checkpoint after damage. P53 defici-
ency leads to an arrest in S and G2/M phase, which relies on an intact CHK1 
and CHK2 protein. Dual inhibition of CHK1 and CHK2 in radiation resistant 
CD133+ GBM stem cells abolished RT-resistance in vitro and in vivo (79). 
 These aforementioned results indicate that targeting checkpoint kina-
ses is an effective way to sensitize RT-resistant cancer cells. However, this 
sensitization depended on the P53 status of the tumour (8, 80). ATM inhibition 
in P53-deficient cancer cells sensitized them to chemotherapy and radiation, 
whereas P53-proficient cells became resistant (80-83). Thus, cancer cells 
that lack functional P53 are vulnerable to G2/M checkpoint inhibition. On the 
other hand, checkpoint inhibition in cancer cells with normal P53 leads to a 
reduction of P53-dependent apoptosis (8). Together this points to a complex 
wiring of the DDR in relation to resistance to DNA-damaging treatments. 
 Downstream of the ATM-CHK1/2-P53 DNA damage-signalling axis se-
veral proteins control the transition of cell cycle to the next phase, which 
includes cyclins and cyclin-dependent kinases (CDK). Cyclins are positive 
regulators of CDKs, which in turn promote progression of the cell through 
the cell cycle and are often overexpressed in cancer cells (84). Knockdown 
of cyclin D1, which is important for G1/S-phase progression, could sensiti-
ze prostate cancer cells to IR, independent of hormone status (85, 86). In 
line with this finding, knockdown of CDK4, which is a target of cyclin D1, 
sensitizes breast cancer cells to IR (87), indicating that transition through 
the G1/S cell cycle checkpoint and subsequent stalling in the S/G2 pha-
se, promotes the survival of RT-resistant cancer cells after DNA damage. 
 Aurora B is important for progression of mitosis and cytokinesis and 
plays a role in the abscission checkpoint (checkpoint just before a dividing 
cell separates into two cells); a direct target of Aurora B is CHMP4C (88). Au-
rora B and CHMP4C are involved in the repair of chromosome bridges during 
the last phase of cytokinesis, which prevents chromosome breakage and 
aneuploidy (89). Often they are up regulated in cancer cells, thereby promo-
ting cancer cell survival (90).  Inhibition of Aurora B sensitizes several cancer 
types to IR (91, 92). In addition, it was recently found that CHMP4C inhibiti-
on also sensitizes lung cancer cells to IR in a P53-independent manner (93). 
 All aforementioned studies depict a picture in which spe-
cific DDR defects in cancer cells lead to an arrest or accumulati-
on of cells in the S/G2 checkpoint. This is thought to prevent cell de-
ath after DNA damage by utilizing additional DNA repair pathways.
The role of DNA repair in acquired RT-resistance
 
 HR, NHEJ and DNA damage signalling are not only affected in intrin-
sic resistance also in acquired resistance they were identified to be abro-
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gated. Several studies generated RT-resistant cell lines or used recurrent/
metastasized tumours to address the role of HR in acquired resistance. The 
downside, however, is that all studies used different ways of inducing acqui-
red resistance with fractionated IR. Even though the outcome is the same, 
RT-resistance, mechanistically these studies are difficult to compare. Never-
theless, they provide insights on the role of HR in acquired resistance. BRCA1 
and BRCA2 are known to form a complex with RAD51, BARD1, BRCC45 and 
BRCC3, called the BRCC complex (94). As part of the BRCC complex BRCC3 
is a de-ubiquitilating enzyme, which counteracts UBC13-RNF8 ubiquitin en-
zyme activity (95, 96). In HNSCC high BRCC3 expression is correlated with 
low overall survival and increased risk of local-regional failure. After in vi-
tro induced acquired resistance, HNSCC cell lines display increased BRCC3 
expression, and inhibition of BRCC3 expression sensitized these cells to IR 
(97). Conversely, RT-resistant lung cancer cells seem to depend on RAD52 
expression (98). Rad52 is an essential HR gene in yeast (99), whereas in 
Rad52-/- mice no DNA repair or recombination phenotype was observed 
(100). However, RAD52 was found to be functionally redundant with BRCA1, 
BRCA2 and PALB2 in mediating RAD51-dependent HR (101), indicating its 
importance in HR. Microarray data of RT-resistant lung cancer cells showed 
an increased expression of RAD52. Knockdown of RAD52 in RT-resistant lung 
cancer cells led to decreased colony formation after fractionated IR (98). 
 Several lines of evidence indicate a role for both HR and NHEJ in 
acquired RT-resistance of prostate cancer cells. Proteins involved in HR 
(BRCA1, BRCA2 and RAD51) and NHEJ (KU70/KU80) were up regulated 
in RT-resistant prostate cancer cells. Whereas phosphorylation of H2AX 
is down regulated. This effect was reversed by inhibition of the PI3K pa-
thway (102). Suggesting that NHEJ and HR are involved in acquired re-
sistance to IR in prostate cancer. In addition, in acquired RT-resistant 
lung cancer cells inhibition of NHEJ factor DNA-PK sensitized these cells 
to additional IR (103). Thus, dependent on the protocol of induction of 
acquired RT-resistance, DSB repair pathways HR or NHEJ are involved. 
The role of DNA damage signalling in acquired RT-resistance
 
 As mentioned previously, the ATM-CHK1/2-P53 DNA damage signal-
ling axis and cell cycle checkpoints are important during intrinsic RT-re-
sistance. However, limited evidence is present on the role of DNA damage 
signalling in acquired resistance. Nonetheless, present studies indicate roles 
for DNA damage signalling in acquired RT-resistance (84). Proteomic analy-
sis of acquired RT-resistant breast cancer cell line MCF7 shows that CHK1, 
CDK1 and CDK2 expression is increased (104). Of those proteins CHK1 is 
associated with acquired RT-resistance in breast cancer. RT-resistant MCF7 
cells exhibit hyperactivity of ATM, which phosphorylates and stabilizes ZEB1 
after DNA damage (105). In turn, ZEB1 interacts with USP7, which stabilizes 
CHK1 and arrests the cells in G2/M phase. As a result, HR was activated and 
RT-resistance was induced. Moreover, microRNA-205 was found to direct-
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ly target ZEB1. Combining RT with microRNA-205 inhibition, RT-resistant 
breast cancer cell lines were sensitized again. Moreover, direct targeting 
of CHK1 also has proven to be effective in sensitizing RT-resistant breast 
cancer cell lines in vitro and breast cancer tumours in mice in vivo (106). 
 Downstream effectors in the cell cycle are, amongst others, cyclins 
and CDKs (84). These proteins are phosphorylated by the protein tyro-
sine phosphatase SHP1, which promotes G1/S phase progression (107, 
108). In RT-resistant A549 lung cancer cells and HNSCC cells, SHP1 and 
its targets cyclin D1 and CDK4 are up regulated, which resulted in S-pha-
se stalling. Down regulation of SHP1 led to G0/1 arrest, down regulation 
of cyclin D1 and CDK4 and sensitization of A549 to IR (109, 110), hig-
hlighting the importance of post-translational modifications in the regu-
lation of RT-resistance. Hence, cells with acquired RT-resistance main-
ly rely on cell cycle stalling in S or G2/M phase. Targeting checkpoint 
kinases, such as CHK1, or phosphatases, such as, SHP1 in combination 
with RT can be an effective strategy to overcome acquired resistance. 
Concluding remarks
 
 To maintain a healthy genome, functional DDR pathways are essen-
tial. Cancer cells exploit their DDR deficiencies in order to survive treat-
ment and develop therapy resistance. Thus, the DDR has an important 
role in RT-resistance development. In general, during RT-resistance cancer 
cells mainly arrest in S- or G2/M-phase due to defective ATM signalling, 
increased CHK1/2 phosphorylation or increased expression of down stream 
cell cycle regulators like cyclin D1, CDK4 and Aurora B. This would sug-
gest that by arresting in S- or G2/M-phase RT-resistant cancer cells are 
able to repair DSBs induced by RT, using the more accurate HR. Indeed, 
RT-resistant cancer cells have increased expression of HR proteins BRCA1, 
BRCA2, RAD51, RAD52 and BRCC3. Upstream HR, DSBs are recognized 
by sensor proteins such as the MRN complex, which consists of MRE11, 
NBS1 and RAD50. The individual components of the MRN complex were 
also up regulated in RT-resistant cancer cells. The MRN complex signals 
not only to downstream HR mediators, it also recruits transducer proteins 
such as ATM, ATR and DNA-PK. RT-resistant cancer cells with altered MRN 
complex also have increased phosphorylation of ATM and CHK2, hence the 
cells arrest in S- and G2/M-phase. Again, highlighting the importance of 
the S- and G2/M-phase arrest. Next to HR, NHEJ can also repair DSBs, 
however it is less accurate and can cause small mutations and indels. Evi-
dence is present that NHEJ is involved in RT-resistance. PC4, via XLF, al-
ters NHEJ in RT-resistant cancer cells. Also increased expression of KU70/
KU80 and transcriptional regulation of LIG4 by β-catenin were identified 
as possible mechanism by which NHEJ can cause RT-resistance. However, 
all NHEJ effects were independent from the cell cycle, suggesting that the 
ATM-CHK1/2-P53 axis is more important for HR repair in RT-resistant can-
cer cells. Therefore, effective strategies to sensitize RT-resistant cancer 
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cells were mostly based on inhibition of checkpoint kinases and checkpoint 
phosphatases. Moreover, specific inhibition of signal transducer proteins 
ATM and DNA-PK were also effective. Therefore, designing a personal tre-
atment strategy based on the DDR characteristics of the tumour in combi-
nation with IR could be an effective strategy to treat RT-resistant tumours.
 Here we focussed primarily on the involvement of the DDR in intrin-
sic and acquired RT-resistance. Even though most research was perfor-
med in intrinsically RT-resistant cancer cells and data on acquired RT-re-
sistance was limited, a general role for the DDR could be found. However, 
the DDR is just a small part of all processes involved in RT-resistance. 
Often it is a combination of multiple factors, which together form a re-
sistant phenotype (Fig. 4). Other mechanisms, which are not discussed 
here, such as de-regulated apoptosis or oncogenic bypass all relate to the 
cancer hallmarks (5), underlining the complexity of therapy resistance. 
Therefore, it could be useful to characterize the tumour’s characteristics 
before treatment in order to predict whether the tumour will respond to RT.
Cancer treatment 
e.g. IR & chemotherapy 
Resistance mechanisms 
Prosurvival signals 
Altered morphology 
Autophagy 
Altered DDR 
Cancer 
Therapy 
resistance 
Genotoxic stress 
De-regulated apoptosis 
Pathway redundancy 
Oncogenic bypass 
Figure 4: Repetitive treatment with DNA-damaging agents leads to treatment re-
sistance via multiple pathways. Repetitive treatment with IR or chemotherapy leads to 
DNA damage and/or inhibition of enzymes, which leads to death of cancer cells. However, can-
cer cells can acquire resistance to these types of treatment and have multiple mechanis-
ms at their disposal to survive treatment. In this review we only focussed on the involvement 
of the DDR, but many more mechanisms were identified to be involved in therapy resistance.
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Scope of the thesis
 
 The work described in this thesis aims to elucidate the role of the 
DNA damage response in acquired resistance to ionizing radiation and its 
differential regulation upon DNA damage. Chapter 2 shows that different 
DNA repair pathways display redundancy in radiotherapy-resistant pros-
tate cancer cells. Chapter 3 unravels the mRNA response in radiotherapy 
resistance using next generation sequencing to identify novel pathways. 
Energy metabolism was identified as one of the main contributors to radio-
therapy resistance next to the DNA damage response. Chapter 4 presents 
the differential response of an important cell type, embryonic stem cells, 
to equitoxic dosages of three genotoxic agents. Based on mRNA and small 
RNA sequencing we were able to identify a novel posttranslational modifi-
cation, citrullination, that is involved in the proper function of homologous 
recombination upon induction of double strand breaks (DSBs) in DNA in 
cancer cells. In Chapter 5 the role of RNA-binding proteins in DSB repair 
in cancer cells was investigated. Unexpectedly, we found that proper homo-
logous recombination repair of DSB is dependent on RNA-binding proteins. 
However, the effect seen in RNA-binding protein knockdown is opposite of 
the effect seen in Chapter 4. This indicates a tight regulation of DSB repair 
upon genotoxic stress. Chapter 6 summarizes the main results and dis-
cusses the implications of the differential response to DSBs in cancer cells.
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Abstract
 
 Radiation therapy by ionizing radiation is an integral part of cancer 
therapy. Initially sensitive tumours can acquire resistance to radiotherapy, 
seriously frustrating curing patients. ~12% of prostate cancer patients ex-
perience clinical failure, in which the recurrent or metastasized tumour has 
acquired resistance to radiotherapy. Ionizing radiation induces DNA damage 
of which double strand DNA breaks are most toxic for a cell. Currently, our 
knowledge about the role of DSB repair and signalling in acquired radiothe-
rapy resistance is still limited. We generated transient radio-resistant pros-
tate cancer cells using a radiotherapy regimen identical to clinical practice, 
which could be reversed by withholding radiotherapy for >2 weeks. These 
radio-resistant cancer cells were retained in the G2-phase of the cell cycle 
in combination with ATM activation. In addition we observed persistent dou-
ble strand breaks in G1-phase cells and reduced canonical non-homologous 
end joining. The NHEJ repair deficiency was compensated by enhanced ho-
mologous recombination in S/G2-phase. Only combined ATM and DNA-PK 
or ATM and PARP inhibition could sensitize radio-resistant cancer cells. In 
summary, we provide a new paradigm in radio-resistance, indicating that 
DSB repair is in part attenuated instead of increased to establish resistance.
Introduction
 
 Radiotherapy (RT) is one of the most frequently used cancer the-
rapies for solid tumours, which relies on inducing cytotoxic DNA dama-
ge. Prostate cancer is the second most common form of cancer in men 
worldwide and is treated with RT, chemotherapy or hormone deprivation 
therapy, often in combination (1). First-line therapy of non-metastasized 
tumours is often surgical removal. Some prostate tumours however, can-
not be resected. In these cases, RT can be a curative treatment. First-li-
ne RT options in localized prostate cancer are external beam radiothera-
py (EBRT) or internal radiotherapy (RT) (2). Although initially sensitive, 
about 12% of patients have clinical failure (CF) within the first five years 
after treatment, which further increases to 26% after ten years (3). In 
the majority of these patients the recurrent or metastasized tumours 
are resistant to therapy, resulting in a decreased patient survival (4, 5). 
 Several mechanisms of radiotherapy resistance in prostate can-
cer have been identified (5-8). For example, activation of PI3K/AKT/
mTOR and Erk pathways in radio-resistant prostate cancer cells is as-
sociated with cancer stem cell (CSC) phenotypes as well as epithe-
lial-to-mesenchymal transition (5, 9). Inhibition of the PI3K/AKT/
mTOR pathway could sensitize radio-resistant prostate cancer cells. 
 RT induces different types of DNA lesions of which DSBs are most 
toxic to the cell (10). DSBs are repaired via either non-homologous end joi-
ning (NHEJ) in all phases the cell cycle or homologous recombination (HR) 
that only takes place in S- and G2-phase of the cell cycle. NHEJ does not re-
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quire a DNA template to repair a DSB, whereas HR needs a sister chromatid 
for repair, hence its cell cycle specificity (11, 12). In NHEJ KU70/KU80 bind 
to the ends of a DSB and recruit DNA-PK, which leads via several steps to 
ligation of the DSB. An alternative form of NHEJ (Alt-EJ) requires micro-ho-
mology in the opposite sides of the DSB, which anneal and overhanging 
flaps are removed (13). Alt-EJ is intrinsically mutagenic as micro-homology 
annealing leads to deletions. The MRN complex can also recognized DSBs, 
which results in the recruitment of HR factors but also ATM that activates 
DNA damage checkpoints. Defects in DNA damage repair and signalling cau-
se genome instability and are causally implicated in carcinogenesis (12). It 
is thought that these defects in combination with continuous cell proliferati-
on may also sensitize tumours to genotoxic cancer treatments, including RT. 
 Here, we show that a RT regimen as applied in the clinic can induce 
radio-resistance in prostate cancer cells. We identified transient alterati-
ons of the DNA damage response, which are implicated in radio-resistance. 
Materials & Methods
Cell culture
Du145 and PC3 prostate cancer cells were cultured in RPMI-1640 (RPMI-1640 
Medium, R2405-500ML, Sigma-Aldrich) supplemented with penicillin-strepto-
mycin (100× diluted, Penicillin-Streptomycin, P0781-100ML, Sigma-Aldrich) 
and 10% fetal bovine serum (Fetal Bovine Serum (FBS) South America, S1810-
500, Biowest) at 5% CO2 and 37°C. A549 and MCF7 were cultured in DMEM 
supplemented with penicillin-streptomycin (100× diluted, Penicillin-Strepto-
mycin, P0781-100ML, Sigma-Aldrich) and 10% fetal bovine serum (Fetal Bo-
vine Serum (FBS) South America, S1810-500, Biowest) at 5% CO2 and 37°C.
Generation of radio-resistant Du145, PC3, MCF7 and A549
Du145, PC3, A549 and MCF7 were seeded in 6-well plates and main-
tained as described. The day after seeding all cell lines were radia-
ted (Gammacell 40 Cesium 137 irradiation unit, Atomic Energy) with 
2 Gy/day (from Monday-Friday; no IR during Saturday and Sunday) 
up to a cumulative dose of 78 Gy. After cells have received the indica-
ted IR dosages (see figures), they were not radiated for two days. On 
the third day after IR experiments were done. For an “IR holiday”, cells 
were analyzed after 10, 17, 24, 31 and 38 days after the last dose of IR. 
Clonogenic cell survival assay
Cells were trypsinised (Trypsin-EDTA solution, T3924-500ML, Sigma-Ald-
rich) and counted (Z2 Coulterparticle count and size analyzer, Beckman 
Coulter). 600 cells per well in triplicates per condition were seeded in 
6-well plates. Next day the cells were treated with different compounds 
at least 15 minutes prior to IR (0-2-4-6-8 Gy): DMSO; ATMi (KU55933, 
Selleckchem; 10 mM stock; 10 μM final); PI3Ki (LY294002, Cell Signaling 
50 mM stock; 50 μM final); DNApKi (NU7441/KU57788, Selleckchem; 5 
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mM stock; 10 μM final); PARPi (Olaparib, AstraZeneca, 10 mM stock; 4 
μM final); CHK2i (C3742-5mg, Sigma-Aldrich, 1.5 mM stock; 120 nM fi-
nal); Nutlin (Nutlin3, N6287, Sigma-Aldrich, 10 mM stock; 10 μM final). 
Cells were incubated for 8-9 days. Then, cells were washed once with 
PBS and fixed and stained with 0.1% Coomassie Brilliant Blue (50% (v/v) 
Methanol, 43% (v/v) H2O, 7% (v/v) Acetic Acid, 0.1% (m/v) Coomassie 
Brilliant Blue). Colonies were counted using Gelcount (Oxford Optronix).
Immunofluorescence
Cells were seeded on coverslips, irradiated with 2 Gy the next day and 
fixed 1, 2, 4, 8, and 24h after IR. Briefly, the coverslips were washed once 
with PBS, fixed with 2% PFA, washed with PBS + 0.1% triton X-100 3× 
short and 2× 10 minutes, once washed with PBS+ (100 ml PBS + 0.5 g 
BSA + 0.15 g Glycine), incubated 1-2h at RT with primary antibodies. Af-
ter incubation coverslips were washed with PBS + 0.1% triton X-100 3× 
short and 2× 10 minutes, once washed with PBS+, incubated 1-2h at RT 
with secondary antibodies. After incubation coverslips were washed with 
PBS + 0.1% triton X-100 3× short and 2× 10’, once washed with PBS+. 
For RAD51 staining (commercial antibody, see primary antibodies) the co-
verslips were washed once with PBS, fixed with 4% PFA. Subsequently, cells 
were permeabilised for 20’ with PBS + 0.2% triton X-100 and washed with 
PBS. After permeabilization cells were treated with 10× diluted DNAse I 
(04536282001, Roche Life Sciences) for 1h at 37°C in a humidified chamber 
and washed with PBS. Blocking was performed using IFF buffer (PBS + 1% 
BSA + 2% FCS) for at least 30’. After blocking cells were incubated with pri-
mary antibodies for 1-2h at RT. After incubation coverslips were washed 3× 
for 5’ with PBS and incubated with secondary antibodies 1-2h at RT. After in-
cubation coverslips were washed 3× for 5’ with PBS. Coverslips were mounted 
in DAPI Vectashield mounting medium (H1200, Vector Laboratories). Ima-
ges were made using a LSM700 microscope (Carl Zeiss Microimaging Inc.). 
Immunoblot analysis
Cells were lysed in 2× sample buffer and boiled at 99°C for 5 minutes. 
Samples were run on a SDS-PAGE gel and transferred to a PVDF mem-
brane (Immobilon FL PVDF Transfer membrane 0.45um, IPFL00010, Mil-
lipore). Membranes were blocked in 5% milk in PBS for 1-2h at RT. After 
blocking, membranes were incubated with primary antibodies 1-2h at RT. 
Then the membranes were washed 5 times for 5 minutes with PBS + 0.05% 
Tween-20 and incubated with secondary antibodies at RT for 1-2h. Again 
the membranes were washed 5× for 5 minutes. Membranes were visua-
lized using Odyssey CLx Infrared Imaging System (LI-COR Biosciences).
BrdU and PI labelling for cell cycle analysis
Cells were labelled with 5 μM BrdU (B5002, Sigma-Aldrich) for 15 minutes at 
37°C. Subsequently, cells were harvested and fixed in 70% ethanol at least 
overnight at 4°C. Fixed cells were washed with ice-cold PBS and re-sus-
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pended in pepsin solution (5 mg pepsin in 10 ml 0.1N HCl) and incubated 
20 minutes at RT. After pepsin-treatment blocking solution (PBS + 0.5% 
Tween-20 + 0.1% BSA) was added and cells were washed. Next, cell were 
re-suspended in 2N HCl for 12 minutes at 37°C. To neutralise, borate buf-
fer (100 mM, pH8.5) was added and the cells were pelleted. BrdU antibody 
was added and the cells were incubated for 2h on ice in the dark. Stained 
cells were washed in blocking solution and re-suspended in 500 μl PBS 
supplemented with 12.5 μl RNase A and 1 μl PI (P3566, Invitrogen). Cell 
cycle was analysed the next day using BD LSRFortessa (BD Biosciences). 
Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
Primary antibodies
53BP1 (1000×, 05-726, Millipore); 53BP1 (1000×, sc-22760, Santa Cruz 
Biotechnology); Akt (Pan) (500×, #4691, Cell Signaling); p-Akt (T308) 
(500×, #2956, Cell Signaling); p-Akt (S473) (500×, #4060, Cell Signa-
ling); p-ATM (500×, #4526, Cell Signaling); BRCA1 (50×, sc-6954, San-
ta Cruz Biotechnology); BrdU Kit (50×, 556028, BD Sciences); CHK2 
(500×, #3440, Cell Signaling); p-CHK2 (500×, #2197, Cell Signaling); 
Geminin (400×, 10802-1-AP, Proteintech); γH2AX (Ser139) (1000×, 
05-636, Millipore); MDC1 (1000×, ab50003, Abcam); p53 (1000×, sc-
126, Santa Cruz Biotechnology); RAD51 (200×, GTX70230, GeneTex); 
p-SQ/TQ (1000×, #2851, Cell Signaling); Tubulin (2000×, sc-12462-R, 
Santa Cruz Biotechnology); Tubulin (5000×, T5168, Sigma-Aldrich)
Secondary antibodies
Goatαmouse Alexa 488 (1000×, A11034, Life Technologies); GoatαRab-
bit Alexa 555 (1000×, A21429, Life Technologies); Donkeyαmouse 
IRDye 800CW (5000×, 926-32212, LI-COR Biosciences); Don-
keyαrabbit IRDye 680RD (5000×, 926-32223, LI-COR Biosciences)
Apoptosis assay
Cells were treated with Cisplatin (20 μM; 1 mg/ml, Accord Healthcare), Do-
cetaxel (1 μM), UV-C (16 J/m2; 254 nm germicidal lamp, Philips) and Cas-
pase 3 activator (100 μM; PAC-1, ab142074, Abcam). After treatment the 
cells were incubated for 48h. Apoptotic cells were analysed according to the 
protocol published by Smid et al. (14). In brief, medium and cells were col-
lected and re-suspended in 998 μl FACS buffer (0.5% BSA + 0.05% NaN3 
in PBS) pre-heated to 37°C. 1 μl diluted Hoechst 33342 (10 mg/ml, H3570, 
Life Technologies) was added and the cells were vortexed and incubated for 
exactly 7 minutes at 37°C. Subsequently, the cells were immediately placed 
on ice and 1 μl 7-AAD (1 mg/ml, A1310, Invitrogen) was added. Cells were 
analysed within 1h after adding 7-AAD using BD LSRFortessa (BD Bioscien-
ces). Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated using Trizol reagent (TriPure Isolation Reagent, 
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11667165001, Roche Life Science). In brief cells were lysed in Trizol reagent 
and chloroform was added. Lysates were spun for 15’ at 4°C. The aqueous 
phase was transferred to a new eppendorf tube and isopropanol was added. 
The aqueous phase was incubated at RT for 10’, then spun down for 10’ at 
4°C. RNA pellets were washed once with 75% ethanol. After washing RNA 
pellets were dried and dissolved in 30 μl of RNAse-free H2O. RNA concentra-
tion and quality was assed using Nanodrop (NanoDrop™ 2000/2000c Spec-
trophotometers, ThermoFischer Scientific). Subsequently, cDNA was made 
using iScript cDNA Synthesis Kit (170-8891, Biorad) according to the manu-
facturer’s protocol. qPCR was performed using Platinum® Taq DNA Polyme-
rase (10966018, Invitrogen) according to the manufacturer’s protocol com-
plemented with SYBR Green I (SYBR® Green I nucleic acid gel stain, S9430, 
Sigma-Aldrich) for detection. The reaction mix was run according to the follo-
wing cycling program: 3’ - 95°C; 45× 15’’ - 95°C/30’’ - 60°C/30’’ - 72°C; 1’ - 
95°C; 1’ - 65°C; 65× 30’’ - 65°C. Data was analyzed using ΔCt method (15). 
Primers 
 Forward primer (5’-3’) Reversed primer (5’-3’) 
Hsa-NQO1 GGAGAGTTTGCTTACACTTACGC AGTGGTGATGGAAGCACTGCCTTC 
Hsa-HO-1 AAGACTGCGTTCCTGCTCAAC AAAGCCCTACAGCAACTGTCG 
Hsa-GADPH AAGGTGAAGGTCGGAGTCAA ACCATGTAGTTGAGGTCAATG 
Hsa-UbC CTGGAAGATGGTCGTACCCTG GGTCTTGCCAGTGAGTGTCT 
	  1	  
End-joining assay
The end-joining assay was performed as described in (16), with some minor 
changes. In short, cells were grown in a 3-cm dish to 50-80% confluency. 
Cells were transiently transfected with 2 µg of a blunt-ended linear DNA 
substrate (EcoRV/Eco47III digested pDvG94 plasmid (16)) using X-treme 
GENE HP DNA Transfection Reagent (Sigma Aldrich), following manufac-
turers protocol. Two days after transfection, extra-chromosomal DNA was 
isolated and re-suspended in a final volume of 20 µl water (17). From this 
solution, 1 µl was PCR amplified with the DAR5 and FM30 primers (16), 
using PuReTaq ready-To-Go PCR beads (GE Healthcare). The PCR product 
was digested with BstXI. Restriction fragments were separated on a 6% 
polyacrylamide gel in TBE buffer, stained with ethidiumbromide. The rela-
tive level of micro homology-directed end joining was determined by quan-
tification of the BstXI digested PCR product using the ImageJ software.
Statistical analysis
Data was processed using GraphPad Prism v7.0a (GraphPad Software 
Inc.). Statistical test used were Student’s T-test and Mann-Whitney 
U test. P-values equal or lower than 0.05 were accepted as significant.
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Results
Prostate cancer cells acquire a transient resistance phenotype early during 
IR treatment
 In order to study the underlying mechanisms of radio-resistance, we 
mimicked IR treatment regimen applied in the clinic to prostate cancer cells 
in vitro by daily exposure to IR to examine whether they develop radio-re-
sistance (Fig. 1A). Briefly, cells were seeded and the next day received 2 Gy 
IR, which was continued the subsequent days except for weekends. After 
receiving the indicated final dose, cells were incubated over the weekend 
without IR and then used for experiments. Prostate cancer cells received 
the indicated cumulative dose at a dose rate of 2 Gy/day (Fig. 1A) and re-
sistance was investigated using a colony survival assay. We chose a colony 
survival assay because it measures both sensitivity as well as the ability of 
a cell to continue proliferation. Resistance occurred between a cumulative 
dose of 8 Gy and 28 Gy (Fig. 1B + C). Therefore, we determined at what 
cumulative dose resistance approximately occurred. From 8 Gy onwards we 
used cumulative dosages of 5 Gy in which the last dose consists of 1 Gy up 
to a cumulative dose of 28 Gy. Increased resistance was already observed 
at a cumulative dose of 23 Gy. A cumulative dose of 28 Gy rendered the 
cells fully resistant, which remained up to a cumulative dose of 78 Gy (Fig. 
1B + C). The generation of radio-resistant cells (RR cells, which received a 
cumulative dose of 28 Gy in future experiments) was not confined to only 
one cancer cell line. PC3 (prostate cancer), A549 (lung cancer) and MCF7 
(breast cancer) cell lines also acquired a similar IR resistance phenotype. 
BPH1 cells, a non-cancerous prostate epithelial cell line, did not acquire a 
radio-resistance phenotype (Supplementary Fig. 1A – D), consistent with 
the idea that IR resistance is a general phenomenon confined to cancer cells. 
 The colony survival assay demonstrated an additional feature of the 
RR-cells, i.e. a reduced capacity to form colonies (Fig. 1D + E), indicating 
that either specific mutations were introduced that drive resistance or that 
many surviving cells enter a state of quiescence. The latter has been found in 
chemotherapy-resistant cancer cells, in which the resistance phenotype was 
transient (18). We generated RR cells, withheld IR for 10, 17, 24 or 31 days 
(IR holiday) and assessed radio-resistance. Interestingly, the observed RT 
resistance was transient and could be reversed by an IR holiday of at least 17 
days (Fig. 1D). We will refer to these as time re-sensitized cells. Subsequently, 
we determined whether re-sensitization was permanent or transient as well. 
Time re-sensitized cells by a 17-day IR holiday were again irradiated with the 
aforementioned regimen of daily 2 Gy doses up to a cumulative dose of 48 
Gy (Fig. 1E). These time re-sensitized cells developed RT resistance again, 
indicating that also time re-sensitization is not permanent (Fig. 1F). Thus, 
IR resistance is an early, but transient phenomenon during RT treatment.
DNA damage-associated cell fates are altered in RR cells
 DNA damage can lead to several cell fates: transient cell cycle arrest, per-
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manent cell cycle arrest (senescence), polyploidization and cell death. To 
further characterize RR cells, we first measured cellular senescence using 
senescence marker HMGB1, in which loss of HMGB1 expression represents 
cellular senescence (19). Almost all parental Du145 cells expressed HMGB1. 
In RR cell cultures however, only normal-sized nuclei expressed HMGB1 and 
micronuclei are present (white arrow tips), which indicate severe DNA da-
mage and chromosomal instability (Fig. 2A). Next, we analysed whether RR 
cells with normal-sized nuclei or polyploid RR cells form visible colonies. We 
seeded RR cells at low density to allow single cells to grow into colonies and 
stained these with DAPI to determine nuclear size and expression of geminin, 
a marker for S- and G2-phase cells to determine proliferation status. Only RR 
cells with normal-sized nuclei could form colonies (Fig. 2B), indicating that RR 
cells retain normal-sized nuclei and do not exhibit signs of cellular senescence. 
 Resistance to chemotherapy has been associated with a prolonged 
stay in G1/G0 phase of the cell cycle. It is thought that chemotherapy 
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Figure 1: Du145 become IR resistant after fractionated IR treatment. A) Treatment proto-
col. Beginning 1 day after seeding Du145 cells were radiated with 2 Gy/day in 5 sequential dosages 
followed by 2 days rest. IR resistance was assessed using colony survival assay. B + C) Du145 cells 
were tested for IR resistance after different accumulated dosages of IR by colony survival. For 13 
and 23 Gy the final dose of IR was 1 Gy instead of 2 Gy. D + E) Percentages of colonies formed by 
radiated cells relative to parental (unirradiated) cells. F) After receiving IR treatment IR-resistant 
Du145 were incubated for different periods of time after receiving the last IR dose. IR resistance 
was addressed using colony survival. G) Treatment schedule. Du145 were radiated up to 28 Gy, then 
they received IR holiday of 17 days. After the IR holiday IR treatment was continued with 2 Gy/day 
for five consecutive days with 2 days rest in between up to an additional dose of 20 Gy (total dose 
is 48 Gy). H) IR resistance was assessed at baseline, after 28 Gy, after IR holiday and after additi-
onal IR treatment. Every experiment was repeated at least three times. Mean ± SEM are depicted.
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is less toxic to a cancer cell in the quiescent state. When chemotherapy 
and its associated effect on a cancer cell are alleviated, quiescent cancer 
cells enter the cell cycle again to continue proliferation (18). We perfor-
med a cell cycle analysis based on BrdU incorporation and PI staining to 
determine the cell cycle profile of RR cells by flow cytometry analysis. We 
observed a shift towards retention in the G2/M-phase, which was norma-
lized again in time re-sensitized cells (Fig. 2C). The G2/M block in RR cells 
led us to investigate the response of RR cells to docetaxel, a conventio-
nal chemotherapeutic drug often used in prostate cancer treatment that 
blocks microtubule formation. The apoptotic response in RR cells treated 
with docetaxel for 48h was attenuated (Fig. 2D). The observed resistan-
ce to apoptosis could be due to a strong G2/M block that prevents early 
entry in M-phase, increased activity of drug clearance systems or a ge-
neral resistance to apoptosis. To test these possibilities, we treated pa-
rental and RR cells with cisplatin, a chemotherapeutic drug that interferes 
with DNA replication, UV-C irradiation that directly induces DNA damage 
and subsequent apoptosis and is not affected by drug clearance systems 
and a Caspase 3 activator that induces apoptosis independent of damage 
(Fig. 2E – G). We observed a clear reduction in cell death induction in RR 
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Figure 2: Altered DNA damage-associated cell fates in Du145 RR cells. A) Immunofluores-
cent staining of parental and RR cells for DAPI and HMGB1. White arrow tips indicate micronu-
clei. Images were taken at 63× magnification. B) Immunofluorescent staining of colonies formed 
by parental and RR cells for DAPI and geminin. Note that the DAPI stain only visualized the pe-
ripheral nuclei of the colony. Images were taken at 20× magnification. C) Cell cycle profile was 
determined by flow cytometry analysis using BrdU incorporation and PI staining. RR cells have a 
block in G2/M-phase, which is reversed after IR holiday. D – G) Cells were incubated for 48 with 
docetaxel (D) or cisplatin (E), radiated with UVC (F) or incubated with caspase-3 activator (G) at 
the indicated dose. Using flow cytometry, apoptotic cells were measured by Hoechst 33342 and 
7-AAD staining. Every experiment was repeated at least three times. Mean ± SEM are depicted.
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cells in all conditions, but not in parental cancer cells. However, apoptosis 
was still attenuated in time re-sensitized cells, indicating that attenuati-
on of apoptosis is not the mechanism by which RT resistance is induced. 
Targeting the ATM signalling pathway did not sensitize RR cells to IR 
 To understand the mechanistic basis of resistance in RR cells, we 
first tested known resistance mechanisms. We could not implicate the NRF2 
anti-oxidant/cytoprotection pathway in RT resistance, which was measu-
red by qRT-PCR of target genes NQO1 and HO-1 (Supplementary fig. 2A). 
Cancer stem cell (CSC) formation/stabilization has been implicated in the 
development of RT resistance. We did not observe an increase in cell sur-
face markers associated with prostate cancer CSC except for CD49b and 
CD133, as was measured by flow cytometry (Suppelmentary fig. 2B – F)
(5). Furthermore, it was shown that the PI3 Kinase signalling pathway is 
involved in RT resistance (9). We could not implicate the PI3 Kinase signal-
ling pathway in the RT resistance model that we developed (Supplementary 
Fig. 2G). An increased fraction of cells in G2/M-phase is usually observed 
after a single dose of IR to allow the cell time to repair IR-induced DSBs 
before entering mitosis. One of the central factors of the G2/M checkpoint is 
the phosphatidyl inositol 3-kinase like serine/threonine kinase ATM, which 
amplifies the damage signal via phosphorylation of SQ/TQ motifs in tar-
get proteins (20, 21). We analysed phosphorylation of ATM (S1981) and 
general ATM target phosphorylation on SQ/TQ motifs and found increased 
phosphorylation of ATM (S1981) and SQ/TQ motifs in RR cells (Fig. 3A + B). 
Furthermore, P53, which is phosphorylated directly and indirectly by ATM 
leading to its stabilization, is modestly increased. CHK2, another target of 
ATM, is highly phosphorylated during IR resistance (Fig. 3C), but also CHK2 
levels itself are increased. Thus, ATM activation is increased in RR cells.
 Since ATM and its downstream targets are activated in RR cells, we 
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tested whether inhibition could sensitize RR cells. An IR colony survival with 
RR cells pre-treated with ATM inhibitor, CHK2 inhibitor or Nutlin (p53 acti-
vator) demonstrated that RR cells could not be sensitized to IR after treat-
ment with either one of these inhibitors (Fig. 3D – F), indicating that ATM 
inhibition is not sufficient to abolish the observed resistance phenotype. 
DSB repair is altered in RR cells
 ATM is rapidly activated by DSBs (22). RR cells still exhibit ATM acti-
vation three days after receiving the last dose of 2 Gy, indicating the pre-
sence of more persistent DSBs. Note that RR cells that recovered for three 
days are able to proliferate at day three as seen in colony survival assays. 
We hypothesized that ATM activation in RR cells is due to more persis-
tent DSBs. We measured the presence of DSBs using the marker γH2AX in 
combination with cell cycle marker geminin, which indicates whether cells 
are in G1 (geminin-) or in S/G2 (geminin+) phase of the cell cycle. This 
distinction is important, since we observed a larger fraction of RR cells 
in the G2-phase of the cell cycle. At baseline, RR cells that reside in the 
G1-phase exhibited a 8-fold increase in γH2AX foci when compared to pa-
rental cells. A 10-day recovery of RR cells, which were still resistant at this 
stage, also exhibited an increased number of γH2AX foci. Time re-sensi-
tized cells that were allowed to recover for 17 days had similar levels of 
DSBs as compared to parental cells (Fig. 4A). We did not observe a diffe-
rence in γH2AX foci between RR and parental cells, which resided in the 
S/G2-phase of the cell cycle (Fig. 4B). This indicates that DSBs in general 
or a subset of DSBs are poorly repaired during the G1-phase in RR cells.
 A reduced DSB repair capacity or differences in repair kinetics can be 
visualized by how fast cells are able to resolve DSBs as seen by a reduction 
of γH2AX foci in time, which are induced by an additional dose of IR. We ap-
plied 2 Gy IR and observed γH2AX foci increase in both parental and RR cells 
1h after IR (Fig. 4C + D and Supplementary Fig. 3A + B). The kinetics of 
resolving DSBs appeared to be slower in RR cells compared to parental cells 
between 4 and 24 hours after IR irrespective of geminin status, but more 
prominently in G1-phase cells (Fig. 4C + D). Moreover, RR cells in G1-phase 
still did not reach parental background γH2AX foci levels 24h after IR. In 
addition to γH2AX foci, we also measured 53BP1 foci, which is recruited by 
phosphorylated H2AX and directs DSB repair pathway choice towards NHEJ 
Figure 3: Activation of ATM and DSB repair during IR resistance. A) Immunofluorescent 
images of p-ATM (S1981; in green) in parental and RR cells. Images were taken at 63× mag-
nification. DAPI was used to stain the nuclei. B) Immunofluorescent images of p-SQ/TQ (in red) 
in parental and RR cells. Images were taken at 63× magnification. DAPI was used to stain the 
nuclei. C) Immunoblot of whole cell extract of parental, IR resistant, IR holiday 10 days and 
IR holiday 17 days cells for p53, CHK2 and p-CHK2. Tubulin was used as loading control. D – 
F) Parental and RR cells were seeded for colony survival and pre-treated with ATM inhibitor 
KU55933 (D), CHK2 inhibitor (E) and P53 activator Nutlin (F) to assess IR resistance after inhi-
bition of the DDR signalling pathway. Colonies formed in non-radiated wells were set 100% (das-
hed line). Every experiment was performed at least three times and mean ± SEM are depicted.
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(23). We already observed an increase in 53BP1 foci at basal level, indicating 
the presence of persistent DSBs in RR cells. Moreover, clearance of 53BP1 foci 
appeared to be slower in RR cells as well again more prominent in G1 (gemi-
nin-) cells (Fig. 4E + F). Thus, DSB repair capacity is altered in RR cells and a 
subset of difficult to repair DSBs are present during the G1-phase of RR cells. 
 Since NHEJ and Alt-EJ are the only DSB repair pathway active in 
the G1-phase, we determined NHEJ capacity using a plasmid-based as-
say (16). This NHEJ assay measures the repair ratio between canonical 
NHEJ (c-NHEJ) and Alt-EJ, in which the latter uses micro-homology to 
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Figure 4: Clearance of DDR foci is slower in RR cells. A + B) Quantification of γH2AX foci in 
at least 25 nuclei/experiment of parental (black) and RR cells (red), time re-sensitized cells 10 
days (blue) and time re-sensitized cells 17 days (green). Geminin was used to discriminate be-
tween G1 (A) and S/G2 phase cells (B). C + D) RR cells were radiated with 2 Gy and after in-
dicated time points γH2AX foci in at least 25 nuclei/experiment of parental (black) and RR cells 
(red) were counted in G1 (C) or S/G2 phase cells (D). E + F) Quantification of 53BP1 foci in at 
least 25 nuclei/experiment of parental (black) and RR cells (red). Geminin was used to discrimi-
nate between G1 (E) and S/G2 phase cells (F). G) End joining assay was use to determine c-NHEJ 
(black) and microhomology (Red) efficiency in parental, partially resistant cells (18 Gy) RR cells 
(28 Gy) and time re-sensitized cells (28 Gy + 10d and 28 Gy + 17d). H) Absolute number of 
BRCA1 foci per geminin positive nucleus. At least 25 nuclei/experiment were counted for parental 
(black) and RR cells (red). I) Absolute number of RAD51 foci per geminin positive nucleus. At least 
25 nuclei/experiment were counted for parental (black) and RR cells (red). Every experiment was 
performed at least three times and mean ± SEM are depicted. Unpaired two-sided Mann-Whit-
ney test was performed to determine statistical significance, *P<0.05, **P<0.01, ***P<0.001.
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repair DSBs. In partially resistant (18 Gy) and RR cells end-joining ac-
tivity is shifted from c-NHEJ to Alt-EJ (Fig. 4G). Such a shift is usually 
seen when c-NHEJ is less functional (24). The observed Alt-EJ phenoty-
pe is reversed again in time re-sensitized RR cells. Therefore, RR cells 
preferentially use Alt-EJ or in combination with the observed incre-
ase in DSBs during the G1-phase in RR cells, c-NHEJ activity is reduced.
 In case of reduced c-NHEJ capacity, it is expected that HR is more active 
to explain the IR resistance phenotype and the clearance of DSBs in S/G2. 
We performed foci analysis of HR proteins BRCA1 and RAD51 in geminin+ 
cells to select S/G2-phase cells. At baseline we did not observe any obvious 
differences in BRCA1 and RAD51 foci between parental and RR cells (Fig. 4I 
+ J). After an additional dose of IR, BRCA1 and RAD51 foci are induced in 
both parental and RR cells (Fig. 4I + J). Interestingly, DSB repair by HR in 
the first hours appeared normal as seen by a reduction in foci. Remarkably, 
24 hours after IR both BRCA1 and RAD51 foci are increased again up to, 
or even higher than, just irradiated RR cells. We interpret this observation, 
as a compensation mechanism by HR to repair DSBs that otherwise would 
have been resolved by NHEJ. Together, our data indicate that DSB repair pa-
thways are differentially wired in RR cells in which c-NHEJ is reduced and/or 
Alt-EJ is increased after which HR compensates for total DSB repair capacity. 
Interference with DNA repair together with ATM signalling sensitizes RR 
cells to IR
 Since RR cells exhibited an altered end joining phenotype, we first 
targeted c-NHEJ using a DNA-PK inhibitor (25). Parental and RR cells 
were treated with DNA-PK inhibitor followed by IR sensitivity measure-
ments. While parental cells were sensitive to DNA-PK inhibition, RR cells 
remained resistant (Fig. 5A). Next, we targeted Alt-EJ. Several proteins 
have been implicated in this pathway of which one is PARP (25, 26). Both 
parental and RR cells were pre-treated with the PARP inhibitor Olaparib 
and sensitivity was assessed. Again, parental cells were sensitized to IR, 
but RR cells maintained their resistance phenotype (Fig. 5B), indicating 
that inhibiting c-NHEJ or Alt-EJ is not sufficient to reverse RT resistance. 
 The unsuccessful attempts to sensitize RR cells by inhibition of ATM 
signalling, DNA-PK or PARP could be due to redundancy. Therefore, we 
performed combination treatments with aforementioned inhibitors. While 
the combination DNA-PK and PARP did not sensitize RR cells, either the 
ATM – PARP and the ATM – DNA-PK inhibitor combination led to increased 
RT sensitivity in RR cells (Fig. 5C – E), which suggests that IR resistance 
is dependent on at least two DSB repair and signalling sub-pathways in 
which PARP and DNA-PK belong to one epistasis group and ATM to another. 
Discussion
 Here we showed that RR cells are established relatively early du-
ring RT using a protocol that closely mimics patient RT treatment in the 
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clinic. IR resistance was maintained up to the end of RT treatment. Im-
portantly, it could be reversed by an ‘IR holiday’, which demonstrates 
not only its dynamic, transient nature, but also suggests that an adjus-
ted RT schedule could reduce therapy resistance and tumour relapse. 
Furthermore, we show that ATM is activated, RR cells remain longer in 
G2/M-phase and DSB repair by NHEJ is altered. Finally, we demonstra-
te that RT resistance is dependent on two epistasis groups of which ATM 
belongs to one, while PARP and DNA-PK to another. On the other hand, 
inhibition of ATR or the combination of ATR inhibition with either PARP in-
hibition or DNA-PK inhibition did not induce sensitivity (data not shown).
 Our interpretation of the data provides evidence for a model in which 
repetitive exposure to IR reduces c-NHEJ capacity thereby relying on Alt-EJ. 
Alternatively, Alt-EJ activity is increased, which subsequently competes with 
c-NHEJ. The consequence of this alteration in DSB repair is an increased num-
ber of DSBs in the G1-phase of the cell cycle. During cell cycle progression, 
these DSBs activate a strong G2/M block, which allows a resistant cell time to 
repair unresolved DSBs. Paradoxically, our data points to a reduction in DSB re-
pair rather than an improvement to establish a RT-resistant phenotype. Based 
on our intervention experiments we can implicate ATM function as essential 
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Figure 5: RR cells are sensitized to IR by dual inhibition of ATM with PARPi or DNApKi. A + B) 
Parental and RR cells were seeded for colony survival and pre-treated with DNApKi inhibitor NU7441 
(A) and PARP inhibitor Olaparib (B) to assess IR resistance after inhibition of the DDR signalling pa-
thway. Colonies formed in non-radiated wells were set 100% (dashed line). C – E) Parental and RR 
cells were seeded for colony survival and pre-treated with a combination of DNApKi inhibitor NU7441 
and PARP inhibitor Olaparib (C), ATM inhibitor KU55933 and PARP inhibitor Olaparib (D) and ATM 
inhibitor KU55933 and DNApK inhibitor NU7441 (E) to assess IR resistance after inhibition of multiple 
components of the DDR signalling pathway. Colonies formed in non-radiated wells were set 100% 
(dashed line). Every experiment was performed at least three times and mean ± SEM are depicted.
 Persistent DSBs and transient rewiring of the DDR induce acquired radio-resistance
43
2
to maintain IR resistance and another branch consists of PARP and DNA-PK. 
 Since all three DDR molecules ATM, DNA-PK and PARP have multiple 
functions in DSB repair and signalling, their exact molecular mechanistic 
implication in radio-resistance is not yet clear. However, we can speculate 
that the inhibition of either ATM or DNA-PK affects the response to DSBs. 
Since they belong to the same family of PI3K-like protein kinases (PIKKs) 
together with ATR, it could be likely that their activity is increased to par-
tially compensate for the missing member (27). That, in turn, can explain 
why single inhibition of ATM and DNA-PK does not sensitize RR cells to IR. 
 DSBs are recognized by PARP, which is involved in facilitating re-
cruitment of MRE11 and NBS1 (which are part of the MRN complex that 
senses DSBs) (28-31). The MRN complex, especially NBS1, is required 
for ATM activation and subsequent downstream signalling and repair by 
HR (27, 32). Inhibition of PARP will therefore not abolish DNA repair, but 
delays the activation of downstream DDR proteins that need ATM phosp-
horylation for their activation (33). Simultaneously, ATM is dispensable 
for HR functioning, although HR will not be as efficient as normal (34). 
Therefore we postulate that PARP and ATM are redundant and that ex-
plains why single PARP or ATM inhibition in RR cells does not sensitize 
them to IR, whereas double inhibition of ATM and PARP does. Interes-
tingly, Atm/Parp1-/- mice are embryonically lethal, suggesting that ATM and 
PARP are also important for normal cell development (PMID: 11238919).
 A striking observation was the reduced repair of DSB in G1-phase of 
the cell cycle in RR cells. It is known that about 80% of IR-induced DSBs in 
G1-phase are repaired via c-NHEJ independent from ATM (35, 36). The remai-
ning 20% of DSBs is localized close to, or reside in, highly condensed regions 
in heterochromatin (HC). Often these breaks are referred to as persistent 
or ‘complex’ breaks and need ATM signalling for repair (35). Under normal 
circumstances HC is condensed by factors such as KAP-1, HP1, HDAC1 and 
HDAC2 (37), thereby keeping the damaged DNA inaccessible for DNA repair 
proteins in the case of a DSB. ATM-dependent phosphorylation of KAP-1, 
which is mediated by 53BP1 (38-40), relaxes the compact chromatin structure 
and facilitate DNA repair. Following chromatin relaxation DNA repair factors 
like ARTEMIS and DNA-PK are required for DSB repair (36). Based on these 
observations we hypothesize that the observed persistent DSBs are located 
near or in HC regions in RR cells. Inhibition of both ATM and DNA-PK will dis-
rupt downstream DSB signalling to other DNA repair factors, impairs c-NHEJ 
in G1-phase and in combination with less efficient HR due to ATM inhibition 
lead to lethal persistent DSBs. This hypothesis could explain the observed 
redundancy between ATM and PARP and ATM and DNA-PK. However, more 
in depth characterization of DSB repair and signalling in RR cells is required. 
 In summary, we showed that a transient IR resistance phenotype 
is acquired early during RT treatment, which can be reversed by an IR 
holiday. We have outlined a mechanistic basis for the observed radio-re-
sistance induced by repetitive RT using a regimen identical to the clinic. 
This new paradigm in radio-resistance states that DSB repair is in part 
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attenuated instead of increased to establish resistance. Further dissec-
tion of the transient rewiring of DSB repair and signalling pathways in 
RT-resistant cancers can lead to the development of novel combinati-
on therapies to sensitize tumours and improve cancer therapy outcome.
Acknowledgements
 The authors would like to thank mem-
bers of the Molecular Genetics department 
en the Experimental Urology department of the Erasmus Medical Cen-
ter Rotterdam for their contributions to the manuscript. This research 
was supported by Dutch Cancer Society (KWF) grant nr. 2011-5030. 
Disclosure
The authors declare no conflict of interest. 
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent 
J, Jemal A. Global cancer statistics, 2012. CA: a 
cancer journal for clinicians. 2015;65(2):87-108.
2. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, 
Joniau S, van der Kwast T, et al. EAU guidelines 
on prostate cancer. part 1: screening, diagnosis, 
and local treatment with curative intent-update 
2013. European urology. 2014;65(1):124-37.
3. Fitch DL, McGrath S, Martinez AA, Vicini FA, 
Kestin LL. Unification of a common biochemi-
cal failure definition for prostate cancer tre-
ated with brachytherapy or external beam 
radiotherapy with or without androgen depri-
vation. International journal of radiation on-
cology, biology, physics. 2006;66(5):1430-9.
4. Fitzgerald TJ, Wang T, Goel HL, Huang J, Stein G, 
Lian J, et al. Prostate carcinoma and radiation the-
rapy: therapeutic treatment resistance and strate-
gies for targeted therapeutic intervention. Expert 
review of anticancer therapy. 2008;8(6):967-74.
5. Kyjacova L, Hubackova S, Krejcikova K, Strauss R, 
Hanzlikova H, Dzijak R, et al. Radiotherapy-induced 
plasticity of prostate cancer mobilizes stem-like 
non-adherent, Erk signaling-dependent cells. Cell 
death and differentiation. 2015;22(6):898-911.
6. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi 
PJ, et al. PI3K/Akt/mTOR pathway inhibitors en-
hance radiosensitivity in radioresistant prostate 
cancer cells through inducing apoptosis, redu-
cing autophagy, suppressing NHEJ and HR repair 
pathways. Cell death & disease. 2014;5:e1437.
7. Josson S, Xu Y, Fang F, Dhar SK, St Clair DK, St Clair 
WH. RelB regulates manganese superoxide dismuta-
se gene and resistance to ionizing radiation of pros
       tate cancer cells. Oncogene. 2006;25(10):1554-9.
8. Kong Z, Xie D, Boike T, Raghavan P, Bur-
ma S, Chen DJ, et al. Downregulation of hu-
man DAB2IP gene expression in prostate 
cancer cells results in resistance to ionizing ra-
diation. Cancer research. 2010;70(7):2829-39.
9. Ni J, Cozzi P, Hao J, Beretov J, Chang L, Duan W, 
et al. Epithelial cell adhesion molecule (EpCAM) is 
associated with prostate cancer metastasis and 
chemo/radioresistance via the PI3K/Akt/mTOR 
signaling pathway. The international journal of bio-
chemistry & cell biology. 2013;45(12):2736-48.
10. Ward JF. DNA damage produced by ionizing radia-
tion in mammalian cells: identities, mechanisms of 
formation, and reparability. Progress in nucleic acid 
research and molecular biology. 1988;35:95-125.
11. Hoeijmakers JH. Genome maintenan-
ce mechanisms for preventing can-
cer. Nature. 2001;411(6835):366-74.
12. ackson SP, Bartek J. The DNA-dama-
ge response in human biology and di-
sease. Nature. 2009;461(7267):1071-8.
13. Seol JH, Shim EY, Lee SE. Microhomo-
logy-mediated end joining: Good, bad 
References
 Persistent DSBs and transient rewiring of the DDR induce acquired radio-resistance
45
2
and ugly. Mutation research. 2017.
14. Schmid I, Uittenbogaart C, Jamieson BD. Live-cell 
assay for detection of apoptosis by dual-laser flow 
cytometry using Hoechst 33342 and 7-amino-ac-
tinomycin D. Nature protocols. 2007;2(1):187-90.
15. Livak KJ, Schmittgen TD. Analysis of rela-
tive gene expression data using real-time 
quantitative PCR and the 2(-Delta Delta 
C(T)) Method. Methods. 2001;25(4):402-8.
16. Verkaik NS, Esveldt-van Lange RE, van Heemst 
D, Bruggenwirth HT, Hoeijmakers JH, Zdzienicka 
MZ, et al. Different types of V(D)J recombinati-
on and end-joining defects in DNA double-strand 
break repair mutant mammalian cells. Euro-
pean journal of immunology. 2002;32(3):701-9.
17. van Gent DC, Ramsden DA, Gellert M. The RAG1 
and RAG2 proteins establish the 12/23 rule in 
V(D)J recombination. Cell. 1996;85(1):107-13.
18. Sharma SV, Lee DY, Li B, Quinlan MP, Taka-
hashi F, Maheswaran S, et al. A chromatin-me-
diated reversible drug-tolerant state in cancer 
cell subpopulations. Cell. 2010;141(1):69-80.
19. Davalos AR, Kawahara M, Malhotra GK, 
Schaum N, Huang J, Ved U, et al. p53-de-
pendent release of Alarmin HMGB1 is a cen-
tral mediator of senescent phenotypes. The 
Journal of cell biology. 2013;201(4):613-29.
20. Kim ST, Lim DS, Canman CE, Kastan MB. Substra-
te specificities and identification of putative sub-
strates of ATM kinase family members. The Journal 
of biological chemistry. 1999;274(53):37538-43.
21. O’Neill T, Dwyer AJ, Ziv Y, Chan DW, Lees-Mil-
ler SP, Abraham RH, et al. Utilization of orien-
ted peptide libraries to identify substra-
te motifs selected by ATM. The Journal of 
biological chemistry. 2000;275(30):22719-27.
22. Marechal A, Zou L. DNA damage sensing by 
the ATM and ATR kinases. Cold Spring Har-
bor perspectives in biology. 2013;5(9).
23. Brandsma I, Gent DC. Pathway choice in DNA 
double strand break repair: observations of a 
balancing act. Genome integrity. 2012;3(1):9.
24. Iliakis G, Murmann T, Soni A. Alternative end-joi-
ning repair pathways are the ultimate backup for 
abrogated classical non-homologous end-joining 
and homologous recombination repair: Implicati-
ons for the formation of chromosome transloca-
tions. Mutation research Genetic toxicology and 
environmental mutagenesis. 2015;793:166-75.
25. Mladenov E, Iliakis G. Induction and repair of 
DNA double strand breaks: the increasing spec-
trum of non-homologous end joining path-
ways. Mutation research. 2011;711(1-2):61-72.
26. Wang M, Wu W, Wu W, Rosidi B, Zhang L, Wang 
H, et al. PARP-1 and Ku compete for repair of DNA 
double strand breaks by distinct NHEJ pathways. 
Nucleic acids research. 2006;34(21):6170-82.
27. Shiloh Y, Ziv Y. The ATM protein kinase: re-
gulating the cellular response to geno-
toxic stress, and more. Nature reviews Mo-
lecular cell biology. 2013;14(4):197-210.
28. Sukhanova MV, Abrakhi S, Joshi V, Pastre D, Ku-
tuzov MM, Anarbaev RO, et al. Single molecu-
le detection of PARP1 and PARP2 interaction 
with DNA strand breaks and their poly(ADP-ri-
bosyl)ation using high-resolution AFM ima-
ging. Nucleic acids research. 2016;44(6):e60.
29. Langelier MF, Pascal JM. PARP-1 mecha-
nism for coupling DNA damage detection to 
poly(ADP-ribose) synthesis. Current opini-
on in structural biology. 2013;23(1):134-43.
30. Ali AAE, Timinszky G, Arribas-Bosacoma R, Ko-
zlowski M, Hassa PO, Hassler M, et al. The 
zinc-finger domains of PARP1 cooperate to re-
cognize DNA strand breaks. Nature structu-
ral & molecular biology. 2012;19(7):685-92.
31. Haince JF, McDonald D, Rodrigue A, Dery U, Mas-
son JY, Hendzel MJ, et al. PARP1-dependent ki-
netics of recruitment of MRE11 and NBS1 pro-
teins to multiple DNA damage sites. The Journal 
of biological chemistry. 2008;283(2):1197-208.
32. Lee JH, Paull TT. Direct activation of the ATM 
protein kinase by the Mre11/Rad50/Nbs1 
complex. Science. 2004;304(5667):93-6.
33. Haince JF, Kozlov S, Dawson VL, Dawson TM, Hend-
zel MJ, Lavin MF, et al. Ataxia telangiectasia mutated 
(ATM) signaling network is modulated by a novel 
poly(ADP-ribose)-dependent pathway in the early 
response to DNA-damaging agents. The Journal 
of biological chemistry. 2007;282(22):16441-53.
34. Blackford AN, Jackson SP. ATM, ATR, and DNA-
PK: The Trinity at the Heart of the DNA Damage 
Response. Molecular cell. 2017;66(6):801-17.
35. Goodarzi AA, Noon AT, Deckbar D, Ziv Y, Shiloh Y, 
Chapter 2
46
2
Lobrich M, et al. ATM signaling facilitates repair of 
DNA double-strand breaks associated with heter-
ochromatin. Molecular cell. 2008;31(2):167-77.
36. Riballo E, Kuhne M, Rief N, Doherty A, Smith 
GC, Recio MJ, et al. A pathway of double-strand 
break rejoining dependent upon ATM, Arte-
mis, and proteins locating to gamma-H2AX 
foci. Molecular cell. 2004;16(5):715-24.
37. Goodarzi AA, Jeggo P, Lobrich M. The influen-
ce of heterochromatin on DNA double strand 
break repair: Getting the strong, silent type 
to relax. DNA repair. 2010;9(12):1273-82.
38. Noon AT, Shibata A, Rief N, Lobrich M, Stewart 
GS, Jeggo PA, et al. 53BP1-dependent robust lo-
calized KAP-1 phosphorylation is essential for 
heterochromatic DNA double-strand break re-
pair. Nature cell biology. 2010;12(2):177-84.
39. Lee JH, Goodarzi AA, Jeggo PA, Paull TT. 
53BP1 promotes ATM activity through di-
rect interactions with the MRN complex. 
The EMBO journal. 2010;29(3):574-85.
40. Ziv Y, Bielopolski D, Galanty Y, Lukas C, Taya Y, 
Schultz DC, et al. Chromatin relaxation in res-
ponse to DNA double-strand breaks is modula-
ted by a novel ATM- and KAP-1 dependent pa-
thway. Nature cell biology. 2006;8(8):870-6.
 Persistent DSBs and transient rewiring of the DDR induce acquired radio-resistance
47
2
Supplemental information
0 2 4 6 8
0
50
100
150
Dose	  (Gy)
Su
rv
iv
al
	  (%
)
Parental
8	  Gy
28	  Gy
48	  Gy
68	  Gy
78	  Gy
PC3A
0 2 4 6 8
0
50
100
150
200
Parental
8	  Gy	  
18	  Gy	  
28	  Gy	  
48	  Gy	  
68	  Gy	  
78	  Gy	  
Dose	  (Gy)
Su
rv
iv
al
	  (%
)
B
0 2 4 6 8
0
50
100
150
Parental
8	  Gy	  
18	  Gy	  
28	  Gy	  
48	  Gy	  
68	  Gy	  
78	  Gy	  
Dose	  (Gy)
Su
rv
iv
al
	  (%
)
MCF7C
A549
0 2 4 6 8
0
50
100
150 Parental
28	  Gy
Dose	  (Gy)
Su
rv
iv
al
	  (%
)
D BPH1
Supplementary Figure 1: IR-resistant phenotype is not restricted to Du145 only. A + B + C) PC3, 
A549 and MCF7 cells received the same IR treatment as Du145. IR resistance was assessed using colony 
survival. D) BPH-1 cells were treated like Du145, PC3, A549 and MCF7 up to 28 Gy. IR resistance was addres-
sed using colony survival. Every experiment was repeated at least three times. Mean ± SEM are depicted.
Chapter 2
48
2
A
NQO1
Parental 28	  Gy
0.0
0.5
1.0
1.5
R
el
a2
ve
	  m
R
N
A
	  e
xp
re
ss
io
n HO-­‐1
Parental 28	  Gy
0.0
0.5
1.0
1.5
Re
la
2
ve
	  m
R
N
A
	  e
xp
re
ss
io
n B CD44
Parental 28	  Gy 28	  Gy	  +	  17d
0.0
0.5
1.0
1.5
Re
la
8
ve
	  M
FI
	  (F
ol
d	  
ch
an
ge
)
CD49f
Parental 28	  Gy 28	  Gy	  +	  17d
0.0
0.5
1.0
1.5
Re
la
:
ve
	  M
FI
	  (F
ol
d	  
ch
an
ge
) CD133
Parental 28	  Gy 28	  Gy	  +	  17d
0
2
4
6
8
Re
la
8
ve
	  M
FI
	  (F
ol
d	  
ch
an
ge
)
AKT
p-AKT (S473)
p-AKT (T308)
Tubulin
Pa
re
nt
al
28
 G
y
28
 G
y 
+ 
1 
w
k
28
 G
y 
+ 
2 
w
ks
0
50
100
150
200 Parental
28	  Gy
DMSO PI3Ki DMSO PI3Ki
2	  Gy 8	  Gy
Su
rv
iv
al
	  (%
)
E F
G
CD29	  
Parental 28	  Gy 28	  Gy	  +	  17d
0.0
0.5
1.0
1.5
Re
la
8
ve
	  M
FI
	  (F
ol
d	  
ch
an
ge
) C
CD49b
Parental 28	  Gy 28	  Gy	  +	  17d
0
1
2
3
Re
la
9
ve
	  M
FI
	  (F
ol
d	  
ch
an
ge
)D
H
Supplementary Figure 2: Known resistance mechanisms are not altered in RR cells. A) mRNA 
levels of NQO1  and HO-1 were determined by qPCR. B – F) Parental and RR cells were stained for prostate 
CSC markers CD29 (B), CD44 (C), CD49b (D), CD49f (E) and CD133 (F) and expression was addres-
sed using flow cytometry. G) Immunoblot for AKT, p-AKT (S473), p-AKT (T308) and Tubulin. WCE were 
isolated from parental, RR cells, time re-sensitized cells 10 days and time re-sensitized cells 17 days. 
H) RR cells were pre-treated with 50 μM of PI3K inhibitor LY294002 and colony survival was performed 
to address IR sensitivity upon PI3K inhibitor treatment. Colonies formed in non-radiated wells were set 
100% (dashed line). Every experiment was repeated at least three times. Mean ± SEM are depicted.
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Supplementary Figure 3: DNA damage foci are induced in parental and RR cells. A 
+ B) Absolute number of number of γH2AX foci per geminin negative (A) and positive (B) nu-
cleus per time point were counted and averaged per experiment. At least 25 nuclei per experi-
ment were quantified per time point in parental and RR cells. C + D) Absolute number of num-
ber of BRCA1 (C) and RAD51 (D) foci per geminin positive nucleus per time point were counted 
and averaged per experiment. At least 25 nuclei per experiment were quantified per time point 
in parental and RR cells. (E – H) Absolute number of number of 53BP1 and MDC1 foci per ge-
minin negative (G + H) and positive (E + F) nucleus per time point were counted and averaged 
per experiment. At least 25 nuclei per experiment were quantified per time point in parental and 
RR cells. Every experiment was performed at least three times and mean ± SEM are depicted.
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Abstract
 
 Non-metastasized prostate cancer is usually resected by surgery fol-
lowed by radiotherapy. In a substantial number of patients, resection is not 
possible and curative treatment solely relies on radiotherapy. Unfortuna-
tely, about 12% of prostate cancer patients experience relapse or meta-
stasis. These recurrent or metastasized tumours can acquire resistance to 
the initial radiotherapy treatment, which is a significant problem for patient 
recovery and survival. To address this problem, we generated transient ra-
dio-resistant cancer cells using a radiotherapy regimen identical to the cli-
nic. These transient therapy-resistant cancer cells can be re-sensitized by 
withholding radiotherapy for 17 days. To identify novel processes in acqui-
red radio-resistant prostate cancer, we defined four distinct experimental 
groups, I) parental cells, II) radio-resistant cells, III) radio-resistant cells 
followed by 10 days without IR and IV) radio-resistant cells followed by 17 
days with out IR, which exhibit radio-sensitivity again. These experimental 
groups were used for mRNA sequencing. We performed expression signatu-
re recognition analysis to identify processes potentially involved in radio-re-
sistance and identified mitochondrial respiration. Experimental validation 
demonstrated normal glycolysis levels, but a dramatic increase in mitochond-
rial respiration in radio-resistant cells. Furthermore, ATP and NAD+ levels 
were increased, which also points to increased mitochondrial respiration. Fi-
nally, we found that shifting the bio-energetic profile of parental (radio-sen-
sitive) prostate cancer cells from glycolysis to mitochondrial respiration by 
2-deoxyglucose led to increased radio-resistance. Thus, the data show that 
increased metabolic respiration contributes to acquired radio-resistance 
in prostate cancer, providing a new target for radiotherapy sensitization. 
Introduction
 Non-metastasized solid tumours are treated via a multi-step approach 
to reduce the chance of relapse and metastasis. In general, the tumour is 
resected, which is often followed by radiotherapy and/or chemotherapy. 
Examples of radiotherapy (RT) are external beam radiotherapy (EBRT), in-
ternal RT, brachytherapy and radionuclide therapy (1, 2). EBRT, internal 
RT and brachytherapy could be selected for first line treatment in prostate 
cancer, which is the second most common cancer in men worldwide (3). Un-
fortunately, about 12% of patients have clinical failure (CF) within the first 
five years after treatment. CF even increases up to 26% after ten years (4). 
The recurrent or metastasized tumours in the majority of these patients are 
resistant to RT, resulting in decreased patient survival (5, 6). RT induces dif-
ferent types of DNA damage of which double-strand DNA breaks (DSBs) are 
the most deleterious to the cell (7). When not properly repaired, DSBs lead 
to apoptosis or cellular senescence (8). Although most cancer cells are initi-
ally sensitive to RT, cancer cells can develop RT resistance, which may lead 
to relapse and metastasis. This process is known as acquired resistance. 
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 Currently, protocols used to generate RT-resistant cells vary widely 
between studies. Therefore, we generated RT-resistant cells using a clini-
cally relevant treatment protocol in which we treated prostate cancer cells 
with 2 Gy per day for 5 days followed by 2 days of rest up to a cumulative 
dose of 78 Gy (9). RT resistance is already fully present after a cumulative 
dose of 28 Gy (10). When these RT-resistant cells were subjected to an 
‘IR holiday’, in which the cells did not receive treatment for a certain time 
period after the final IR dose, the resistant phenotype was reversed (10).
 Several mechanisms have been described by which acquired RT re-
sistance is induced. One example is the induction of cancer stem cells (CSC) 
or tumour-initiating cells (TIC), which are characterized by their ability to 
self-renew and to restore tumour growth (11-13). In addition, several sig-
nalling pathways have been identified to contribute to RT resistance such 
as the epidermal growth factor receptor (EGFR) pathway (14, 15). Another 
example of a signalling pathway is the PI3K/AKT pathway, which could be ac-
tivated directly by IR or by the EGFR pathway during RT (16). The activation 
of the PI3K/AKT/mTOR pathway in radio-resistant cancer cells is associated 
with CSC phenotypes as well as epithelial-to-mesenchymal transition (6, 
17-19). The inhibition of the PI3K/AKT/mTOR pathway also led to the sen-
sitisation of radio-resistant prostate cancer cells to radiation. Many of these 
studies however, use different protocols to generate RT-resistant cells. Our 
approach to generate RT-resistant prostate cancer cells based on a clinically 
relevant protocol indicated that CSC and the PI3K pathway are not involved 
in RT resistance in prostate cancer (10). Since RT induces DSBs, we spe-
culated that the transient alterations in DSB repair and/or signalling were 
involved in the acquired RT resistance phenotype. Indeed, we showed that 
the DNA damage response (DDR) is affected in acquired RT resistance (10). 
 In addition to alterations in DSB repair and signalling, supplementary 
processes could be involved in acquired RT resistance or act in conjunc-
tion with the observed alterations in DSB repair and signalling. To iden-
tify these new processes in acquired radio-resistance we designed RT-re-
sistant and -sensitive experimental groups based on IR treatment and IR 
holiday followed by mRNA sequencing. Overrepresented pathway analysis 
identified energy metabolism, which we verified via bio-energetic measu-
rements. Moreover, adjusting the bio-energetic profile of parental can-
cer cells induced RT resistance, indicating the validity of this approach. 
Materials & Methods
Cell culture
Du145 prostate cancer cells (20) were cultured in RPMI-1640 (RPMI-
1640 Medium, R2405-500ML, Sigma-Aldrich) supplemented with pe-
nicillin-streptomycin (100× diluted, Penicillin-Streptomycin, P0781-
100ML, Sigma-Aldrich) and 10 % foetal bovine serum (Foetal Bovine 
Serum (FBS) South America, S1810-500, Biowest) at 5% CO2 and 37°C. 
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Generation of radio-resistant Du145
Du145 were seeded in 6-well plates and maintained as described. The day 
after seeding all cell lines were radiated (Gammacell 40 Cesium 137 ir-
radiation unit, Atomic Energy) with 2 Gy/day (from Monday-Friday; Sa-
turday-Sunday no IR) up to 28 Gy of cumulative dose, comparable to 
clinical radiation regimen (9). After cells obtained the indicated dosa-
ge of IR (see Figure 1A), they were not radiated for two days. On the 
third day after the last dose experiments were done. For “IR holiday” the 
cells were analysed after 10 days and 17 days after the last dose of IR. 
Clonogenic cell survival assay
Cells were trypsinised (Trypsin-EDTA solution, T3924-500ML, Sigma-Ald-
rich) and counted (Z2 Coulterparticle count and size analyzer, Beck-
man Coulter). 600 cells per well in triplicates per condition were seeded 
in 6-well plates. The next day, cells were irradiated with IR (0-2-4-6-8 
Gy). Cells were then incubated for 8-9 days and washed once with PBS 
followed by 0.1% Coomassie Brilliant Blue staining (50% (v/v) Me-
thanol, 43% (v/v) H2O, 7% (v/v) Acetic Acid, 0.1% (m/v) Coomas-
sie Brilliant Blue). Colonies were counted using Gelcount (Oxford Optro-
nix). Clonogenic survivals with 2-Deoxy-Glucose (2-DG) were performed 
as described above, with the addition of 5 mM 2-DG (D6134-1G, Sigma 
Aldrich, 1 M stock; 5 mM final) at least 15 minutes prior to IR dosages.
mRNA sequencing
Total RNA was isolated using the miRNeasy Mini Kit (217004, Qiagen) accor-
ding to the manufacturer’s protocol. RNA quality was assed using capillary 
gel electrophoresis (RIN >7.6) (Bioanalyzer 2100, Agilent Technologies). 
The resulting 50-bp single-ended sequencing files were aligned to the hu-
man reference genome (hg19) using Tophat (21) with the –g 1 option. The 
resulting aligned reads were then analysed by Cufflinks (22). FPKM (frag-
ments per kilo base of exon per million fragments mapped) was applied to 
quantify the expression of each transcript. To identify differentially expres-
sion genes, the average transcripts level was calculated for each set (three 
3 time points damage-induced experiments). Lowly expressed transcripts 
were removed from analysis (cut-off: at least 10 reads in each sample). 
Differentially expressed genes were identified with cuffdiff, with the cut-off 
of Log2 fold-change > 1.5 and FDR < 0.05. The statistics plots (i.e. Principal 
component analysis, Pearson’s correlation, heatmap) were created by Rstudio 
(v0.99.486) (RStudio Team (2015). RStudio: Integrated Development for R. 
RStudio, Inc., Boston, MA URL http://www.rstudio.com/). Short Time-series 
Expression Miner (STEM) was used to perform clustering analysis (23). The 
data was summarized and visualized by Graphpad Prism. (One-way ANOVA 
with Dunnett’s posttest was performed using GraphPad Prism version 7.00 
for Windows, GraphPad Software, San Diego California USA, www.graphpad.
com). The functional analysis was performed in Ingenuity Pathway Analysis 
(IPA) (version 36601845, QIAGEN Redwood City, www.qiagen.com/ingenuity) 
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for canonical pathway, molecular function and upstream regulator analysis. 
Bio-energetic profiling 
The Seahorse XF24 Extracellular Flux Analyzer (Seahorse Biosciences) was 
used to generate bio-energetic profiles of irradiated Du145 cells by simulta-
neous measure of oxygen consumption rates (OCR) and glycolysis (ECAR; 
extracellular acidification rate) in real time (Ambrosi 2014). Cells were seeded 
on a cell-tak coated Seahorse XF-24 plate (3.5 µg/cm2; BD biosciences) at a 
density of 50,000 cells and incubated 30 minutes at 37˚ C in presence of CO2 
in un-buffered DMEM (XF Assay Medium; Agilent Technologies, Santa Clara, 
Ca, USA) supplemented with 5 mM glucose and 1 mM pyruvate. Medium was 
adjusted to pH 7.4 prior to use. The plate was additionally incubated 30 mi-
nutes at 37˚ C in absence of CO2 and then moved to the Seahorse machine 
for the analysis. After four baseline measurements of OCR and ECAR levels, 
cells were challenged with sequential injections of mitochondrial toxins: 0.5 
µM oligomycin (ATP synthase inhibitor), 0.3 µM FCCP (mitochondrial respira-
tion uncoupler), 0.5 µM rotenone (complex I inhibitor), and 0.5 µM antimy-
cin (complex III inhibitor); 3 measurements per injection were performed.
Acetyl CoA, Citrate, NADP(H) and NAD(H) assay
Acetyl CoA (Acetyl-Coenzyme A Assay Kit, MAK039-1KT, Sigma-Aldrich), Ci-
trate (Citrate Assay Kit, MAK057-1KT, Sigma-Aldrich), NADP(H) (NADP/NAD-
PH Quantitation Kit, MAK038-1KT, Sigma-Aldrich) and NAD(H) (NAD/NADH 
Quantitation Kit, MAK-037-1KT, Sigma-Aldrich) concentrations were deter-
mined using their respective kits according to the manufacturer’s protocol. 
Statistical analysis
Data was processed using GraphPad Prism v7.0a (GraphPad Software Inc.). 
Statistical test used were unpaired and paired Student’s T-test and Mann-Whit-
ney U test. P-values equal or lower than 0.05 were accepted as significant.
Results
Repetitive IR treatment leads to IR resistance, which is reversed by IR 
holiday
 To identify pathways involved in IR resistance by mRNA sequencing we 
designed 4 experimental groups of which one group is the IR-sensitive Du145 
parental prostate cancer cell line. We obtained radio-resistant (RR) cells ac-
cording to the protocol shown in Fig. 1A (10). Prostate cancer cells received 
2 Gy/day on weekdays and no radiation during weekends. Once a total dose 
of 28 Gy was reached, one group was incubated over the weekend (3 days); 
one group was incubated for 10 days and one group for 17 days without 
RT. First, IR sensitivity/resistance of these experimental groups was tested. 
Compared to parental cells, RR cells (3 days) and RR cells that were cultured 
for 10 days without RT exhibited resistance, while 17 day-incubated RR cells 
without RT treatment (IR holiday) were re-sensitized (Fig. 1B). Thus, our 
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experimental design for mRNA sequencing includes two IR-sensitive groups 
(parental cell line and RR cells with 17 day IR holiday) and two IR-resistant 
groups (RR cells with 3 and 10 day incubation). This experimental set up 
allows us to correlate IR resistance/sensitivity to gene expression patterns.
 Subsequently, total RNA was isolated for mRNA sequencing (Fig. 
1C). Raw data with an average of approximately 25.6 million reads per 
sample were aligned to the human reference genome of which more than 
90% could be uniquely mapped (Fig. 1D). A Pearson correlation analy-
sis shows a high similarity between all conditions (Supplementary Fig. 1), 
indicating that IR treatment and IR holiday do not induce large numbers 
of differential expressed genes (DEGs) nor the presence of substantial 
technical variation. Next, we identified DEGs by comparing the treated ex-
perimental groups to the sensitive parental cell line. Transcripts with at 
least 2.8 fold difference (log2 fold change (FC) of >1.5 and <-1.5; false 
discovery rate (FDR)<0.05) were classified as DEGs. We observed large 
numbers of DEGs and overlapping genes in radiated samples over time 
(Fig. 1E). Genes overlapping across all three conditions correlated with 
a persistent DNA damage response, while genes that overlap between 
28 Gy and 28 Gy + 10 days correlated with an IR resistance response. 
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Figure 1: Generation of RR cells and subsequent NGS sequencing. A) Radiation protocol for the 
generation of RR cells and time re-sensitized cells. B) Colony survival assay of RR cells and time re-sen-
sitized cells. RR cells are resistant to additional IR and time re-sensitized cells have a similar survival 
curve as parental cells. C) Workflow sequencing different RT-resistant populations. Of each population 
3 independent RNA samples were collected, total RNA isolated and run via Illumina TruSec v3 protocol. 
The data generated was analysed using different analysis programs. The outcomes of these analyses 
have been verified by experimental approaches. D) Mapping rate of all samples run. All samples have 
a mapping rate of at least 90%. E) Venn diagram of DEGs between different populations, which were 
normalized to parental cells. The diagram shows subsets of uniquely regulated genes and overlap-
ping genes between the different populations. All experiments were performed at least three times.
Gene clusters analysis reveals involvement of energy metabolism in RT 
resistance
 Since we have one experimental group without IR treatment and 
three experimental groups that were exposed to 28 Gy, we are able to iso-
late DEGs that correlate with a persisting response after IR treatment. Si-
milarly, we have two IR- sensitive and two IR-resistant groups, which allows 
us to detect DEGs that correlate with IR sensitivity/resistance. Because our 
data represents a time series, we used Short Time-series Expression Miner 
(STEM) to perform gene expression profile clustering. STEM analysis allows 
identification of significant temporal expression profiles in genes associa-
ted with these profiles and the comparison of the behaviour of these genes 
across multiple conditions (23). To prevent underrepresentation of signifi-
cant gene expression patterns, total DEGs were used to analyse significant 
gene expression patterns instead of the overlapping genes from the Venn 
diagram (Fig. 1E). Gene expression patterns of interest were designated as 
persistent or resistant patterns. Indeed, we identified significant persistent 
up- and down-regulated DEG patterns (Fig. 2A). Using Ingenuity pathway 
analysis (IPA), we analysed up- and down-regulated persistent patterns se-
parately, which showed enrichment of cell cycle related pathways and ATM 
signalling in the up-regulated DEGs and pathways related to senescence 
and apoptosis such as HMGB1 signalling and Myc-mediated apoptosis in 
the down-regulated DEGs (Fig. 2C + Supplementary Fig. 2B). In addition, 
we applied a gene ontology term (GO term) analysis that implicated se-
veral processes in the persistent response to IR treatment (Supplementary 
Fig. 3A + B). Thus, repeated IR treatment leads to long-term changes in 
several cellular processes and pathways regardless of sensitivity status.
 Subsequently, we analysed DEGs that correlate with IR resistance 
(Fig. 2A). IPA analysis of canonical pathways correlating with IR resistan-
ce using upregulated genes identified metabolic processes such as NADH 
repair, arginine degradation and glutamine biosynthesis (Fig. 2D + Sup-
plementary Fig. 2C). IPA analysis of canonical pathways correlating with 
IR resistance using downregulated genes also identified alterations in me-
tabolism such as acetate conversion to acetyl-coA and nicotine degrada-
tion (Fig. 2E + Supplementary Fig. 2D). Although only few significant GO 
terms were identified, metabolism was also present in the gene expres-
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sion patterns correlating with resistance (Supplementary Fig. 3C + D). 
 Since a recurrent theme in our analyses was energy metabolism, 
we performed a molecular function analysis using IPA in which we com-
bined both up- and down-regulated DEGs derived from STEM analysis 
that correlate with resistance. Indeed, we observed that processes such 
as DNA repair, cell cycle, apoptosis, energy metabolism and carbohydra-
te metabolism were altered (Fig. 2F). Next, we also performed an up-
0.0 0.5 1.0 1.5 2.0 2.5
Glucocor,coid	  Receptor	  Signaling
GABA	  Receptor	  Signaling
UVB-­‐Induced	  MAPK	  Signaling
Wnt/β-­‐catenin	  Signaling
iNOS	  Signaling
Role	  of	  JAK1,	  JAK2	  and	  TYK2	  in	  Interferon	  Signaling
Cell	  Cycle:	  G1/S	  Checkpoint	  Regula,on
Paxillin	  Signaling
Cdc42	  Signaling
Inhibi,on	  of	  Angiogenesis	  by	  TSP1
-­‐Log(P-­‐value)
Persistent	  paXern	  up	  CPA B
C D
E
F
Pa
re
nt
al
28
	  G
y
28
	  G
y	  +
	  10
d
28
	  G
y	  +
	  17
d-­‐3
-­‐2
-­‐1
0
1
2
3
Lo
g2
(F
C)
Persistent	  pa>ern	  up
Persistent	  pa>ern	  down
Resistant	  pa>ern	  up
Resistant	  pa>ern	  down
0.0 0.5 1.0 1.5 2.0 2.5
NF-­‐κB	  Signaling
Myc	  Mediated	  Apoptosis	  Signaling
mTOR	  Signaling
FXR/RXR	  AcBvaBon
PEDF	  Signaling
Methylthiopropionate	  Biosynthesis
Methylglyoxal	  DegradaBon	  III
IGF-­‐1	  Signaling
SAPK/JNK	  Signaling
HMGB1	  Signaling
-­‐Log(P-­‐value)
Persistent	  paSern	  down	  CP
0 1 2 3 4 5
Arginine	  Degrada1on	  VI	  (Arginase	  2	  Pathway)
Urea	  Cycle
Arginine	  Degrada1on	  I	  (Arginase	  Pathway)
IL-­‐6	  Signaling
iNOS	  Signaling
NADH	  Repair
Glutamine	  Biosynthesis	  I
Toll-­‐like	  Receptor	  Signaling
LXR/RXR	  Ac1va1on
IL-­‐10	  Signaling
-­‐Log(P-­‐value)
Resistant	  paSern	  up	  CP
0.0 0.5 1.0 1.5 2.0 2.5
Melatonin	  Degrada3on	  I
IL-­‐6	  Signaling
Tryptophan	  Degrada3on	  to	  2-­‐amino-­‐3-­‐carboxymuconate	  Semialdehyde
Gαi	  Signaling
Zymosterol	  Biosynthesis
Nico3ne	  Degrada3on	  III
CMP-­‐N-­‐acetylneuraminate	  Biosynthesis	  I	  (Eukaryotes)
Acetate	  Conversion	  to	  Acetyl-­‐CoA
Acute	  Phase	  Response	  Signaling
Nico3ne	  Degrada3on	  II
Resistant	  paRern	  down	  CP
-­‐Log(P-­‐value)
0.00 0.01 0.02 0.03 0.04 0.05
DNA	  Replica3on,	  Recombina3on,	  and	  Repair
Carbohydrate	  Metabolism
Small	  Molecule	  Biochemistry
Cell	  Death	  and	  Survival
Nucleic	  Acid	  Metabolism
Energy	  Produc3on
Lipid	  Metabolism
Cell	  Cycle
Cellular	  Growth	  and	  Prolifera3on
Amino	  Acid	  Metabolism
Total	  resistant	  paMerns	  MF
P-­‐value
Resistant	  patterns	  
Upstream	  Regulator	   Molecule	  Type	   p-­‐value	  
Gm-­‐csf	   group	   3,89E-­‐04	  
NAMPT	   cytokine	   8,33E-­‐04	  
TRIM38	   other	   1,44E-­‐03	  
Fcer1	   complex	   1,48E-­‐03	  
MGEA5	   enzyme	   1,84E-­‐03	  
CD2	   transmembrane	  receptor	   2,00E-­‐03	  
TNFSF9	   cytokine	   2,64E-­‐03	  
Interferon	  alpha	   group	   3,66E-­‐03	  
CASP8	   peptidase	   4,19E-­‐03	  
NMNAT1	   enzyme	   4,19E-­‐03	  
	  
G
Figure 2: Analysis of persistent gene expression patterns and resistant gene expression 
patterns. A) Significant expression patterns of DEG, which show persistent (black and red) or re-
sistant (blue and green) expression patterens. Patterns were generated by STEM analysis. Mean 
± SEM are depicted. B – E) Canonical pathway (CP) analysis of persistent pattern with up-regu-
lated genes (B), persistent pattern with down-regulated genes (C), resistant pattern with up-re-
gulated genes (D) and resistant pattern with down-regulated genes (E). For all CP analysis the 
top 10 and the –Log(p-value) are depicted. F) Analysis of molecular functions (MF) of resistant 
patterns combined, the top 10 per pattern is given sorted based on average p-value. Each dot 
per function represents a significant pathway within the molecular function. G) Upstream re-
gulator analysis of resistant patterns combined. The top 10 of upstream regulators is depicted.
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stream regulator analysis, which predicts which factors could control the 
altered expression of the observed DEGs. This analysis identified NAMPT 
and NMNAT1 as upstream regulators (Fig. 2G), which are both involved 
in the de novo synthesis of NAD+ by the salvage pathway (24). This fin-
ding is also in accordance with the canonical pathway analysis in which 
NADH repair was enriched (Fig. 2D). Together our analyses indicate that 
IR resistance is correlated with genes involved in energy metabolism. 
Bio-energetic alterations in IR-resistant cancer cells
 Our mRNA sequencing analyses supports the observation that high 
metabolic activity, as measured by labelled glucose uptake by the tumour, is 
associated with cancer therapy resistance (25-27). We measured the bioe-
nergetics profile of parental, RR cells and re-sensitized RR cells by IR holiday. 
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Figure 3: Increased metabolic activity in RR cells. A) Oxygen consumption rate (OCR) was 
measured in normal prostate epithelial cells BPH1 (black) and Du145 (red) cells. B) Quantificati-
on of the basal respiration rate based on the first four time points of the OCR measurement (A). 
C) Glycolysis was measured in BPH1 (black) and Du145 (red) cells by measuring the extracellular 
acidification rate (ECAR). D) Quantification of basal glycolysis based on the first four time points of 
the ECAR measurement (B). E) Normalized ratio of ECAR over OCR as a measure for the Warburg 
effect, where the ratio of BPH1 cells was set to 1. F) OCR measurement for parental (black), RR cells 
(red) and RR cells with a 2-week IR holiday (blue). G) ECAR measurement for parental (black), RR 
cells (red) and RR cells with a 2-week IR holiday (blue). H) Relative ADP, ATP and ATP/ADP ratio in 
parental (black) and RR cells (red). I) Relative Acetyl CoA and citrate levels in parental (black) and 
RR cells (red). All experiments were repeated at least three times and mean ± SEM are depicted. 
Unpaired two-sided T-test was performed to determine statistical significance. * P>0.05; ** P>0.01
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First, we compared the bio-energetics profiles of normal prostate epithelial 
cells (BPH1 cells), which do not acquire resistance upon repetitive IR treat-
ment (10), with prostate cancer cells. We observed that the basal respiration 
of normal prostate epithelial cells as measured by the oxygen consumption 
rate (OCR) is higher than prostate cancer cells (Fig. 3A, 3B). On the other 
hand, glycolysis, which was measured by the extracellular acidification rate 
(ECAR), is increased in prostate cancer cells when compared to normal pros-
tate epithelial cells (Fig. 3C, 3D). This shift from oxidative phosphorylation 
to glycolysis is also known as the Warburg effect, in which cancer cells pre-
fer glycolysis instead of oxidative phosphorylation for ATP production (28). 
Indeed, the ECAR/OCR ratio indicates increased glycolysis levels in prostate 
cancer cells, indicating the presence of the Warburg effect (Fig. 3E). Subse-
quently, we performed bioenergetics profiling of parental, RR cells and RR 
cells with a 17-day IR holiday. We observed that the OCR of RR cells is tre-
mendously increased when compared to parental cells (Fig. 3F) and returns 
towards parental cell levels after a 17-day IR holiday. On the other hand, gly-
colysis does not differ between the three groups (Fig. 3G). This indicates that 
RT-resistant prostate cancer cells have increased mitochondrial respiration. 
 Increased ATP levels are expected to increase, because of the obser-
ved increase in mitochondrial respiration. While ADP levels between pa-
rental cells and RR cells are similar, ATP levels are increased (Fig. 3H). As 
a consequence, the ATP/ADP ratio is also increased (Fig. 3H). The incre-
ase in ATP levels and the OCR in RR cells is not due to increased activity 
of upstream parts of the energy metabolism chain: glycolysis was not al-
tered (Fig. 3G), but also the citric acid cycle was not altered as measu-
red by acetyl CoA and citrate levels (Fig. 3I). Thus, increased oxidative 
phosphorylation and ATP production during RT resistance is not due to in-
creased activity of upstream components of energy metabolic pathways.
 Next, we measured the coenzymes NADP+/NADPH and NAD+/NADH 
that are involved in the mitochondrial electron transport chain (ETC). The 
pentose phosphate pathway (PPP) mainly produces NADP+/NADPH that 
are involved in cellular redox capacity and nucleotide synthesis (29, 30). 
NAD+/NADH shuttle electrons produced during oxidative reactions in the 
citric acid cycle to the ETC. During IR resistance, NADP+ and NADPH are 
both increased compared to parental cells, but the ratio between NADP+ 
and NADPH remains similar (Fig. 4A), indicating increased activity of the 
PPP. However, more experiments need to be done to confirm the involve-
ment of the PPP in IR resistance. In addition, we observed that the NAD+ 
concentration is increased in RR cells, but NADH is not altered. The ra-
tio NAD+/NADH is by extension also increased during IR resistance (Fig. 
4B). This observation is in agreement with the mRNA sequencing data in 
which we observed NADH repair as a significant enriched process (Fig. 2D). 
 Our observations indicate that a shift in the bio-energetic profi-
le from glycolysis to mitochondrial respiration could be causally invol-
ved in RT resistance. To test this hypothesis, we determined in a clo-
nogenic survival assay whether parental prostate cancer cells could 
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acquire RT resistance when we shift their bio-energetic profile from gly-
colysis to mitochondrial respiration using 2-deoxyglucose (2-DG), which 
blocks ATP production by glycolysis and forces cells to use oxidative 
phosphorylation (31). Interestingly, parental cells are more resistant to 
IR after 2-DG treatment (Fig. 4C), indicating that increased mitochond-
rial respiration contributes to RT resistance in prostate cancer cells. 
Discussion
 We have previously shown that repeated IR treatment leads to radio-re-
sistance, which can be reversed by an ‘IR holiday’ (10). Here, we designed 
well-defined experimental groups to identify genes and cellular processes by 
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RT resistance. Every experiment was performed at least three times and mean ± SEM are depicted. 
Unpaired two-sided T-test was performed to determine statistical significance. *P>0.05, **P>0.01.
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mRNA sequencing that could be causally involved in RT resistance. We showed 
that DNA repair was associated with RT resistance, which verified our previous 
findings in which specific transient alterations in the DNA damage response 
were functionally implicated in acquired RT resistance (10). In addition, we 
found that the expression of genes involved in energy metabolism was alte-
red in RT resistance. We verified our RNA sequencing data by bio-energetic 
profiling, in which we observed increased mitochondrial respiration in RR 
cells, which was reversed after an IR holiday. Glycolysis however, was not 
altered. The changes in energy metabolism are likely important for RT re-
sistance, since an experimentally-induced shift from glycolysis to mitochond-
rial respiration increased RT resistance in parental prostate cancer cells. 
 Based on these data, we propose a model in which repetitive IR tre-
atment leads to RT resistance via increased oxidative phosphorylation and 
subsequent increased ATP and NAD+ levels (Fig. 4D). Several lines of evi-
dence further support this model. For instance, glioblastoma cancer cells 
and oesophageal adenocarcinoma cells are both treated with RT in the clinic 
and often acquire resistance to RT. When metabolic parameters were analy-
sed, both showed increased oxidative phosphorylation and ATP production 
(32, 33). The emerging model is likely more complicated, because hepato-
cellular carcinoma cells, cervical cancer cells and medulloblastoma stem-li-
ke cells showed increased glycolysis in acquired RT resistance, which can 
be sensitized by 2-DG treatment (34, 35). We speculate that the complex 
wiring of all energy metabolic components and pathways may be diffe-
rent for distinct tumour types, each with their specific genomic alterations. 
 In addition, we also observed increased levels of NAD+ but not 
NADH. NAD+ is produced de novo or via the salvage pathway (24). In 
the salvage pathway NAMPT is the rate-limiting enzyme in the produc-
tion of NAD+ and it is up-regulated in several cancers (24, 36-39). We 
identified NAMPT as an upstream regulator in our data set, suggesting 
that the increased amounts of NAD+ are due to an increased production 
via the salvage pathway. Moreover, genes involved in the de novo syn-
thesis of NAD+ or the Preiss-Handler pathway (40) were not differentially 
expressed in our dataset, which indicates that the increased NAD+ level 
could be attributed to increased NAD+ production by the salvage pathway.
NAD+ is not only a coenzyme in mitochondrial respiration, but it is also a sub-
strate for the sirtuin class of histone deacetylases (SIRT) (40). Seven SIRT 
proteins have been identified each with a different cellular location. SIRT1, 
SIRT 6 and SIRT7 are located in the nucleus, whereas SIRT2 is the only 
SIRT situated in the cytosol and SIRT3, SIRT4 and SIRT5 reside in the mi-
tochondria (41). SIRT5 was the only sirtuin that was differentially expressed 
in our data set (data not shown). Interestingly, it was shown that SIRT5 is 
highly expressed in non-small cell lung cancer (NSCLC) patients and its high 
expression correlated with poor survival and drug resistance (42).  Not only 
SIRTs but also PARP uses NAD+ as a substrate to exert its function(43), we 
speculate that high NAD+ levels prevents PARP to deplete the NAD+ pool that 
leads to cell death (44), but also maintains DNA repair capacity in RR cells. 
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 At this moment we do not know exactly how the elevated and altered 
energy metabolism contributes to RT resistance, since inhibition of the dif-
ferent essential components of oxidative phosphorylation has proven to be 
difficult, either all cells died or inhibition was incomplete (data not shown). 
Furthermore, we have previously shown that the DNA damage response 
also contributes to acquired RT resistance (10). Therefore, it is plausible 
that these two pathways work together in accomplishing resistance to RT. 
 In summary, we have shown that by using well-defined groups of 
radio-resistant and -sensitive prostate cancer cells, novel pathways in-
volved in RT resistance can be identified by mRNA sequencing, which 
includes energy metabolism. Further experiments showed increased 
mitochondrial respiration in RR cells and increased metabolic parame-
ters such as ATP and NAD+, indicating that energy metabolism is indeed 
more active in RR cells. Targeting energy metabolism led to a change 
in radiosensitivity, indicating that energy metabolism could be a promi-
sing target, despite its essential role in cells. Future research should fo-
cus on exactly pinpointing the role of energy metabolism in acquired 
RT resistance to design novel interventions to sensitize prostate cancer. 
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Supplementary Figure 1: Pearson correlation plot of all sequenced samples. Pearson correlation 
analysis of all samples shows a significant correlation between samples and between the different groups.
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A B
C D
Persistent	  pattern	  up	  
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
Inhibition	  of	  Angiogenesis	  by	  TSP1	   2,13E00	  
Cdc42	  Signaling	   1,85E00	  
Paxillin	  Signaling	   1,73E00	  
Cell	  Cycle:	  G1/S	  Checkpoint	  Regulation	   1,72E00	  
Role	  of	  JAK1,	  JAK2	  and	  TYK2	  in	  Interferon	  Signaling	   1,69E00	  
iNOS	  Signaling	   1,68E00	  
Wnt/β-­‐catenin	  Signaling	   1,67E00	  
UVB-­‐Induced	  MAPK	  Signaling	   1,64E00	  
GABA	  Receptor	  Signaling	   1,64E00	  
Glucocorticoid	  Receptor	  Signaling	   1,63E00	  
p38	  MAPK	  Signaling	   1,6E00	  
Renin-­‐Angiotensin	  Signaling	   1,56E00	  
ErbB	  Signaling	   1,49E00	  
Toll-­‐like	  Receptor	  Signaling	   1,48E00	  
Assembly	  of	  RNA	  Polymerase	  III	  Complex	   1,47E00	  
Regulation	  of	  eIF4	  and	  p70S6K	  Signaling	   1,44E00	  
EIF2	  Signaling	   1,43E00	  
IL-­‐6	  Signaling	   1,43E00	  
IL-­‐15	  Signaling	   1,41E00	  
Cyclins	  and	  Cell	  Cycle	  Regulation	   1,39E00	  
Chronic	  Myeloid	  Leukemia	  Signaling	   1,38E00	  
ATM	  Signaling	   1,35E00	  
UDP-­‐D-­‐xylose	  and	  UDP-­‐D-­‐glucuronate	  Biosynthesis	   1,31E00	  
Taurine	  Biosynthesis	   1,31E00	  
Protein	  Ubiquitination	  Pathway	   1,31E00	  
Chronic	  Myeloid	  Leukemia	  Signaling	   1,38E00	  
ATM	  Signaling	   1,35E00	  
UDP-­‐D-­‐xylose	  and	  UDP-­‐D-­‐glucuronate	  Biosynthesis	   1,31E00	  
Taurine	  Biosynthesis	   1,31E00	  
Protein	  Ubiquitination	  Pathway	   1,31E00	  
	  
Persistent	  pattern	  down	  
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
HMGB1	  Signaling	   1,94E00	  
SAPK/JNK	  Signaling	   1,9E00	  
IGF-­‐1	  Signaling	   1,84E00	  
Methylglyoxal	  Degradation	  III	   1,77E00	  
Methylthiopropionate	  Biosynthesis	   1,73E00	  
PEDF	  Signaling	   1,69E00	  
FXR/RXR	  Activation	   1,53E00	  
mTOR	  Signaling	   1,52E00	  
Myc	  Mediated	  Apoptosis	  Signaling	   1,38E00	  
NF-­‐κB	  Signaling	   1,32E00	  
	  
Resistant	  pattern	  up	  
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
IL-­‐10	  Signaling	   3,9E00	  
LXR/RXR	  Activation	   2,95E00	  
Toll-­‐like	  Receptor	  Signaling	   2,58E00	  
Glutamine	  Biosynthesis	  I	   2,42E00	  
NADH	  Repair	   1,95E00	  
iNOS	  Signaling	   1,94E00	  
IL-­‐6	  Signaling	   1,91E00	  
Airway	  Inflammation	  in	  Asthma	   1,82E00	  
Arginine	  Degradation	  I	  (Arginase	  Pathway)	   1,82E00	  
Urea	  Cycle	   1,65E00	  
Arginine	  Degradation	  VI	  (Arginase	  2	  Pathway)	   1,65E00	  
TREM1	  Signaling	   1,54E00	  
Citrulline	  Biosynthesis	   1,53E00	  
IL-­‐15	  Signaling	   1,48E00	  
	  
Resistant	  pattern	  down	  
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
Nicotine	  Degradation	  II	   2,37E00	  
Acute	  Phase	  Response	  Signaling	   1,7E00	  
Acetate	  Conversion	  to	  Acetyl-­‐CoA	   1,61E00	  
CMP-­‐N-­‐acetylneuraminate	  Biosynthesis	  I	  (Eukaryotes)	   1,52E00	  
Nicotine	  Degradation	  III	   1,47E00	  
Zymosterol	  Biosynthesis	   1,44E00	  
Gαi	  Signaling	   1,42E00	  
LPS/IL-­‐1	  Mediated	  Inhibition	  of	  RXR	  Function	   1,4E00	  
Tryptophan	  Degradation	  to	  2-­‐amino-­‐3-­‐carboxymuconate	  Semialdehyde	   1,37E00	  
IL-­‐6	  Signaling	   1,36E00	  
Melatonin	  Degradation	  I	   1,35E00	  
	  
Supplementary Figure 2: Canonical pathway analysis of the different significant 
STEM patterns. Complete tables with all significant canonical pathways identified in persis-
tent pattern up (A), persistent pattern down (B), resistant pattern up (C) and resistant pattern 
down (D) using Ingenuity Pathway Analysis. The tables depict the pathways and –Log(p-value).
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A Persistent	  pattern	  up	  
GO-­‐terms	   P-­‐value	  
GO:	  0009749	  response	  to	  glucose	   0.004	  
GO:	  0030195	  negative	  regulation	  of	  blood	  coagulation	   0.005	  
GO:	  0048247	  lymphocyte	  chemotaxis	   0.009	  
GO:	  2000145	  regulation	  of	  cell	  motility	   0.009	  
GO:	  0006954	  inflammatory	  response	   0.011	  
GO:	  0007182	  common-­‐partner	  SMAD	  protein	  phosphorylation	   0.012	  
GO:	  0006893	  Golgi	  to	  plasma	  membrane	  transport	   0.013	  
GO:	  0070374	  positive	  regulation	  of	  ERK1	  and	  ERK2	  cascade	   0.016	  
GO:	  0019221	  cytokine-­‐mediated	  signaling	  pathway	   0.017	  
GO:	  0006417	  regulation	  of	  translation	   0.019	  
GO:	  0050729	  positive	  regulation	  of	  inflammatory	  response	   0.022	  
GO:	  0070723	  response	  to	  cholesterol	   0.022	  
GO:	  0007369	  gastrulation	   0.024	  
GO:	  0042127	  regulation	  of	  cell	  proliferation	   0.024	  
GO:	  0007173	  epidermal	  growth	  factor	  receptor	  signalling	  pathway	   0.026	  
GO:	  0060021	  palate	  development	   0.026	  
GO:	  0006959	  humoral	  immune	  response	   0.028	  
GO:	  0071346	  cellular	  response	  to	  interferon-­‐gamma	   0.028	  
GO:	  0055088	  lipid	  homeostasis	   0.029	  
GO:	  0050679	  positive	  regulation	  of	  epithelial	  cell	  proliferation	   0.034	  
GO:	  0051149	  positive	  regulation	  of	  muscle	  cell	  differentiation	   0.034	  
GO:	  0035265	  organ	  growth	   0.034	  
GO:	  0097191	  extrinsic	  apoptotic	  signalling	  pathway	   0.036	  
GO:	  0034067	  protein	  localization	  to	  Golgi	  apparatus	   0.041	  
GO:	  0042592	  homeostatic	  process	   0.041	  
GO:	  0060338	  regulation	  of	  type	  I	  interferon-­‐mediated	  signalling	  pathway	   0.042	  
GO:	  0023014	  signal	  transduction	  by	  protein	  phosphorylation	   0.042	  
GO:	  0001822	  kidney	  development	   0.044	  
GO:	  0051384	  response	  to	  glucocorticoid	   0.045	  
GO:	  0030838	  positive	  regulation	  of	  actin	  filament	  polymerization	   0.045	  
GO:	  0030593	  neutrophil	  chemotaxis	   0.048	  
GO:	  0008334	  histone	  mRNA	  metabolic	  process	   0.048	  
	  
B Persistent	  pattern	  down	  
GO-­‐terms	   P-­‐value	  
GO:	  0045187	  regulation	  of	  circadian	  sleep/wake	  cycle	  sleep	   0.007	  
GO:	  0042503	  tyrosine	  phosphorylation	  of	  Stat3	  protein	   0.007	  
GO:	  0007608	  sensory	  perception	  of	  smell	   0.010	  
GO:	  0051216	  cartilage	  development	   0.010	  
GO:	  0007160	  cell-­‐matrix	  adhesion	   0.016	  
GO:	  0000387	  spliceosomal	  snRNP	  assembly	   0.024	  
GO:	  0007030	  Golgi	  organization	   0.026	  
GO:	  0048706	  embryonic	  skeletal	  system	  development	   0.029	  
GO:	  0051492	  regulation	  of	  stress	  fiber	  assembly	   0.033	  
GO:	  0006486	  protein	  glycosylation	   0.042	  
	  
C Resistant	  pattern	  up	  
GO-­‐terms	   P-­‐value	  
GO:	  1901896	  positive	  regulation	  of	  calcium-­‐transporting	  ATPase	  activity	   0.021	  
GO:	  0031642	  negative	  regulation	  of	  myelination	   0.037	  
GO:	  0032057	  negative	  regulation	  of	  translational	  initiation	  in	  response	  to	  stress	   0.037	  
GO:	  0051646	  mitochondrion	  localization	   0.037	  
GO:	  0002467	  germinal	  center	  formation	   0.042	  
GO:	  0001825	  blastocyst	  formation	   0.042	  
GO:	  0034599	  cellular	  response	  to	  oxidative	  stress	   0.045	  
	  
D Resistant	  pattern	  down	  
GO-­‐terms	   P-­‐value	  
GO:	  0071456	  cellular	  response	  to	  hypoxia	   0.022	  
GO:	  0042572	  retinol	  metabolic	  process	   0.069	  
	  
Supplementary Figure 3: GO-term analysis of the different significant STEM pat-
terns. GO-term analysis of persistent pattern up (A), persistent pattern down (B), re-
sistant pattern up (C) and resistant pattern down (D) using DAVID array tools. 
Only significant GO-terms are depicted (A – C) or all GO-terms are depicted (D).
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Abstract
 Since damaged DNA cannot be replaced by a newly synthesized DNA 
molecule, genetic integrity solely dependent on DNA repair. Loss or dys-
function of genetic information is particularly harmful, because it has been 
causally linked to carcinogenesis, the aging process and age-related disea-
ses. Genome stability is maintained by DNA repair systems, but also elabo-
rate DNA damage signaling pathways that transiently halt cell proliferation 
to allow repair and in case of extensive damage, induce cell death, cellular 
senescence or terminal differentiation. This DNA damage response network 
is comprised of numerous factors and cellular processes, but the intricate 
wiring of the DNA damage response and regulatory steps are still unclear. 
Here, we mapped the transcriptional response of both genes as well as 
microRNAs in time to three types of genotoxic agents, i.e. UV-C, ionizing 
radiation and cisplatin, which induce their own spectrum of DNA lesions. 
We delineated a general DNA damage-induced transcriptional signature and 
identified several upstream regulators, in which microRNAs predominantly 
control gene expression only in the first hours after DNA damage after which 
more permanent transcriptional changes take over. Moreover, we identi-
fied several novel processes in the DNA damage response, one of which is 
protein citrullination, the intra-peptidal conversion of amino acid arginine 
into citrulline. We show that citrullination facilitates replication fork stability 
and is required for homologous recombination repair of double strand DNA 
breaks. In conclusion, we provide a time-resolved mechanistic framework 
of the transcriptional response to DNA damage in mouse embryonic stem 
cells that integrates gene and microRNA expression as well as post-transla-
tional modifications. Our extensive resource permits identification of novel 
processes in the DNA damage response, with relevance to cancer and aging. 
Introduction
 DNA is continuously damaged by genotoxic agents from both exogenous 
sources (e.g. ultraviolet (UV) light, cigarette smoke) and endogenous sour-
ces (e.g. replication, transcription, metabolism) (1). Each genotoxic agent 
induces its own spectrum of DNA lesions, which in turn is repaired by a spe-
cific DNA repair pathway to maintain genome integrity. Single strand breaks 
(SSB) and subtle lesions are mainly repaired via base excision repair, base-
pair-disrupting lesions via nucleotide excision repair, interstrand crosslinks 
via interstrand crosslink repair and double strand breaks (DSB) by either 
non-homologous end joining (NHEJ), homologous recombination (HR) or 
single strand annealing (SSA) (2). In addition to DNA repair activation, DNA 
damage can induce DNA damage checkpoint signalling pathways, which 
determine cell fate. First, a temporary cell cycle arrest is induced to allow 
the cell time to repair the damage. DNA damage that is too extensive and 
beyond repair triggers cell death, cellular senescence or terminal differenti-
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ation (2-4). The cellular outcome of DNA damage signalling is dependent on 
the number and type of lesions, their intrinsic characteristics (e.g. genomic 
location), cell type and cellular context (e.g. cell proliferation status) (5). 
Collectively, the response to DNA damage that includes DNA damage repair 
and signalling is designated the DNA damage response (DDR). DNA da-
mage accumulation has several clinical implications. Exposure to environ-
mental genotoxic agents induces mutations that drive carcinogenesis. In 
addition, genetic defects in the DDR are causal drivers of carcinogenesis 
as well. Moreover, many cancer therapies such as radiation and chemo-
therapy act via induction of DNA damage (6). During surgical procedures, 
ischemia reperfusion injury inflicts DNA damage that impairs organ function 
(7). Furthermore, defects in specific DNA repair pathways can lead to se-
vere premature aging syndromes. Finally, it is becoming clear that gradual 
accumulation of DNA damage causing genome dysfunction and cell death 
can cause common age-related diseases and pathologies (1, 8, 9). For fin-
ding effective interventions for both cancer and ageing associated disea-
ses, it is important to understand the complex wiring of the DDR network.
 The complex DDR network needs to be tightly regulated and fi-
ne-tuned. Decreased activity will lead to mutations and chromosomal aber-
rations that drive cancer. Hyper-activation induces premature apoptosis 
and senescence that accelerate aging. Many regulatory steps in the DDR 
have been discovered. Directly after DNA damage is inflicted, protein–pro-
tein interactions and a wealth of post-translational modifications (PTMs) 
such as phosphorylation, acetylation, methylation, glycosylation, sumoyla-
tion, unbiquitylation, neddylation and polyADP-ribosylation are required 
for activation of DNA repair, the DNA damage checkpoint and cell cycle 
arrest (10, 11). To maintain a prolonged cell cycle arrest, but also to di-
rect a damaged cell into a specific cell fate such as apoptosis, senescence 
or terminal differentiation, gene expression programs are induced. Sever-
al transcription factors have been identified to play a role in the DDR. For 
example, transcription factor P53 induces expression of genes that maintain 
cell cycle arrest and induce apoptosis (12, 13). Besides the relatively fast 
protein-protein interactions and PTMs on one hand and the relatively slow 
gene expression changes via transcription factors on the other hand, we 
identified another level of DDR regulation by microRNAs that act between 
the fast protein/PTM level and relatively slow transcription factor-control-
led gene expression changes (14). MicroRNAs are small (± 22 nucleotides) 
endogenously encoded non-coding RNAs, which repress gene expression 
by binding to complementary target sites that mainly reside in the 3’UTR 
of mRNAs, leading to mRNA degradation and/or translation inhibition (15). 
Since one microRNA can target several mRNAs at once, a comprehensi-
ve set of gene expression patterns can be rapidly altered by only a few 
microRNAs. The mechanistic basis of microRNA action in the DDR relies 
on their fast maturation. A pool of primary microRNA transcripts is pre-
sent in the nucleus. The DDR signalling kinase ATM directly phosphorylates 
and activates microRNA-binding protein KHSRP, which detects and binds 
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specific primary microRNAs from this nuclear pool and preferentially di-
rects them into the microRNA biogenesis/maturation pathway (16). Since 
post-transcriptional regulation of microRNAs bypasses transcription, it is 
much faster than gene expression changes by altering promoter activity. 
 Numerous studies have been published in which global gene expressi-
on changes after genotoxic stress have been documented using micro-array 
or next generation sequencing technology. However, comparing these stu-
dies is difficult, since conditions, cell types, tissues, doses, timing, but also 
the number of replicates, are all different. Moreover, most DNA-damaging 
agents are not completely specific for DNA and will damage additional cel-
lular macromolecules, which hampers mapping specific transcriptional res-
ponses induced by DNA damage. Here, we generated an extensive sequen-
cing dataset in which gene and microRNA expression changes are analysed 
after three types of genotoxic stresses (UV-C, IR and cisplatin) at equitoxic 
doses in mouse embryonic stem (mES) cells at three time points (4, 8, 12 
hours) to construct a map of the early transcriptional response to DNA da-
mage. Each genotoxic agent induces a specific spectrum of DNA lesions: 
UV-C causes mainly helix-distorting lesions, ionizing radiation (IR) induces 
a range of oxidative DNA lesions, SSBs and DSBs, and cisplatin generates 
inter- and intra-strand crosslinks (4, 6, 17). Each DNA-damaging agent has 
its own side effects, e.g. UV-C causes very abundant transcription blocking 
lesions, with slow repair kinetics and replication bypass, causing lower re-
lative toxicity (18). In addition, UV-C can damage cell membranes and RNA 
(19). IR causes very abundant SSBs, most of which are quickly repaired, 
and few DSBs, which are strong signalling-type of lesions in replicating cells 
(17). Furthermore, IR can oxidize proteins as well (20). Cisplatin induces 
the less abundant interstrand and intrastrand DNA crosslinks with a strong 
S-phase block and cell death (21). Besides DNA, cisplatin also damages RNA 
and can not only react with, but can also crosslink proteins (22). Covering 
this spectrum of DNA lesions allowed us to map a general gene and microR-
NA expression response to genotoxic stress, which likely is not influenced 
by the side effects of each treatment. In addition, we can map genotoxic 
stress-specific processes.  Finally, we show that our rich and well-cura-
ted dataset allows for the identification of novel processes in the DDR.
Materials & Methods
Total RNA isolation
mES cells (HM1; 129/ola) were cultured as described (23). One vial of 
mES cells was thawed and grown for two passages on feeder-coated plates 
followed by one passage on gelatin-coated plates before taken into ex-
periment. The mES cells in experiment were treated with 5μM cisplatin 
(Platosin), exposed to 4J/m2 UVC or, 4 Gy IR or mock-treated. Treat-
ments with cisplatin, UVC and IR were carefully calibrated to be equitoxic, 
resulting in a 50% survival based on clonogenic assays (or ‘colony-for-
ming ability’) (24, 25). After 4, 8 and 12h exposure total RNA was iso-
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lated using Qiazol Lysis Reagent (Qiagen) and total RNA was purified 
with the miRNeasy kit (Qiagen), according to manufacturer’s protocols. 
The integrity of the RNA was determined on the Agilent 2100 Bioanaly-
zer (Agilent) according to manufacturer’s instructions. All scores were
>9.0. This procedure was repeated three times to obtain indepen-
dent biological replicates. Subsequent sequencing protocols were 
performed on the total RNA from the same biological samples.
RNA Sequencing Library Preparation and Deep Sequencing
Total RNA enrichment for sequencing poly(A)+ RNAs was performed with the 
TruSeq mRNA sample preparation kit (Illumina) according to the manufac-
turer’s protocols. In short, 1 µg of total RNA for each sample was used for 
poly(A)+ RNA selection using magnetic beads coated with poly-dT, followed 
by thermal fragmentation. The fragmented poly(A)+ RNA enriched samples 
were subjected to cDNA synthesis using Illumina TruSeq preparation kit ac-
cording to the manufacturer’s protocol. Then, cDNA was synthesized by re-
verse transcriptase (Super-Script II) using poly-dT and random hexamer pri-
mers. These cDNA fragments were subsequently blunt-ended by end-repair 
reaction, followed by dA-tailing. Finally, specific double-stranded bar-coded 
adapters were ligated and library amplification for 15 cycles was performed. 
cDNA libraries for small RNA sequencing were generated by Illumina Tru-
Seq smallRNA kit v1.5 (smallRNASeq), according to the manufacturer’s in-
structions. In short, specific bar-coded adapters were ligated to 1 µg of 
total RNA followed by reverse transcriptase and amplification for 11 cycles. 
Small RNAs were enriched by fractionation on a 15% Tris-borate-EDTA gel, 
excising the RNAs of 15-30 nucleotide of length. Pooled cDNA libraries all 
consisted of equal concentrations of bar-coded samples. The pooled libra-
ries were sequenced, all 36bp single read on the HiSeq2000 (Illumina).
Analysis of sequencing data
The resulting 50-bp single-ended sequencing files were aligned to the Mus 
musculus genome (mm9) using Tophat (26) with the –g 1 option. The re-
sulting aligned reads were then analysed by Cufflinks (27). FPKM (frag-
ments per kilobase of exon per million fragments mapped) was applied 
to quantify the expression of each transcript. To identify the differential-
ly expression genes (DEG), the average transcript level was calculated 
for each set (three damage-induced experiments consisting of three time 
points). The transcripts at low level were removed by requiring an aver-
age of at least 10 reads in each sample. Differentially expressed genes 
were identified using EdgeR (28), Deseq2 (29) and limma-voom (30, 31), 
with the cut-off of fold-change > 2 and FDR < 0.05. The statistics plots 
(i.e. principal component analysis, Pearson’s correlation, heatmap) were 
created by Rstudio (v0.99.486) (RStudio Team (2015). RStudio: Integra-
ted Development for R. RStudio, Inc., Boston, MA URL http://www.rstudio.
com/). Short Time-series Expression Miner (STEM) using STEM clustering 
method was used to perform clustering analysis (32). The data were sum-
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marized and visualized by Graphpad Prism. (One-way ANOVA with Dun-
nett’s posttest was performed using GraphPad Prism version 5.00 for Win-
dows, GraphPad Software, San Diego California USA, www.graphpad.com). 
Functional analysis was performed in Ingenuity Pathway Analysis (IPA) 
(QIAGEN Redwood City, www.qiagen.com/ingenuity) for canonical path-
way analysis and upstream regulator analysis. The GO enrichment ana-
lysis was performed with PANTHER (33). Networks of GO term interacti-
ons were created using Cytoscape (34) under the BINGO package (35).
Cell culture
U2OS cells were cultured in DMEM supplemented with penicillin-streptomycin 
(100× diluted, Penicillin-Streptomycin, P0781-100ML, Sigma-Aldrich) and 10 
% fetal bovine serum (Fetal Bovine Serum (FBS) South America, S1810-500, 
Biowest) at 5% CO2 and 37°C. To induce PADI4 KD cells were incubated with 
Cl-amidine (200 mM stock; 200 μM final, 506282-10MG, Millipore) for 48h. 
Clonogenic cell survival assay
After treatment with Cl-amidine cells were trypsinised (Trypsin-ED-
TA solution, T3924-500ML, Sigma-Aldrich) and counted (Z2 Coulter-
particle count and size analyzer, Beckman Coulter). 300 cells per well 
in triplicates per condition were seeded in 6-well plates. Cells were in-
cubated 8-9 days, after incubation the cells were washed once with 
PBS, then stained with 0.1% Coomassie Brilliant Blue (50% (v/v) Me-
thanol, 43% (v/v) H2O, 7% (v/v) Acetic Acid, 0.1% (m/v) Coomassie 
Brilliant Blue). Colonies were counted using Gelcount (Oxford Optronix).
Proliferation assay
Cell proliferation was assessed using xCelligence RTCA DP (Roche Life Sci-
ences). Briefly, cells were treated with Cl-amidine for 48h and trypsini-
sed and counted. All wells of a special 2-row 96-well plate (E plate VIEW 
16, 06 324 738 001, Acea bioscience) were filled with 50 μl pre-warmed 
medium (DMEM + 10% FCS + pen/strep). The remainder spaces were 
filled with pre-heated PBS. The plate was put in the xCelligence machi-
ne to measure background. 1000 cells/150 μl cell suspension was ad-
ded to the wells. The cells were adhered for 30’ at RT. The plate was put 
in the machine and measured for 96h with a measurement every 30’.
Immunofluorescence
U2OS were seeded on coverslips and incubated with Cl-amidine for 48h. The 
cells were radiated with 1 Gy and fixed 1, 2, 4, 8, and 24h after IR. Briefly, the 
coverslips were washed once with PBS, fixed with 2% PFA, washed with PBS 
+ 0.1% triton X-100 3× short and 2× 10 minutes, once washed with PBS+ 
(100 ml PBS + 0.5 g BSA + 0.15 g Glycine), incubated 1-2h at RT with primary 
antibodies. After incubation coverslips were washed with PBS + 0.1% triton 
X-100 3× short and 2× 10 minutes, once washed with PBS+, incubated 1-2h 
at RT with secondary antibodies. After incubation coverslips were washed 
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with PBS + 0.1% triton X-100 3× short and 2× 10’, once washed with PBS+. 
For RAD51 staining the coverslips were washed once with PBS, fixed with 
4% PFA. Subsequently, cells were permeabilised for 20’ with PBS + 0.2% 
triton X-100 and washed with PBS. After permeabilization cells were tre-
ated with 10× diluted DNAse I (04536282001, Roche Life Sciences) for 
1h at 37°C in a humidified chamber and washed with PBS. Blocking was 
performed using IFF buffer (PBS + 1% BSA + 2% FCS) for at least 30’. 
After blocking cells were incubated with primary antibodies for 1-2h at 
RT. After incubation coverslips were washed 3× for 5’ with PBS and in-
cubated with secondary antibodies 1-2h at RT. After incubation cover-
slips were washed 3× for 5’ with PBS. Coverslips were mounted in DAPI 
Vectashield mounting medium (H1200, Vector Laboratories). Images 
were made using a LSM700 microscope (Carl Zeiss Microimaging Inc.). 
Immuno-blot analysis
Cells were lysed in 2× sample buffer and boiled at 99°C for 5 minutes. 
Samples were run on a SDS-PAGE gel and transferred to a PVDF mem-
brane (Immobilon FL PVDF Transfer membrane 0.45um, IPFL00010, Mil-
lipore). Membranes were blocked in 5% milk in PBS for 1-2h at RT. Af-
ter blocking, membranes were incubated with primary antibodies 1-2h at 
RT. Then the membranes were washed 5 times for 5 minutes with PBS + 
0.05% Tween-20 and incubated with secondary antibodies at RT for 1-2h. 
Again the membranes were washed 5× for 5 minutes. Membranes were 
visualized using Odyssey CLx Infrared Imaging System (LI-COR Biosci-
ences). For (phospho-)RPA32 analysis cells were treated with Cl-amidi-
ne for 48h. Medium was replaced for medium containing Cl-amidine and 
4 mM HU. Cell lysates were made directly, 1h or 5h after HU treatment. 
BrdU and PI labelling for cell cycle analysis
Cells were labelled with 5 μM BrdU (B5002, Sigma-Aldrich) for 15 minutes at 
37°C. Subsequently, cells were harvested and fixed in 70% ethanol at least 
overnight at 4°C. Fixed cells were washed with ice-cold PBS and re-sus-
pended in pepsin solution (5 mg pepsin in 10 ml 0.1N HCl) and incubated 
20 minutes at RT. After pepsin-treatment blocking solution (PBS + 0.5% 
Tween-20 + 0.1% BSA) was added and cells were washed. Next, cell were 
re-suspended in 2N HCl for 12 minutes at 37°C. To neutralise, borate buf-
fer (100 mM, pH8.5) was added and the cells were pelleted. BrdU antibody 
was added and the cells were incubated for 2h on ice in the dark. Stained 
cells were washed in blocking solution and re-suspended in 500 μl PBS 
supplemented with 12.5 μl RNase A and 1 μl PI (P3566, Invitrogen). Cell 
cycle was analysed the next day using BD LSRFortessa (BD Biosciences). 
Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
Primary antibodies
ATM (500×, #2873, Cell Signaling); p-ATM (500×, #4526, Cell Sig-
naling); BRCA1 (50×, sc-6954, Santa Cruz Biotechnology); BrdU Kit 
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(50×, 556028, BD Sciences); Geminin (400×, 10802-1-AP, Protein-
tech); γH2AX (Ser139) (1000×, 05-636, Millipore); p53 (1000×, sc-
126, Santa Cruz Biotechnology); RAD51 (200×, GTX70230, GeneTex); 
RPA32 (2000×, A300-244A, Bethyl Laboratories); phopho-RPA32 (S4/
S8) (2000×, A300-245A, Bethyl Laboratories); phospho-RPA32 (S33) 
(2000×, A300-246A, Bethyl Laboratories); Tubulin (2000×, sc-12462-R, 
Santa Cruz Biotechnology); Tubulin (5000×, T5168, Sigma-Aldrich)
Secondary antibodies
Goatαmouse Alexa 488 (1000×, A11034, Life Technologies); GoatαRab-
bit Alexa 555 (1000×, A21429, Life Technologies); Donkeyαmouse 
IRDye 800CW (5000×, 926-32212, LI-COR Biosciences); Don-
keyαrabbit IRDye 680RD (5000×, 926-32223, LI-COR Biosciences)
Apoptosis assay
Apoptotic cells were analysed according to the protocol published by 
Smid et al. (36). In brief, medium and cells were collected and re-sus-
pended in 998 μl FACS buffer (0.5% BSA + 0.05% NaN3 in PBS) pre-he-
ated to 37°C. 1 μl Hoechst 33342 (10 mg/ml, H3570, Life Technologies) 
was added and the cells were vortexed and incubated for exactly 7 minu-
tes at 37°C. Subsequently, the cells were immediately placed on ice and 
1 μl 7-AAD (1 mg/ml, A1310, Invitrogen) was added. Cells were analy-
sed within 1h after adding 7-AAD using BD LSRFortessa (BD Biosciences). 
Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
RNA isolation, cDNA synthesis and qPCR
Total RNA was isolated using Trizol reagent (TriPure Isolation Reagent, 
11667165001, Roche Life Science). In brief cells were lysed in Trizol re-
agent and chloroform was added. Lysates were spun 12000 g for 15’ at 
4°C. The aqueous phase was transferred to a new eppendorf tube and 
isopropanol was added. The aqueous phase was incubated at RT for 10’, 
then spun 12000 g for 10’ at 4°C. RNA pellets were washed once with 
75% ethanol. After washing RNA pellets were dried and dissolved in 30 
μl of RNAse-free H2O. RNA concentration and quality was assessed using 
Nanodrop (NanoDrop™ 2000/2000c Spectrophotometers, ThermoFischer 
Scientific). Subsequently, cDNA was made using iScript cDNA Synthesis 
Kit (170-8891, Biorad) according to the manufacturer’s protocol. qPCR 
was performed using Platinum® Taq DNA Polymerase (10966018, Invitro-
gen) according to the manufacturer’s protocol complemented with SYBR 
Green I (SYBR® Green I nucleic acid gel stain, S9430, Sigma-Aldrich) for 
detection. The reaction mix was run according to the following cycling 
program: 3’ - 95°C; 45× 15’’ - 95°C/30’’ - 60°C/30’’ - 72°C; 1’ - 95°C; 
1’ - 65°C; 65× 30’’ - 65°C. Data was analyzed using ΔCt method (37). 
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Primers
 Forward primer (5’-3’) Reversed primer (5’-3’) 
Mmu-Padi1 TAGTGGCGGACACAGTCAGTA ACAGCAGTTAGGTAGAGCAC 
Mmu-Padi2 AAGGGGCTATCCTGCTGGT GACCTTTTCGTCACTACAGTCC 
Mmu-Padi3 CTACAGAGGATTGTGCGTGTG AGGAACCGCCCCATAAATGTC 
Mmu-Padi4 TCTGCTCCTAAGGGCTACACA GTCCAGAGGCCATTTGGAGG 
Hsa-PADI4 TTCTCTAAGGCGGAAGCTTTT AGCAGGGAACACACCTTCTC 
Mmu-Tubg2 CAGACCAACCACTGCTACAT AGGGAATGAAGTTGGCCAGT 
Mmu-B2m CCCTGGTCTTTCTGGTGCTT ATTTCAATGTGAGGCGGGTG 
Hsa-GADPH AAGGTGAAGGTCGGAGTCAA ACCATGTAGTTGAGGTCAATG 
Hsa-UbC CTGGAAGATGGTCGTACCCTG GGTCTTGCCAGTGAGTGTCT 
	1	
End-joining assay
The end-joining assay was performed as described in (38), with some minor 
changes. In short, cells were grown in a 3-cm dish to 50-80% confluency. 
Cells were transiently transfected with 2 µg of a blunt-ended linear DNA 
substrate (EcoRV/Eco47III digested pDvG94 plasmid (38)) using X-treme 
GENE HP DNA Transfection Reagent (Sigma Aldrich), following manufac-
turers protocol. Two days after transfection, extrachromosomal DNA was 
isolated and resuspended in a final volume of 20 µl water (39). From this 
solution, 1 µl was PCR amplified with the DAR5 and FM30 primers (38), 
using PuReTaq ready-To-Go PCR beads (GE Healthcare). The PCR product 
was digested with BstXI. Restriction fragments were separated on a 6% 
polyacrylamide gel in TBE buffer, stained with ethidium bromide. The rela-
tive level of microhomology-directed end-joining was determined by quan-
tification of the BstXI-digested PCR product using the ImageJ software.
Statistical analysis
Data was processed using GraphPad Prism v7.0a (GraphPad Software 
Inc.). Statistical tests used were Student’s T-test and Mann-Whitney 
U test. P-values equal or lower than 0.05 were accepted as significant.
Results
A general gene expression response after DNA damage
 To generate a time-resolved map of differentially expressed genes 
(DEGs) induced by genotoxic stress we used mES cells because of they are 
non-transformed, wild-type cells with high proliferation rates in which the 
effects of DNA damage are immediately present. Therefore, mES cells were 
exposed to cisplatin, UV-C and IR each with its own spectrum of specific DNA 
lesions. These genotoxic agents together cover a wide range of DNA lesions, 
which enable identification of both general as well as lesion-specific geno-
toxic stress responses. To obtain total RNA for mRNA sequencing we thawed 
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one vial of mES cells that were grown for two passages on feeder-coated 
plates followed by one passage on gelatin-coated plates and exposed those 
cell cultures to cisplatin, UV-C, IR or mock-treatment. Genotoxic stress was 
applied in equitoxic doses, correlating with 50% survival in a colony forma-
tion assay. Total RNA was isolated 4, 8 and 12 hours after treatment. This 
complete procedure was repeated three times to obtain independent, com-
plete biological replicates for statistical analysis (Fig. 1A). After the raw se-
quence data was obtained we designed an informatics workflow to identify 
DEGs (Fig. 1B). Briefly, raw datasets with on average 28 million reads per 
sample were aligned to the mouse reference genome. More than 70% of all 
reads could be uniquely mapped. The number of mapped reads to each open 
reading frame (ORF) was counted and used as input for statistical analysis. 
 First, we analysed total transcript numbers per sample and observed 
similar percentages of transcripts in each sample with the expected distri-
bution in classes (on average 69.1% in exonic regions) (Fig. 1C). A Pearson 
correlation between all conditions showed >94% overlap between different 
conditions (Supplemental Figure 1), indicating very low technical or biologi-
cal variation, which could negatively influence data analysis and indicates, 
as expected, that only a relatively small subset of genes (<10% of total 
genes) is significantly altered by DNA damage. Next, we performed varia-
tion analysis using a principal component analysis (PCA), which shows that 
samples belonging to the same condition cluster largely together indicating 
distinct effects on transcription and gene expression (Fig. 1D). PC1 (34.8%) 
seems to mostly discriminate based on treatment, whereas PC2 (19.2%) 
appears to predominantly correlate with time. Of note: the PCA indica-
ted that only few DEGs are present 4h after UV-C exposure as seen by its 
clustering together with the control samples. However, at later time points 
the UV profiles start to deviate progressively more from the 4h time point. 
This contrasts with IR, in which the 4h time point deviates quite strongly 
from mock, but progression in time is relatively modest. The 8h and 12h 
time points demonstrate that the DEGs induced by UV-C are most similar 
to mES cells exposed to IR. Furthermore, the PCA indicates that cisplatin 
treatment results in much more and different DEGs compared to UV and IR. 
 To further investigate gene expression kinetics after DNA damage, we 
determined DEGs in all conditions. We only identified 3 DEGs in the 4h UV-C 
time point consistent with the PCA plot analyses. We calculated correlations 
between all conditions and clustered them using a dendrogram, using DEG-
fold changes over mock-treatment (Fig. 1E). A high correlation in DEGs bet-
ween all conditions was observed, except for 4h after UV-C. For example, at 
least 50% of all DEGs identified after IR and cisplatin treatment overlapped 
in each time point, indicating that the same genes are regulated in the ge-
neral response to DNA damage. Importantly, most genes that are differen-
tially expressed at 4h after IR and cisplatin were also regulated in the same 
direction 4h after UV-C, but to a much lesser extent. This indicates that gene 
expression changes after UV-C is delayed, which is confirmed by comparing 
correlation values of IR 4h and cisplatin 4h with UV 4h and the correlation 
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value of UV 8h with IR 4h and cisplatin 4h (Fig. 1Fi + ii).  Finally, we observed 
the strongest overlap in the 12 hour time point across all three genotoxic 
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Figure 1: General gene expression profiles after different genotoxic stresses in mES cells. 
A) Schematic representation of the workflow from cells to RNA. B) Schematic representation of the 
bioinformatics analysis pipeline. C) Distribution of different RNA classes analysed by mRNA sequen-
cing. D) Principal component analysis of all samples. E) Dendrogram of Pearson correlation coeffi-
cient using fold changes of all DEGs in each condition. Fi + ii) Correlation values of IR 4h and cisplatin 
4h compared to UV 4h (i) and correlation values of UV 8h compared to IR 4h and cisplatin 4h (ii). 
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stresses, which indicates that although differences between treatments are 
present in earlier time points, the general gene expression pattern in res-
ponse to DNA damage evolves and culminates into a common response. 
Upstream regulator analysis identifies transcription factors and microRNAs
 In order to classify transcriptional programs of the mES cell transcip-
tome after DNA damage, we performed gene expression pattern clustering 
using Short Time-series Expression Miner (STEM). STEM identifies signi-
ficant temporal expression profiles in genes and compares the behaviour 
of these genes across multiple conditions (32). First, we selected all DEGs 
from one genotoxic agent and performed a genotoxic stress-based cluste-
ring. ~50% of DEGs clustered in one significant pattern, which is a gradual 
up regulation in all treatments (Fig. 2A). We performed an upstream regula-
tor analysis using ingenuity pathway analysis (IPA) on this cluster and iden-
tified predominantly overrepresented transcription factors, growth factors 
and to a minor extend microRNAs (Fig. 2B). As expected, transcription fac-
tors such as TP73 and TP53 were present (Fig. 2C and Supplementary Table 
1). In addition, we identified a second significant expression pattern (Fig. 
2D), in which DEGs are up regulated only at the 8h and 12h time point. Up-
stream regulator analysis on the DEGs in these patterns showed a predicted 
increase of microRNAs (Fig. 2E + F and Supplementary Table 2), sugge-
sting that a subset of genes is regulated by microRNAs after DNA damage. 
 Canonical pathway analysis of the upstream regulators identified 
in Fig. 2B and Fig. 2E showed expected pathways related to embryo-
nic cell development such as Wnt/β-catenin signalling and the DDR such 
as ATM signalling in both analysis (Fig. 2G + H and Supplementary Ta-
ble 3 and 4). Remarkably, the overlap in upstream regulators between 
the two expression patterns is ~30%, which indicates that either a tran-
scription factor can establish two different expression patterns or a lar-
ge proportion of genes are regulated by a secondary process as well.
microRNAs and mRNAs have different expression kinetics upon DNA da-
mage 
 To confirm the upstream regulator analysis, we performed microR-
NA sequencing on the very same samples as used for gene expression 
analysis. We designed an informatics workflow to identify differential ex-
pressed microRNAs (DEmiRs) (Fig. 3A). In short, the raw sequencing data 
with an average of 12 million reads per sample was aligned to the mouse 
small RNA reference genome (including rRNA, tRNA, miRBase database 
(microRNA) and piwi-interaction RNA database). On average 73.3% of all 
reads per sample could be uniquely mapped to the small RNA referen-
ce database and statistical analysis identified several DEmiRs (Fig. 3B). 
In contrast to the PCA plot generated from mRNA expression data (Fig. 
1D), the microRNA PCA plot shows a classification per time point rather 
than genotoxic stress (Fig. 3C). Importantly, the 4h after UV-C conditi-
on is similar to the 4h IR and cisplatin conditions, indicating that sam-
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TP73	   transcription	  regulator	   5,14E-­‐06	  
MYOG	   transcription	  regulator	   2,32E-­‐05	  
TGFB1	   growth	  factor	   1,49E-­‐04	  
TP53	   transcription	  regulator	   3,76E-­‐04	  
MYF6	   transcription	  regulator	   5,47E-­‐04	  
Sry	   transcription	  regulator	   8,32E-­‐04	  
SREBF1	   transcription	  regulator	   1,04E-­‐03	  
HTT	   transcription	  regulator	   1,43E-­‐03	  
SP1	   transcription	  regulator	   1,57E-­‐03	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   transcription	  regulator	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   transcription	  regulator	   2,75E-­‐03	  
CUX1	   transcription	  regulator	   4,10E-­‐03	  
SRF	   transcription	  regulator	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   transcription	  regulator	   4,75E-­‐03	  
KMT2D	   transcription	  regulator	   4,75E-­‐03	  
EPC1	   transcription	  regulator	   4,80E-­‐03	  
KLF2	   transcription	  regulator	   4,94E-­‐03	  
BRCA1	   transcription	  regulator	   5,20E-­‐03	  
HR	   transcription	  regulator	   6,95E-­‐03	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SIM1	   transcription	  regulator	   8,36E-­‐04	  
NGF	   growth	  factor	   1,78E-­‐03	  
ARNT2	   transcription	  regulator	   3,16E-­‐03	  
miR-­‐130a	   microrna	   4,45E-­‐03	  
PAX7	   transcription	  regulator	   4,50E-­‐03	  
TAL1	   transcription	  regulator	   4,64E-­‐03	  
HDAC4	   transcription	  regulator	   5,06E-­‐03	  
CREB1	   transcription	  regulator	   6,71E-­‐03	  
NOTCH1	   transcription	  regulator	   8,55E-­‐03	  
ISL1	   transcription	  regulator	   8,75E-­‐03	  
NFKBIL1	   transcription	  regulator	   9,27E-­‐03	  
POU5F2	   transcription	  regulator	   9,27E-­‐03	  
OTP	   transcription	  regulator	   9,27E-­‐03	  
miR-­‐675-­‐5p	   mature	  microrna	   9,27E-­‐03	  
miR-­‐688-­‐3p	   mature	  microrna	   9,27E-­‐03	  
mir-­‐668	   microrna	   9,27E-­‐03	  
mir-­‐1258	   mature	  microrna	   9,27E-­‐03	  
miR-­‐1343-­‐5p	   microrna	   9,27E-­‐03	  
mir-­‐939	   microrna	   9,27E-­‐03	  
ZFP36L1	   transcription	  regulator	   9,27E-­‐03	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   6,5E00	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  Pathway	   6,2E00	  
ATM	  Signaling	   6,09E00	  
Wnt/β-­‐catenin	  Signaling	   5,84E00	  
p53	  Signaling	   5,81E00	  
ERK5	  Signaling	   5,63E00	  
Neurotrophin/TRK	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   5,26E00	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  Stem	  Cell	  Pluripotency	   5,12E00	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FLT3	  Signaling	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  Cells	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FGF	  Signaling	   3,69E00	  
PPAR	  Signaling	   3,66E00	  
ATM	  Signaling	   3,6E00	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  Cell	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  into	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Figure 2: STEM analysis identifies different expression patterns and leads to identification 
of upstream regulators and transcription factors. A) STEM analysis of significant up-regulated 
DEGs in cisplatin, IR and UV treated mES cells. B) Top-20 of predicted upstream regulators of all 
genes identified in (A). C) Percentage of predicted microRNAs and genes in the upstream regulator 
analysis identified in (B). D) STEM analysis of ‘delayed’ up-regulated genes in cisplatin, IR and UV 
treated mES cells. E) Top-20 of predicted upstream regulators of all genes identified in (D). F) Per-
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ple preparation for mRNA sequencing was performed correctly, since the 
identical RNA samples were used to analyse microRNA expression. At the 
same time this indicates that UV, IR and cisplatin treated mES cells have 
similar and rapid responses at the microRNA level. Similarly, the Pearson 
correlation plot in which we used the fold change of all DEmiRs per condi-
tion shows that time after treatment is the main determinant for microRNA 
expression (Fig. 3D). This implies that either each four hours another set 
of microRNAs is regulated in all three genotoxic stresses or the presen-
ce of one dominant microRNA signature across all three genotoxic agents. 
T o further dissect these microRNA expression changes we performed 
a STEM analysis to identify microRNA expression signatures. We identified 
a large subset of microRNAs (81% of total DEmiRs) exhibiting a single ex-
pression signature: up-regulated 4h after DNA damage that returns to basal 
levels or is down-regulated 8h and 12h after DNA damage (Fig. 3E). Thus, 
our data indicate that microRNAs act predominantly in the first hours after 
DNA damage, which verifies and strengthens our previous finding (14).
 To examine the observation that microRNAs are mainly active in the 
first hours after DNA damage on a global scale, we performed an exon-in-
tron split analysis (EISA) that measures changes in mature mRNA (exonic 
sequences) and pre-mRNA (intronic sequences) across different experi-
mental conditions to quantify transcriptional and post-transcriptional re-
gulation of gene expression (40). While the majority of sequence reads 
are mapped in exonic regions due to mRNA selection in the procedure, 
mRNA sequencing also detects some intronic reads (Fig 1C), which serve as 
a proxy for nascent transcription. Therefore, expression changes between 
treatment and control were identified separately for exonic (Δexon (treat-
ment – control)) and intronic (Δintron (treatment – control)) reads and the 
relationship between Δexon and Δintron was investigated. If a gene is re-
gulated at the transcriptional level, we expected an increase or decrease in 
both the Δexon and Δintron in the same direction, while post-transcriptional 
regulation results in a decrease or increase in Δexon, but not in Δintron, as 
transcription of this gene is not affected. Thus, the ratio of Δexon to Δintron 
can reflect whether genes are under transcriptional or post-transcriptional 
control, e.g. by microRNAs. Dividing Δexon by Δintron leads to a value in 
which 1 represents either similar expression levels between control and 
treatment or gene regulation by transcription. Values <1 indicate increased 
post-transcriptional silencing, e.g. by microRNAs, and a value >1 indicates 
decreased post-transcriptional silencing. Indeed, EISA analysis showed that 
the majority of DEGs 4h after DNA damage had a low ratio of Δexon to 
Δintron, indicating that post-transcriptional gene regulation is mainly oc-
curring 4h after DNA damage (Fig. 3G). We conclude that microRNA-con-
trolled gene expression acts mainly in the first hours after DNA damage.
centage of predicted microRNAs and genes in the upstream regulator analysis identified in (E). G + H) 
Canonical pathway analysis of the significant upstream regulators identified in (B = G) and (E = H).
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Classification of transcriptional responses after DNA damage
 We further explored which processes and pathways were altered by DNA 
damage in mES cells. DEGs that were identified using STEM analysis (Fig. 2A 
+ D) were subjected to canonical pathway analysis using IPA. In both analy-
ses pathways related to embryonic development such as the role of NANOG 
(Fig. 4A) and Oct4 (Fig. 4B) in mammalian embryonic stem cell pluripotency 
were identified. In the canonical pathway analysis related to Fig. 2A we also 
found DDR related pathways such as p53 signalling (Fig. 4A). Interestingly, 
in the canonical pathway analysis related to Fig. 2D we found pathways re-
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Figure 3: Expression patterns of microRNAs and mRNAs differ after different genotoxic 
stresses. A) Schematic representation of the bioinformatics pipeline to analyse small RNAs. B) 
Distribution of different small RNA classes analysed by microRNA sequencing. C) Principal com-
ponent analysis of differentially expressed microRNAs in all samples. D) Dendrogram of Pears-
on correlation coefficient using fold changes of all DEmiRs in each condition. E) Dominant pat-
tern in STEM analysis using all differentially expressed microRNAs. F) Exon-intron split analysis.
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lated to metabolism such as NAD biosynthesis and Uracil degradation (Fig. 
4B). Remarkably, in both analyses protein citrullination was highly significant.
 In addition we constructed enriched canonical pathway network by 
IPA for both Fig. 4A and Fig. 4B. All significant overrepresented canonical 
pathways were connected if they share at least one gene. As expected, 
we identified several well-known DDR pathways, such as the p53 pathway 
(Fig. 4C). Several pathways that are essential for stem cell self-renewal, 
pluripotency and cellular differentiation (Wnt signalling, Oct4 signalling and 
NANOG signalling) were linked to damage signalling in this network (Fig. 
4C + D), indicating that DNA damage signalling can crosstalk to stem cell 
self-renewal and pluripotency pathways. Interestingly, one pathway ap-
peared unconnected with the main DNA damage transcriptional network, 
which is protein citrullination. Protein citrullination was also identified as 
one of the significant overrepresented canonical pathways in the STEM 
analysis (Fig. 4A + B). Protein citrullination is the intra-peptide conver-
sion of arginine into the amino acid citrulline (41, 42) and is controlled 
by the peptidyl arginine deiminase (PADI) enzyme family, which consists 
of 5 genes. In the analysis of Fig. 4C PADI1, PADI2, PADI3 and PADI4 
were found, whereas in Fig. 4D PADI6 was found in protein citrullinati-
on. In summary, GO term and canonical pathway network analysis demon-
strates that cell death and terminal differentiation are the main cell fates 
induced by DNA damage in mES cells. Moreover, several, previously uni-
dentified, GO terms and canonical pathways could be linked to DNA da-
mage signalling, indicating the implication of novel processes in the DDR. 
Citrullination inhibition induces replication stress
 Protein citrullination is the intra-peptide conversion of arginine into 
the amino acid citrulline (41, 42) and is controlled by the peptidyl arginine 
deiminase (PADI) enzyme family, which consists of 5 genes. Arginine to 
citrulline conversion alters amino acid mass and acidity (arginine is stron-
gly basic, while citrulline is neutral). As a consequence the overall charge 
and charge distribution of the peptide or protein changes when arginine is 
converted into citrulline. First, we confirmed differential expression of PADI 
genes by qRT-PCR in mES cells (Supplementary Fig. 2A + B). Next, we 
analysed whether PADI gene expression induction is specific for mES cells. 
We focused on PADI4, the only member that has a known nuclear locali-
zation signal (42). We exposed U2OS cell cultures to cisplatin, IR or UV-C 
and performed qRT-PCR and immunoblot to determine mRNA and protein 
levels. We observed that PADI4 mRNA and protein levels are increased after 
DNA damage (Supplementary Fig. 2C – F), indicating that at least PADI4 
expression is increased after DNA damage in another cell type as well. 
 Since 4 out of 5 PADI genes are up-regulated in our dataset, we used 
Cl-amidine, which is a chemical inhibitor of total citrullination (43). First, 
we tested if Cl-amidine inhibits citrullination and indeed observed a reduc-
tion in citrullinated H3 expression (Supplementary Fig. 2G + H). Next we 
tested the effect of citrullination inhibition on cellular outcomes such as 
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A
C
BIngenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
Protein	  Citrullination	   5,47E00	  
Human	  Embryonic	  Stem	  Cell	  Pluripotency	   3,56E00	  
Regulation	  of	  the	  Epithelial-­‐Mesenchymal	  Transition	  Pathway	   2,9E00	  
Superpathway	  of	  Inositol	  Phosphate	  Compounds	   2,84E00	  
GP6	  Signaling	  Pathway	   2,74E00	  
PCP	  pathway	   2,73E00	  
Phospholipases	   2,69E00	  
Role	  of	  NANOG	  in	  Mammalian	  Embryonic	  Stem	  Cell	  Pluripotency	   2,53E00	  
Eicosanoid	  Signaling	   2,49E00	  
eNOS	  Signaling	   2,35E00	  
Antioxidant	  Action	  of	  Vitamin	  C	   1,88E00	  
3-­‐phosphoinositide	  Biosynthesis	   1,85E00	  
p53	  Signaling	   1,81E00	  
D-­‐myo-­‐inositol-­‐5-­‐phosphate	  Metabolism	   1,7E00	  
Endothelin-­‐1	  Signaling	   1,64E00	  
Notch	  Signaling	   1,63E00	  
Dopamine	  Receptor	  Signaling	   1,62E00	  
Wnt/β-­‐catenin	  Signaling	   1,54E00	  
Sorbitol	  Degradation	  I	   1,54E00	  
Gustation	  Pathway	   1,5E00	  
D-­‐myo-­‐inositol	  (1,4,5)-­‐Trisphosphate	  Biosynthesis	   1,37E00	  
VEGF	  Family	  Ligand-­‐Receptor	  Interactions	   1,37E00	  
Pregnenolone	  Biosynthesis	   1,34E00	  
nNOS	  Signaling	  in	  Neurons	   1,33E00	  
	  
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
Tryptophan	  Degradation	  to	  2-­‐amino-­‐3-­‐carboxymuconate	  
Semialdehyde	  
2,65E00	  
NAD	  biosynthesis	  II	  (from	  tryptophan)	   2,09E00	  
Role	  of	  Oct4	  in	  Mammalian	  Embryonic	  Stem	  Cell	  Pluripotency	   2,06E00	  
G-­‐Protein	  Coupled	  Receptor	  Signaling	   1,85E00	  
Cholecystokinin/Gastrin-­‐mediated	  Signaling	   1,85E00	  
cAMP-­‐mediated	  signaling	   1,73E00	  
Tryptophan	  Degradation	  III	  (Eukaryotic)	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Figure 4: Protein citrullination is a novel process in the DDR. A) Canonical pathway analysis of 
genes identified in Fig. 2A. All significant canonical pathways are depicted. B) Canonical pathway ana-
lysis of genes identified in Fig. 2D. All significant canonical pathways are depicted. C) Network analysis 
of significant canonical pathways (p<0.05) by IPA of overlapping DEGs identified in Fig. 2A. D) Network 
analysis of significant canonical pathways (p<0.05) by IPA of overlapping DEGs identified in Fig. 2D.
proliferation, apoptosis and cell cycle and noted reduced proliferation (Fig. 
5A). In accordance with reduced proliferation, we observed a significant 
decrease in clonogenicity by citrullination inhibition (Fig. 5B). Similar re-
sults were obtained by a siRNA against PADI4 (data not shown). Reduced 
colony forming capacity could be explained by increased apoptosis. Ho-
wever, we failed to observe increased apoptosis (Fig. 5C), indicating that 
a cell cycle arrest rather than apoptosis is involved. Insteas, we observed 
a higher proportion of cells in S-phase after citrullination inhibition. Thus, 
our data indicate that citrullination facilitates progression through S-phase. 
 Cell cycle stalling in S-phase could indicate that inhibition of citrul-
lination induces replication stress. RPA32 phosphorylation of serine 33 
(Ser33) and serine 4/8 (Ser4/Ser8) is induced by replication stress, which 
is a mark for stalled or collapsed replication forks, respectively (44, 45). 
To determine whether inhibition of citrullination affected replication stress, 
we treated cells with 4 mM hydroxyurea (HU) for 1h (enrichment for stal-
led replication forks) and 5h (enrichment for collapsed replication forks) 
in the presence or absence of inhibition of citrullination. HU exposure for 
1h already led to an increase in stalled replication forks as represented 
by phospho-Ser33 (Fig. 5E). 5h after HU exposure both stalled and col-
lapsed replication forks (represented by phospho-Ser4/8) are significant-
ly increased after citrullination inhibition. Together, these data indica-
te that protein citrullination is necessary in maintaining replication forks.
Citrullination inhibition reduces DSB repair during S-phase
 Citrullination facilitates progression through S-phase. All three geno-
toxic agents used in this study block DNA synthesis, leading to stalled and 
collapsed replication forks. Collapsed replication forks will result in DSBs 
and require DSB repair to correct the damage and replication fork restart 
to continue DNA synthesis. We determined DSB levels after inhibition of cit-
rullination by γH2AX foci formation. To discriminate between G1-phase and 
S/G2-phase cells we co-stained with geminin in which geminin-negative 
cells represent G1-phase cells, whereas geminin-positive cells represent S/
G2-phase cells (46). We observed 11-fold more γH2AX foci after citrullination 
inhibition in S/G2-phase cells (Fig. 6A; Supplementary Fig. 3A). The incre-
ase in DSBs during S-phase could be due to persistent DSBs in the G1-pha-
se that are transferred to S-phase or to poor repair of DSBs in S-phase. We 
only observed a modest 1.7 fold increase in γH2AX foci in G1-phase cells by 
citrullination inhibition, indicating that DNA repair in S-phase is not defec-
tive (Fig. 6B; Supplementary Fig. 3A). Next, we assessed DSB repair in both 
G1-phase and S/G2-phase cells by applying an additional dose of IR and 
monitoring γH2AX foci clearance in time, which is an indication of DSB repair 
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Figure 5: Inhibition of protein citrullination leads to replication stress. A) U2OS cells were 
incubated with DMSO or Cl-amidine for 48h and proliferation rate was measured for 96h. B) Co-
lony forming assay with or without Cl-amidine, colonies were fixed 8-9 days later. C) Apoptosis 
assay based on Hoechst 33342 and 7-AAD labelling 48h after citrullination inhibition. D) Cell cycle 
analysis based on BrdU and PI labelling 48h after Cl-amidine treatment in U2OS cells. E – F) Ana-
lysis and quantification of replication fork stalling or collapsed replication forks. Cl-amidine treated 
cells (48h incubation with Cl-amidine prior HU treatment) were incubated with 4 mM HU for 1h 
or 5h. WCE-based immunoblot for total RPA and phosphorylated RPA (S4/8 and S33). All experi-
ments were performed at least three times. Mean ± SEM are indicated. ** P<0.01; *** P<0.001
capacity. DSB repair in G1-phase cells was only modestly slower by citrulli-
nation inhibition (Fig. 6C). Interestingly, in S/G2-phase cells γH2AX foci were 
increased by IR and remained present up to 24h after inhibition of citrullina-
tion (Fig 6D), indicating that DSB repair in S/G2-phase cells was impaired. 
We conclude that citrullination is required for DSB repair during S/G2 phase. 
 The observation that citrullination is probably important for DSB re-
pair in S/G2-phase, likely implicates DDR activation in which DNA damage 
checkpoint kinase ATM plays a central role. Therefore, we stained for activa-
ted phosphorylated ATM (S1981) and ATM target proteins that are phospho-
rylated on SQ/TQ motifs. We observed increased numbers of phospho-ATM 
and phospho-SQ/TQ foci were present at basal levels (Fig. 6E + F; Supple-
mentary Fig. 3B). Interestingly, the general kinetics of p-ATM and p-SQ/TQ 
foci induction and clearance after IR was similar between control and citrul-
lination inhibited cells, indicating that ATM signalling itself is not affected. 
 DSBs are repaired by NHEJ in all phases of the cell cycle, while 
HR repairs DSBs only in S/G2-phase. We first analysed whether citrulli-
nation inhibition leads to NHEJ defects by monitoring 53BP1 foci forma-
tion after IR. 53BP1 in DSB foci directs DSB repair choice towards NHEJ 
(47). Both G1- and S/G2-phase cells showed only a modest increase in 
basal 53BP1 foci at un-irradiated levels by inhibition of citrullination. Af-
ter IR however, we observed increased 53BP1 foci formation directly af-
ter IR independent of cell cycle phase after citrullination inhibition and 
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normal repair kinetics (Fig. 6G + H; Supplementary Fig. 3C), indicating 
that NHEJ is not affected and might even compensate for a putative re-
pair defect of other DSB repair pathways. Indeed, a plasmid-based end-joi-
ning assay demonstrated normal and functional NHEJ (Fig. 6I) (38). 
 The increase in DSBs primarily in S/G2-phase cells suggests that HR, 
which can only repair DSBs in S/G2 when a sister chromatid is present, is 
reduced by inhibition of citrullination. We monitored foci formation of HR 
proteins BRCA1 and RAD51 at base line as well as after IR. Both BRCA1 and 
RAD51 foci were already increased in unirradiated cells after citrullination 
inhibition, which is in agreement with the elevated γH2AX foci levels (Fig. 
6J + 6K; Supplementary Fig. 3D). After IR, citrullination inhibition resulted 
only in a modestly increased number of BRCA1 foci and a slight decrease of 
BRCA1 foci in time, suggesting a mild HR defect (Fig. 6J). Although RAD51 
foci exhibited different kinetics compared to BRCA1 foci after IR, an altered 
HR response was also apparent. RAD51 foci were induced by IR, but were not 
cleared (Fig. 6K), indicating that HR is stalled at the RAD51 level. Together the 
data indicate that citrullination is important for proper HR repair of DSBs in S/
G2-phase. Insufficient HR is probably leading to collapsed replication forks. 
Discussion
 Here, we generated a time-resolved transcriptional map of the cel-
lular response to DNA damage in mES cells. These extensive RNA se-
quencing datasets will not only be a major resource to identify novel 
pathways in the DDR, but can also be used to analyse DDR-related di-
seases such as cancer or medical treatments that utilize or genera-
te DNA damage such as cancer therapy or ischemia reperfusion injury. 
Several studies have been published in which gene and/or microRNA ex-
pression profiling have been performed after DNA damage. However, each 
study uses different time points, cell types, genotoxic stresses, dosages and 
technologies to generate expression profiles (23, 48-54). Hence, compari-
sons between studies to derive specific DNA damage-induced transcriptio-
nal signatures are hampered. Our experimental design allows us to com-
pare different types of genotoxic stresses, each with their own spectrum 
of DNA lesions, in the first 12 hours of the transcriptional response to DNA 
damage. Such a design could furthermore discriminate RNA expression res-
ponses induced by DNA damage from possible side effects, since genotoxic 
agents are usually not only damaging DNA. Cisplatin can also damage pro-
teins and RNAs, IR generates oxidative stress that damages all cellular 
macromolecules and UV-C also damages RNA and lipid membranes. These 
side effects are likely to elicit additional cellular responses, including tran-
scriptional alterations. Indeed, differences between genotoxic agents are 
apparent. The general transcriptional DDR map deduced from those three 
genotoxic agents however, contains several pathways known to respond 
to DNA damage of which the P53 pathway is the best-studied example. 
 This study provides a mechanistic framework of the transcriptional 
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Figure 6: More spontaneous DSBs and reduced DNA repair in S-phase after protein citrul-
lination inhibition. A + B) γH2AX foci formation G1-phase cells (A) and S-/G2-phase U2OS cells 
(B) 48h after Cl-amidine treatment using immunofluorescent staining. At least 50 cells per experi-
ment were quantified using Image J imaging software. C + D) Kinetics of γH2AX foci formation after 
additional IR over time in G1- (C) and S-/G2-phase (D) cells 48h after Cl-amidine treatment using 
immunofluorescent staining. At least 50 cells per experiment were quantified using Image J software. 
E + F) p-ATM (S1981) (E) and p-SQ/TQ (F) foci kinetics 48 after Cl-amidine treatment and additional 
IR using immunofluorescent staining. At least 50 cells per experiment were quantified using Image 
J imaging software. G + H) Kinetics of 53BP1 foci formation after additional IR over time in G1- (G) 
and S-/G2-phase (H) cells 48h after Cl-amidine treatment using immunefluorescent staining. At least 
50 cells per experiment were quantified using Image J software. I) Plasmid-based end joining assay 
48h after Cl-amidine treatment. J + K) Kinetics of BRCA1 (J) and RAD51 (K) foci formation after ad-
ditional IR over time in S-/G2-phase cells 48h after Cl-amidine treatment using immunefluorescent 
staining. At least 50 cells per experiment were quantified using Image J software. All experiments 
were performed at least three times. Mean ± SEM are indicated. * P<0.05; ** P<0.01; *** P<0.001
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DDR in mES cells (Fig. 7). The most dominant gene expression signature that 
represents most DEGs is a linear up-regulation across time. Furthermore, 
two additional gene expression signatures were found: a gradual up regula-
tion starting from 8h onwards with a lag at 4h and a gradual down regulati-
on of genes. The high overlap between DEGs 12h after treatment compared 
to earlier time points indicates that all three types of genotoxic stress, each 
with their own characteristics and expression kinetics, culminate into a sin-
gle end point. Although gene expression changes were highly similar across 
time and different genotoxic stresses, some noticeable differences were ob-
served in which the virtual absence of DEGs 4 hours after UV-C treatment 
was most obvious. The experimental set up renders technical errors as unli-
kely. Moreover, many DEGs that were identified 4h after IR and cisplatin tre-
atment were already regulated in the same direction 4h after UV-C exposure 
(Fig. 1E), but to a much lesser extent. Finally, the identification of DEmiRs 
from the identical 4h UV-C treated samples that are overlapping with IR 
and cisplatin also argue against technical errors. Thus, we conclude that the 
transcriptional response to a dose of 4 J/m2 UV-C in mES cells is delayed. 
 The observed delayed UV-response in mES cells could be explained by 
4h 12h8h
microRNAs Transcription factors (P53, P73, P63, SP1)
mRNA
Protein citrullination
Transcription factors (NOTCH1, POU4F1)
mRNA
Time after DNA damage
Fo
ld
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Figure 7: Schematic representation of microRNA and mRNA expression pat-
terns over time after DNA damage. Gene and microRNA expression patterns af-
ter DNA damage are visualized, including upstream regulators, canonical pathways and ci-
trullination. Protein citrullination as seen by PADI gene expression is also indicated.
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DDR characteristics that are induced by UV-lesions. UV-lesions can induce 
DDR signalling by blocking DNA replication, leading to replication fork collap-
se and DDR signalling or by blocking transcription, which also poses a signal 
for DDR activation (2, 18, 55). Specialized trans-lesion DNA polymerases by-
pass damaged DNA during S-phase, which initially prevents replication fork 
arrest and DDR activation (56). In addition, nucleotide excision repair (NER) 
is the main DNA repair machinery to repair UV-lesions. NER consists of two 
sub-branches: transcription-coupled NER (TC-NER) that repairs UV-lesions 
in transcribed DNA strands and global genome NER (GG-NER), which repairs 
UV-lesions across the genome (18). Since mES cells rely more on GG-NER 
and to a lesser extent on TC-NER in combination with trans-lesion synthesis 
(24), it is conceivable that the transcriptional response elicited by TC-NER is 
delayed. Studies that have identified DEGs early after UV treatment all use 
much higher doses UV, which could accelerate the transcriptional response.
 In addition to the specific transcriptional signatures themselves, we 
identified several significantly overrepresented upstream regulators that 
were predicted to control the expression of the identified DEGs. As expected, 
the P53 pathway was identified, but also transcription factors that control 
stem cell self-renewal, pluripotency and terminal differentiation. Moreover, 
our analyses predicted that microRNAs could control numerous DEGs as 
well. Small RNA sequencing of the identical samples used for mRNA se-
quencing and subsequent analyses showed that a single dominant microR-
NA signature was induced after DNA damage in general, in which DEmiR ex-
pression is increased 4 hours after genotoxic stress treatment and returned 
to basal levels at 8 and 12 hours. This is further strengthened by microR-
NA-gene interaction analysis, demonstrating that many DEGs are under 
microRNA control in the first hours after damage. This is in agreement with 
our earlier proposed model in which microRNAs act between the fast pro-
tein post-translational modification responses and relatively slow transcrip-
tion activation/repression (14). The observed fast and transient induction 
of microRNAs themselves is likely due to post-transcriptional regulation. 
Specialized microRNA-binding proteins can bind specific primary microRNA 
transcripts from the nuclear pool and present them to the microRNA bioge-
nesis/maturation pathway. Both the DNA damage checkpoint proteins ATM 
and p53 are shown to control post-transcriptional microRNA expression via 
this mechanism (16, 57). These microRNA kinetics could have several im-
plications for the DDR. For example, microRNA expression induction likely 
contributes to the timing of gene expression and thereby the timing of or 
fine-tuning specific steps in the DDR. Moreover, these microRNAs are likely 
acting in concert with transcription factors, since several predicted upstream 
transcription factors are also target genes of these microRNAs. Thus, this 
study favours a model in which DDR-related transcription factors activate a 
general gene expression response, while microRNAs control the fine-tuning 
and timing of these events in the first hours after DNA damage exposure. 
 Finally, we also mapped significantly overrepresented pathways. In-
deed, we observed several expected pathways such as P53 signalling. Mo-
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reover, overrepresented pathways also demonstrated the various cell fates 
associated with DNA damage in mES cells. The applied equitoxic doses of 
genotoxic stresses will lead to ~50% mES cell survival in a colony survival 
assay and ~50% of mES cells that cannot form colonies due to cell de-
ath or terminal differentiation. The latter two cell fates of DNA damage in 
mES cells are well reflected in the transcriptional signature of DNA dama-
ge. The transcriptional changes induced by genotoxic stress in mES cells 
implicates several new cellular processes in the DDR such as protein cit-
rullination, the intra-peptidal conversion of arginine into citrulline by PADI 
enzymes. It has been shown that PADI4 expression is induced by P53, 
which lead to subsequent histone modifications, which opened chromatin 
structure (58-60). We provide evidence that citrullination is required for 
replication fork stability. Chemical inhibition of citrullination enhances cell 
cycle stalling in S-phase and replication fork stalling and collapse, particu-
larly for IR and cisplatin. DNA lesions induced by the used genotoxic stres-
ses will block the DNA polymerase machinery, which stalls replication and 
lead to replication fork collapse and associated DSBs. It is conceivable that 
citrullination is not needed for replication fork restart, but repair of these 
collapsed replication forks. Indeed, we observed that DNA damage-indu-
ced DSBs are poorly repaired in S and G2-phase cells after inhibition of 
protein citrullination. We show that both γH2AX and RAD51 foci are not 
resolved as well, indicating that DSBs are poorly repaired likely due to a 
homologous recombination deficiency. The exact molecular mechanism by 
which citrullination is required in the HR pathway is not known. Whether 
DSB repair by HR is attenuated or RAD51 and γH2AX foci are not properly 
cleared from the site of damage remain an open question. It is also con-
ceivable that RAD51 is not translocated from the repaired double-stranded 
DNA (dsDNA). Translocation of RAD51 from dsDNA is performed by RAD54 
and loss of RAD54 leads to an accumulation of RAD51 independent of DNA 
damage sites (61). Thus, we propose that up regulation of PADI enzymes 
after DNA damage will facilitate replication fork repair by enhancing HR.
In conclusion, we generated an extensive resource that describes the tran-
scriptional responses, pathways and upstream regulators after genotoxic 
stress exposure in mES cells. We provide a mechanistic framework of gene 
and microRNA expression in the DDR, including the identification of new 
processes.  This will not only serve as a resource for future DDR studies, 
but can also be used to analyse cancer and cancer therapy responses.
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Supplementary figure 1: Pearson correlation of all samples. Pears-
on correlation coefficient plot of all samples together based on all genes.
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Supplementary figure 2: Verification of PADI expression on mRNA and protein le-
vel. A) Heatmap constructed from gene expression levels determined after mRNA sequencing. 
B) qPCR verification of PADI mRNA expression levels in the same mES cell samples that were 
used for mRNA sequencing. C – E) PADI4 mRNA expression in U2OS cells over time after cispla-
tin, IR and UVC. F) PADI4 protein expression in U2OS cells over time after IR. G) Immunoflu-
orescent staining of citrullinated histone H3 after mock and Cl-amidine treatment. H) Quantifi-
cation of citrullinated histone H3 expression in U2OS cells after mock and Cl-amidine treatment. 
All experiments were performed at least three times. Mean ± SEM are indicated. *** P<0.001
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Supplementary figure 3: Foci formation of different DDR markers after DNA damage. Im-
munofluorescent staining of basal levels and after 1 Gy IR of γH2AX (A), p-ATM and p-SQ/TQ (B), 
53BP1 (C), BRCA1 (D) and RAD51 (E) foci after 48h Cl-amidine treatment. Images were generated 
using Image J software. A representative image out of three independent experiments is shown.
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Supplementary Table 1
Upstream	  Regulator	   Molecule	  Type	   p-­‐value	  of	  overlap	  
TP73	   transcription	  regulator	   5,14E-­‐06	  
MYOG	   transcription	  regulator	   2,32E-­‐05	  
TGFB1	   growth	  factor	   1,49E-­‐04	  
TP53	   transcription	  regulator	   3,76E-­‐04	  
MYF6	   transcription	  regulator	   5,47E-­‐04	  
Sry	   transcription	  regulator	   8,32E-­‐04	  
SREBF1	   transcription	  regulator	   1,04E-­‐03	  
HTT	   transcription	  regulator	   1,43E-­‐03	  
SP1	   transcription	  regulator	   1,57E-­‐03	  
CREBBP	   transcription	  regulator	   2,39E-­‐03	  
TAF7L	   transcription	  regulator	   2,75E-­‐03	  
CUX1	   transcription	  regulator	   4,10E-­‐03	  
SRF	   transcription	  regulator	   4,48E-­‐03	  
SMAD7	   transcription	  regulator	   4,75E-­‐03	  
KMT2D	   transcription	  regulator	   4,75E-­‐03	  
EPC1	   transcription	  regulator	   4,80E-­‐03	  
KLF2	   transcription	  regulator	   4,94E-­‐03	  
BRCA1	   transcription	  regulator	   5,20E-­‐03	  
HR	   transcription	  regulator	   6,95E-­‐03	  
mir-­‐365	   microrna	   7,85E-­‐03	  
INHA	   growth	  factor	   1,05E-­‐02	  
SOX15	   transcription	  regulator	   1,16E-­‐02	  
JUN	   transcription	  regulator	   1,16E-­‐02	  
PRDM1	   transcription	  regulator	   1,23E-­‐02	  
FOSL2	   transcription	  regulator	   1,32E-­‐02	  
NOTCH1	   transcription	  regulator	   1,34E-­‐02	  
BCL6	   transcription	  regulator	   1,63E-­‐02	  
CDX1	   transcription	  regulator	   1,68E-­‐02	  
SIM2	   transcription	  regulator	   1,89E-­‐02	  
EED	   transcription	  regulator	   1,95E-­‐02	  
NGF	   growth	  factor	   1,95E-­‐02	  
BDNF	   growth	  factor	   2,02E-­‐02	  
SIM1	   transcription	  regulator	   2,06E-­‐02	  
PLAG1	   transcription	  regulator	   2,10E-­‐02	  
PAX2	   transcription	  regulator	   2,16E-­‐02	  
MYOD1	   transcription	  regulator	   2,17E-­‐02	  
RUNX2	   transcription	  regulator	   2,21E-­‐02	  
GATA2	   transcription	  regulator	   2,25E-­‐02	  
SP3	   transcription	  regulator	   2,27E-­‐02	  
NKX2-­‐3	   transcription	  regulator	   2,50E-­‐02	  
USF1	   transcription	  regulator	   2,52E-­‐02	  
HMGB1	   transcription	  regulator	   2,52E-­‐02	  
EP300	   transcription	  regulator	   2,62E-­‐02	  
FGF3	   growth	  factor	   2,62E-­‐02	  
MNX1	   transcription	  regulator	   2,62E-­‐02	  
NLRC5	   transcription	  regulator	   2,76E-­‐02	  
Chapter 4
102
4
Supplementary Table 1 - continuation
TCFL5	   transcription	  regulator	   2,89E-­‐02	  
MEF2B	   transcription	  regulator	   2,89E-­‐02	  
EAF1	   transcription	  regulator	   2,89E-­‐02	  
EID1	   transcription	  regulator	   2,89E-­‐02	  
TP63	   transcription	  regulator	   2,96E-­‐02	  
NFYA	   transcription	  regulator	   3,12E-­‐02	  
NODAL	   growth	  factor	   3,44E-­‐02	  
CRX	   transcription	  regulator	   3,44E-­‐02	  
MKL2	   transcription	  regulator	   3,46E-­‐02	  
TGFB3	   growth	  factor	   3,55E-­‐02	  
NKX2-­‐1	   transcription	  regulator	   3,66E-­‐02	  
EGF	   growth	  factor	   3,67E-­‐02	  
ARNT2	   transcription	  regulator	   3,74E-­‐02	  
KLF11	   transcription	  regulator	   3,76E-­‐02	  
MYF5	   transcription	  regulator	   3,85E-­‐02	  
POU4F1	   transcription	  regulator	   4,03E-­‐02	  
IRF8	   transcription	  regulator	   4,23E-­‐02	  
mir-­‐193	   microrna	   4,60E-­‐02	  
ZFHX3	   transcription	  regulator	   4,60E-­‐02	  
FOXC2	   transcription	  regulator	   4,93E-­‐02	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Supplementary Table 2
Upstream	  Regulator	   Molecule	  Type	   p-­‐value	  of	  overlap	  
SIM1	   transcription	  regulator	   8,36E-­‐04	  
NGF	   growth	  factor	   1,78E-­‐03	  
ARNT2	   transcription	  regulator	   3,16E-­‐03	  
miR-­‐130a-­‐3p	  	   mature	  microrna	   4,45E-­‐03	  
PAX7	   transcription	  regulator	   4,50E-­‐03	  
TAL1	   transcription	  regulator	   4,64E-­‐03	  
HDAC4	   transcription	  regulator	   5,06E-­‐03	  
CREB1	   transcription	  regulator	   6,71E-­‐03	  
NOTCH1	   transcription	  regulator	   8,55E-­‐03	  
ISL1	   transcription	  regulator	   8,75E-­‐03	  
NFKBIL1	   transcription	  regulator	   9,27E-­‐03	  
POU5F2	   transcription	  regulator	   9,27E-­‐03	  
OTP	   transcription	  regulator	   9,27E-­‐03	  
miR-­‐675-­‐5p	  	   mature	  microrna	   9,27E-­‐03	  
miR-­‐668-­‐3p	  	   mature	  microrna	   9,27E-­‐03	  
mir-­‐668	   microrna	   9,27E-­‐03	  
miR-­‐1258	  	   mature	  microrna	   9,27E-­‐03	  
mir-­‐1258	   microrna	   9,27E-­‐03	  
miR-­‐1343-­‐5p	  	   mature	  microrna	   9,27E-­‐03	  
mir-­‐939	   microrna	   9,27E-­‐03	  
ZFP36L1	   transcription	  regulator	   9,27E-­‐03	  
LHX9	   transcription	  regulator	   9,27E-­‐03	  
DMRT1	   transcription	  regulator	   1,27E-­‐02	  
TLX3	   transcription	  regulator	   1,32E-­‐02	  
MNT	   transcription	  regulator	   1,32E-­‐02	  
SRF	   transcription	  regulator	   1,36E-­‐02	  
GFI1	   transcription	  regulator	   1,36E-­‐02	  
TWIST1	   transcription	  regulator	   1,45E-­‐02	  
ETV1	   transcription	  regulator	   1,45E-­‐02	  
GATA3	   transcription	  regulator	   1,46E-­‐02	  
FIGLA	   transcription	  regulator	   1,59E-­‐02	  
SRA1	   transcription	  regulator	   1,60E-­‐02	  
ADNP	   transcription	  regulator	   1,84E-­‐02	  
ASH2L	   transcription	  regulator	   1,84E-­‐02	  
STAG2	   transcription	  regulator	   1,84E-­‐02	  
CREB5	   transcription	  regulator	   1,84E-­‐02	  
UHRF1	   transcription	  regulator	   1,84E-­‐02	  
WDR77	   transcription	  regulator	   1,90E-­‐02	  
POU4F1	   transcription	  regulator	   1,93E-­‐02	  
FGF2	   growth	  factor	   2,03E-­‐02	  
TLX1	   transcription	  regulator	   2,23E-­‐02	  
NODAL	   growth	  factor	   2,23E-­‐02	  
NTF3	   growth	  factor	   2,23E-­‐02	  
FOXL2	   transcription	  regulator	   2,25E-­‐02	  
CBX5	   transcription	  regulator	   2,36E-­‐02	  
VAV1	   transcription	  regulator	   2,40E-­‐02	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Supplementary Table 2 - continuation
RELB	   transcription	  regulator	   2,43E-­‐02	  
ATOH1	   transcription	  regulator	   2,58E-­‐02	  
miR-­‐199a-­‐5p	  	   mature	  microrna	   2,73E-­‐02	  
LHX5	   transcription	  regulator	   2,75E-­‐02	  
LHX8	   transcription	  regulator	   2,75E-­‐02	  
miR-­‐125b-­‐1-­‐3p	  	   mature	  microrna	   2,75E-­‐02	  
mir-­‐132	   microrna	   2,76E-­‐02	  
POU5F1	   transcription	  regulator	   2,91E-­‐02	  
NEUROG3	   transcription	  regulator	   2,93E-­‐02	  
CITED2	   transcription	  regulator	   3,33E-­‐02	  
ASCC1	   transcription	  regulator	   3,66E-­‐02	  
IRF2BP2	   transcription	  regulator	   3,66E-­‐02	  
SIX4	   transcription	  regulator	   3,66E-­‐02	  
CTNNB1	   transcription	  regulator	   3,71E-­‐02	  
MSX2	   transcription	  regulator	   4,16E-­‐02	  
FOSB	   transcription	  regulator	   4,16E-­‐02	  
FOXN4	   transcription	  regulator	   4,55E-­‐02	  
SSBP2	   transcription	  regulator	   4,55E-­‐02	  
TRIM27	   transcription	  regulator	   4,55E-­‐02	  
ZIC1	   transcription	  regulator	   4,55E-­‐02	  
SOX18	   transcription	  regulator	   4,55E-­‐02	  
MYOCD	   transcription	  regulator	   4,58E-­‐02	  
STAT5A	   transcription	  regulator	   4,80E-­‐02	  
EP300	   transcription	  regulator	   4,81E-­‐02	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Supplementary Table 3
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
TGF-­‐β	  Signaling	   1,1E01	  
p38	  MAPK	  Signaling	   7,01E00	  
Aryl	  Hydrocarbon	  Receptor	  Signaling	   6,5E00	  
Sumoylation	  Pathway	   6,2E00	  
ATM	  Signaling	   6,09E00	  
Wnt/β-­‐catenin	  Signaling	   5,84E00	  
p53	  Signaling	   5,81E00	  
ERK5	  Signaling	   5,63E00	  
Neurotrophin/TRK	  Signaling	   5,26E00	  
Human	  Embryonic	  Stem	  Cell	  Pluripotency	   5,12E00	  
Corticotropin	  Releasing	  Hormone	  Signaling	   4,49E00	  
RAR	  Activation	   4,43E00	  
Regulation	  of	  the	  Epithelial-­‐Mesenchymal	  Transition	  Pathway	   4,41E00	  
BMP	  signaling	  pathway	   4	  
VDR/RXR	  Activation	   3,87E00	  
Prolactin	  Signaling	   3,78E00	  
Inhibition	  of	  Angiogenesis	  by	  TSP1	   3,74E00	  
PEDF	  Signaling	   3,7E00	  
PPARα/RXRα	  Activation	   3,57E00	  
HIF1α	  Signaling	   3,24E00	  
Cell	  Cycle:	  G2/M	  DNA	  Damage	  Checkpoint	  Regulation	   3,23E00	  
NGF	  Signaling	   3,18E00	  
Glucocorticoid	  Receptor	  Signaling	   3,17E00	  
Estrogen	  Receptor	  Signaling	   3,09E00	  
HMGB1	  Signaling	   3,07E00	  
Adipogenesis	  pathway	   3,02E00	  
Granzyme	  A	  Signaling	   2,95E00	  
GNRH	  Signaling	   2,93E00	  
Cell	  Cycle:	  G1/S	  Checkpoint	  Regulation	   2,91E00	  
EGF	  Signaling	   2,81E00	  
GADD45	  Signaling	   2,74E00	  
DNA	  damage-­‐induced	  14-­‐3-­‐3σ	  Signaling	   2,74E00	  
Sirtuin	  Signaling	  Pathway	   2,69E00	  
Cyclins	  and	  Cell	  Cycle	  Regulation	   2,66E00	  
Calcium	  Signaling	   2,6E00	  
NF-­‐κB	  Signaling	   2,57E00	  
FGF	  Signaling	   2,45E00	  
PPAR	  Signaling	   2,43E00	  
Circadian	  Rhythm	  Signaling	   2,26E00	  
Androgen	  Signaling	   2,25E00	  
Telomerase	  Signaling	   2,25E00	  
UVC-­‐Induced	  MAPK	  Signaling	   2,04E00	  
iNOS	  Signaling	   2,02E00	  
P2Y	  Purigenic	  Receptor	  Signaling	  Pathway	   2	  
Role	  of	  Oct4	  in	  Mammalian	  Embryonic	  Stem	  Cell	  Pluripotency	   2	  
Activation	  of	  IRF	  by	  Cytosolic	  Pattern	  Recognition	  Receptors	   1,88E00	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Supplementary Table 3 - continuation
Transcriptional	  Regulatory	  Network	  in	  Embryonic	  Stem	  Cells	   1,88E00	  
Role	  of	  CHK	  Proteins	  in	  Cell	  Cycle	  Checkpoint	  Control	   1,83E00	  
Tight	  Junction	  Signaling	   1,77E00	  
Wnt/Ca+	  pathway	   1,72E00	  
Ephrin	  Receptor	  Signaling	   1,7E00	  
UVB-­‐Induced	  MAPK	  Signaling	   1,7E00	  
IL-­‐10	  Signaling	   1,68E00	  
Lymphotoxin	  β	  Receptor	  Signaling	   1,68E00	  
ErbB2-­‐ErbB3	  Signaling	   1,66E00	  
NRF2-­‐mediated	  Oxidative	  Stress	  Response	   1,63E00	  
ILK	  Signaling	   1,6E00	  
Gap	  Junction	  Signaling	   1,59E00	  
ERK/MAPK	  Signaling	   1,57E00	  
Role	  of	  BRCA1	  in	  DNA	  Damage	  Response	   1,53E00	  
Macropinocytosis	  Signaling	   1,53E00	  
LPS-­‐stimulated	  MAPK	  Signaling	   1,48E00	  
FLT3	  Signaling	  in	  Hematopoietic	  Progenitor	  Cells	   1,47E00	  
HER-­‐2	  Signaling	  in	  Breast	  Cancer	   1,47E00	  
PDGF	  Signaling	   1,44E00	  
IL-­‐7	  Signaling	  Pathway	   1,44E00	  
Protein	  Kinase	  A	  Signaling	   1,42E00	  
Phospholipase	  C	  Signaling	   1,41E00	  
TR/RXR	  Activation	   1,4E00	  
ErbB	  Signaling	   1,39E00	  
CDK5	  Signaling	   1,38E00	  
SAPK/JNK	  Signaling	   1,35E00	  
DNA	  Double-­‐Strand	  Break	  Repair	  by	  Homologous	  Recombination	   1,34E00	  
IGF-­‐1	  Signaling	   1,33E00	  
UVA-­‐Induced	  MAPK	  Signaling	   1,32E00	  
Mouse	  Embryonic	  Stem	  Cell	  Pluripotency	   1,31E00	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Supplementary Table 4
Ingenuity	  Canonical	  Pathways	   -­‐log(p-­‐value)	  
Neurotrophin/TRK	  Signaling	   5,36E00	  
Human	  Embryonic	  Stem	  Cell	  Pluripotency	   5,24E00	  
ERK5	  Signaling	   4,29E00	  
Circadian	  Rhythm	  Signaling	   3,8E00	  
FLT3	  Signaling	  in	  Hematopoietic	  Progenitor	  Cells	   3,79E00	  
FGF	  Signaling	   3,69E00	  
PPAR	  Signaling	   3,66E00	  
ATM	  Signaling	   3,6E00	  
RAR	  Activation	   3,5E00	  
Embryonic	  Stem	  Cell	  Differentiation	  into	  Cardiac	  Lineages	   3,35E00	  
p38	  MAPK	  Signaling	   3,33E00	  
NGF	  Signaling	   3,26E00	  
Transcriptional	  Regulatory	  Network	  in	  Embryonic	  Stem	  Cells	   3,21E00	  
Wnt/Ca+	  pathway	   2,97E00	  
Wnt/β-­‐catenin	  Signaling	   2,69E00	  
Calcium	  Signaling	   2,68E00	  
ILK	  Signaling	   2,52E00	  
Regulation	  of	  the	  Epithelial-­‐Mesenchymal	  Transition	  Pathway	   2,52E00	  
ERK/MAPK	  Signaling	   2,48E00	  
Gαs	  Signaling	   2,32E00	  
Corticotropin	  Releasing	  Hormone	  Signaling	   2,29E00	  
Phospholipase	  C	  Signaling	   2,25E00	  
P2Y	  Purigenic	  Receptor	  Signaling	  Pathway	   2,06E00	  
Role	  of	  Oct4	  in	  Mammalian	  Embryonic	  Stem	  Cell	  Pluripotency	   2,04E00	  
GNRH	  Signaling	   2,01E00	  
Ephrin	  Receptor	  Signaling	   1,76E00	  
NF-­‐κB	  Signaling	   1,75E00	  
Glucocorticoid	  Receptor	  Signaling	   1,73E00	  
Lymphotoxin	  β	  Receptor	  Signaling	   1,73E00	  
CREB	  Signaling	  in	  Neurons	   1,68E00	  
Ephrin	  B	  Signaling	   1,65E00	  
Growth	  Hormone	  Signaling	   1,56E00	  
Prolactin	  Signaling	   1,55E00	  
LPS-­‐stimulated	  MAPK	  Signaling	   1,52E00	  
TGF-­‐β	  Signaling	   1,52E00	  
AMPK	  Signaling	   1,52E00	  
PEDF	  Signaling	   1,51E00	  
cAMP-­‐mediated	  signaling	   1,49E00	  
Protein	  Kinase	  A	  Signaling	   1,49E00	  
CDK5	  Signaling	   1,42E00	  
Mouse	  Embryonic	  Stem	  Cell	  Pluripotency	   1,35E00	  
p53	  Signaling	   1,34E00	  
Granzyme	  A	  Signaling	   1,33E00	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Abstract
 RNA binding proteins are causally implicated in many cellular proces-
ses and control RNA expression, stability and function. It is becoming clear 
that RNA and RNA binding proteins are an essential element of the DNA 
damage response. One of those proteins is KHSRP, which is phosphoryla-
ted by ATM that leads to the specific processing of microRNAs. The specific 
functions and implications of KHSRP in the DNA damage response are not 
well known. Here, we show that siRNA-mediated silencing of KHSRP does 
not affect DNA damage signalling outcomes such as cell cycle arrest and 
apoptosis, but reduces DSB repair by homologous recombination. KHSRP 
knockdown has no effect on general DNA repair kinetics, but specifical-
ly diminishes HR function by affecting the accumulation kinetics of RPA, 
BRCA1 and RAD51 in the early time points after DNA damage. Based on 
these results we hypothesize that KHSRP interacts with BRCA1, thereby 
promoting HR via displacement of RPA and loading of RAD51 on the break. 
Introduction
 RNA binding proteins (RBPs) are a large family of proteins that bind 
RNA, each with different degrees of sequence-specificity and affinity, and 
target RNA species (1, 2). RBPs are classified according to their RNA-binding 
domain and perform their function in either the nucleus or the cytoplasm. In 
the nucleus, RBPs control transcription, pre-mRNA splicing and polyadenyla-
tion (2-7).  In the cytoplasm, RBPs regulate processes such as transport, 
translation, RNA modification, RNA localization and RNA turnover (2, 8-12). It 
is becoming apparent that RBPs play pivotal roles in many cellular processes.
 Proteome-wide and RNAi screens have implicated RBPs in the res-
ponse to DNA damage (13-15). To counteract the harmful consequen-
ces of DNA damage, cells have various DNA repair systems and elabo-
rate DNA damage checkpoint pathways that halt cell proliferation and 
if DNA damage is too extensive, activate apoptotic or senescent pro-
grams (16-19). The combined response to DNA damage is designated 
the DNA damage response (DDR). Several RBPs are directly phosphory-
lated by DNA damage checkpoint kinases ATR/ATM or CHK1/CHK2 (14, 
15, 20). Interestingly, known DDR proteins such as KU70, KU80, DNA-
PK, 53BP1 and BRCA1 were identified as novel RBPs themselves (21). 
 A plethora of RBP functions in the DDR have been described. For 
example, RNAse H1/2 is required to prevent harmful R-loop formation 
(22). RBPs control the expression of DDR genes p53, p21 and RhoB via 
promotion of mRNA translation by HuR after DNA damage (23-25). Ano-
ther RBP, EWS, mediates alternative splicing of DDR genes CHK2 and 
MDM2 after DNA damage by dissociating from the transcribed RNA (26). 
In addition, RBPs are also directly involved in DNA repair (1). PSF is an 
RBP that binds to DNA, RAD51D and TOPBP1 thereby affecting DSB re-
pair via non-homologous end joining (NHEJ) and homologous recom-
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bination (HR) (27, 28). Furthermore, hnRNPUL directly interacts with 
the double strand DNA break (DSB) recognition complex MRN, there-
by promoting end resection and subsequent DSB repair via HR (29).
 One of the RBPs identified in DNA damage-induced phosphoprote-
omic screens is the KH-type splicing regulatory protein (KHSRP or KSRP, 
also known as FBP2 or FUBP2). It is characterized by four KH-domains 
and has multiple functions in RNA biogenesis, including mRNA decay and 
promotion of pre-microRNA maturation (13). Several studies link KHS-
RP to the DDR (13, 30-32). It was shown that BRCA1 negatively regu-
lates KHSRP, although it was not linked to its DNA repair function (31). 
In addition, ATM directly phosphorylates KHSRP after DNA damage, which 
resulted in KHSRP-dependent microRNA processing of specific microR-
NAs (30). Another described function of KHSRP in the DDR is cell cycle 
progression control downstream of the p38/MK2 kinase complex (32). 
 Currently, KHSRP has been implicated in the DDR, but its exact role 
is not clear. We analyzed KHSRP function in the DDR and provide eviden-
ce that KHSRP is involved in proper functioning of HR after DNA damage. 
Materials & Methods
Cell culture and transfection
U2OS cells were cultured in DMEM supplemented with penicillin-strep-
tomycin (100× diluted, Penicillin-Streptomycin, P0781-100ML, Sig-
ma-Aldrich) and 10 % fetal bovine serum (Fetal Bovine Serum (FBS) 
South America, S1810-500, Biowest) at 5% CO2 and 37°C. Single siR-
NA transfections were performed using Lipofectamine RNAiMax (56532, 
Invitrogen) according to manufacturer’s instructions. Experiments were 
carried out 48h after transfection. Non-targeting siRNA #5 (D-001210-
05-50, Dharmacon) and SMARTpool: ON-TARGETplus KHSRP siRNA (L-
009490-00-0020, Dharmacon) were used to carry out transfections.
Clonogenic cell survival assay
After siRNA treatment cells were trypsinised (Trypsin-EDTA solution, 
T3924-500ML, Sigma-Aldrich) and counted (Z2 Coulterparticle count and 
size analyzer, Beckman Coulter). 500 cells per well in triplicates per con-
dition were seeded in 6-well plates. The next day, cells were irradiated by 
ionizing radiation (IR) (Gammacell 40 Cesium 137 irradiation unit, Ato-
mic Energy). Cells were incubated 8-9 days and afterwards washed once 
with PBS, then stained with 0.1% Coomassie Brilliant Blue (50% (v/v) 
Methanol, 43% (v/v) H2O, 7% (v/v) Acetic Acid, 0.1% (m/v) Coomassie 
Brilliant Blue). Colonies were counted using Gelcount (Oxford Optronix).
Primary antibodies
53BP1 (1000×, sc-22760, Santa Cruz Biotechnology); BRCA1 (50×, sc-6954, 
Santa Cruz Biotechnology); BrdU Kit (50×, 556028, BD Sciences); CHK2 
(500×, #3440, Cell Signaling); p-CHK2 (500×, #2197, Cell Signaling); Ge-
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minin (400×, 10802-1-AP, Proteintech); γH2AX (Ser139) (1000×, 05-636, 
Millipore); KHSRP (1000×, ab140648, Abcam); RAD51 (5000×, Home made); 
p53 (1000×, sc-126, Santa Cruz Biotechnology); RAD51 (200×, GTX70230, 
GeneTex); RPA34 (500×, NA18, Calbiochem); Tubulin (2000×, sc-12462-R, 
Santa Cruz Biotechnology); Tubulin (5000×, T5168, Sigma-Aldrich).
Secondary antibodies
Goat-α-mouse Alexa 488 (1000×, A11034, Life Technologies); Goat-
α-Rabbit Alexa 555 (1000×, A21429, Life Technologies); Donkey-α-
mouse IRDye 800CW (5000×, 926-32212, LI-COR Biosciences); Don-
key-α-rabbit IRDye 680RD (5000×, 926-32223, LI-COR Biosciences).
Immunofluorescence
After siRNA treatment U2OS cells were seeded on coverslips. The cells were 
irradiated with 5 Gy and fixed 1, 2, 4, 8, and 24h after IR. Briefly, the co-
verslips were washed once with PBS, fixed with 2% PFA, washed with PBS 
+ 0.1% triton X-100 3× short and 2× 10 minutes, once washed with PBS+ 
(100 ml PBS + 0.5 g BSA + 0.15 g Glycine), incubated 1-2h at RT with 
primary antibodies. After incubation coverslips were washed with PBS + 
0.1% triton X-100 3× short and 2× 10 minutes, once washed with PBS+, 
incubated 1-2h at RT with secondary antibodies. After incubation coverslips 
were washed with PBS + 0.1% triton X-100 3× short and 2× 10’, once 
washed with PBS+. For RAD51 staining (commercial antibody) the cover-
slips were washed once with PBS, fixed with 4% PFA. Subsequently, cells 
were permeabilised for 20’ with PBS + 0.2% triton X-100 and washed with 
PBS. After permeabilization cells were treated with 10× diluted DNAse I 
(04536282001, Roche Life Sciences) for 1h at 37°C in a humidified cham-
ber and washed with PBS. Blocking was performed using IFF buffer (PBS + 
1% BSA + 2% FCS) for at least 30’. After blocking cells were incubated with 
primary antibodies for 1-2h at RT. After incubation coverslips were washed 
3× for 5’ with PBS and incubated with secondary antibodies 1-2h at RT. Af-
ter incubation coverslips were washed 3× for 5’ with PBS. Coverslips were 
mounted in DAPI Vectashield mounting medium (H1200, Vector Laborato-
ries). Images were made using a LSM700 microscope (Carl Zeiss Microima-
ging Inc.). Analysis of the images was performed using the ImageJ software. 
Alpha track assay
The Alpha track assay was performed as previously described (33). In brief, 
cells were transfected with siRNA and seeded on mylar dishes 24h after 
transfection. 48h after transfection, dishes were radiated three times for 
30’’ with 241americium source. Cells were washed once with ice-cold PBS. 
Extraction was performed with cold CSK buffer (10 mM HEPES-KOH, pH7.9; 
100 mM NaCl; 300 mM sucrose; 3 mM MgCl2; 1 mM EGTA; 0.5% (v/v) tri-
ton-X100) and cold CSS buffer (10 mM Tris-HCl, pH7.4; 10 mM NaCl; 3 mM 
MgCl2; 1% (v/v) tween-20; 0.5% (w/v) sodium deoxycholate) for 5’ each. 
After extraction cells were fixed in 4% PFA in PBS for 20’ at RT and stain-
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ed according to the protocol for immunofluorescence as described above. 
Immunoblot assay
Cells were lysed in 2× sample buffer and boiled at 99°C for 5 minutes. 
Samples were run on a SDS-PAGE gel and transferred to a PVDF mem-
brane (Immobilon FL PVDF Transfer membrane 0.45um, IPFL00010, Mil-
lipore). Membranes were blocked in 5% milk in PBS for 1-2h at RT. After 
blocking, membranes were incubated with primary antibodies 1-2h at RT. 
Then the membranes were washed 5 times for 5 minutes with PBS + 0.05% 
Tween-20 and incubated with secondary antibodies at RT for 1-2h. Again 
the membranes were washed 5× for 5 minutes. Membranes were visua-
lized using Odyssey CLx Infrared Imaging System (LI-COR Biosciences).
BrdU and PI labelling for cell cycle analysis
Cells were labelled with 5 μM BrdU (B5002, Sigma-Aldrich) for 15 minutes at 
37°C. Subsequently, cells were harvested and fixed in 70% ethanol at least 
overnight at 4°C. Fixed cells were washed with ice-cold PBS and re-sus-
pended in pepsin solution (5 mg pepsin in 10 ml 0.1N HCl) and incubated 
20 minutes at RT. After pepsin-treatment blocking solution (PBS + 0.5% 
Tween-20 + 0.1% BSA) was added and cells were washed. Next, cell were 
re-suspended in 2N HCl for 12 minutes at 37°C. To neutralise, borate buf-
fer (100 mM, pH8.5) was added and the cells were pelleted. BrdU antibody 
was added and the cells were incubated for 2h on ice in the dark. Stained 
cells were washed in blocking solution and re-suspended in 500 μl PBS 
supplemented with 12.5 μl RNase A and 1 μl PI (P3566, Invitrogen). Cell 
cycle was analysed the next day using BD LSRFortessa (BD Biosciences). 
Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
Apoptosis assay
Apoptotic cells were analysed according to the protocol published by Smid 
et al. (34). In brief, medium and cells were collected and re-suspended 
in 998 μl FACS buffer (0.5% BSA + 0.05% NaN3 in PBS) pre-heated to 
37°C. 1 μl diluted Hoechst 33342 (10 mg/ml, H3570, Life Technologies) 
was added and the cells were vortexed and incubated for exactly 7 minu-
tes at 37°C. Subsequently, the cells were immediately placed on ice and 
1 μl 7-AAD (1 mg/ml, A1310, Invitrogen) was added. Cells were analy-
sed within 1h after adding 7-AAD using BD LSRFortessa (BD Biosciences). 
Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
Homologous recombination reporter assay
The homologous recombination reporter assay was performed as described 
previously (35). In brief, 48h after transfection of U2OS cells with an I-Sce res-
triction site were transfected using X-tremeGENE HP DNA Transfection Reagent 
(06366244001, Roche Life Sciences) with I-Sce-GFP plasmid. 48h after trans-
fection GFP positive cells were analysed using BD LSRFortessa (BD Bioscien-
ces). Flow Cytometry data was analysed using FlowJo vX.0.7 (Tree Star Inc.).
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End joining assay
The end-joining assay was performed as described in (36), with some minor 
changes. In short, cells were grown in a 3-cm dish to 50-80% confluency. 
Cells were transiently transfected with 2 µg of a blunt-ended linear DNA 
substrate (EcoRV/Eco47III digested pDvG94 plasmid (36)), using X-treme 
GENE HP DNA Transfection Reagent (Sigma Aldrich), following manufac-
turers protocol. Two days after transfection, extrachromosomal DNA was 
isolated and resuspended in a final volume of 20 µl water (37). From this 
solution, 1 µl was PCR amplified with the DAR5 and FM30 primers (36), 
using PuReTaq ready-To-Go PCR beads (GE Healthcare). The PCR product 
was digested with BstXI. Restriction fragments were separated on a 6% 
polyacrylamide gel in TBE buffer, stained with ethidium bromide. The rela-
tive level of microhomology-directed end-joining was determined by quan-
tification of the BstXI digested PCR product using the ImageJ software.
Statistical analysis
Data was processed using GraphPad Prism v5.0a (GraphPad Software 
Inc.). Statistical test used were Student’s T-test and Mann-Whitney 
U test. P-values equal or lower than 0.05 were accepted as significant.
Results
KHSRP is not essential for maintaining cell cycle and apoptosis
 In literature the role of KHSRP in the DDR is described to some extend 
(REF 13, 30-32), but more information on how KHSRP exactly functions in 
the DDR is unknown. Therefore, in order to determine the role of KHSRP in 
the DDR, we first analysed KHSRP expression on protein and mRNA level 
using immunofluorescence, qRT-PCR and western blot. KHSRP is mainly ex-
pressed in the nucleus of U2OS cells in a speckled pattern with different in-
tensities per nucleus (Fig. 1A). IR resulted in increased KHSRP mRNA levels 
24h after damage (Fig. 1B) and a gradual increase in protein levels (Fig. 
1C), indicating that DNA damage induces KHSRP mRNA and protein levels. 
 Next, we analysed standard cellular outcomes of DDR. First, we op-
timized KHSRP knockdown (Fig. 1D) and assessed cell cycle distribution. 
KHSRP silencing did not affect cell cycle distribution compared to control 
cells (Fig. 1E), indicating that KHSRP does not control cell cycle status. We 
also monitored whether KHSRP silencing altered the apoptotic response. 
We saw a very modest, but non-significant, increase in apoptosis (Fig. 
1F). Finally, we assessed whether KHSRP affects cell survival after DNA 
damage. A colony survival assay after IR indicated that KHSRP silencing 
by siRNAs did not alter sensitivity (Fig. 1G). In addition, colony survival 
after cisplatin or UV-C treatment was also not affected (data not shown). 
Thus, KHSRP silencing does not alter cell fates induced by DNA damage. 
The DNA damage response is activated in the absence of KHSRP 
 An important signalling molecule in the DDR is the phosphatidyl ino-
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Figure 1: KHSRP knockdown does not affect cellular processes. A) Expression pattern of KHSRP 
in U2OS cells was determined using immunofluorescence. B) mRNA expression of KHSRP at different 
time points after 5 Gy of IR. qPCR was used to determine mRNA levels, n = 3 and mean with SEM are 
given. C) Western blot was used to determine protein expression of KHSRP at different time points 
after 5 Gy IR. A representative of 3 independent experiments is shown. D) Western blot for KHSRP af-
ter siKHSRP treatment. E) Cell cycle analysis after siKHSRP treatment. Cells were pulse labelled with 
BrdU and then stained for BrdU and with PI. Expression analysis was performed using flow cytome-
try, n = 3 and mean with SEM are depicted. F) Apoptotic cells were stained with Hoechst 33342 and 
7-AAD after siKHSRP treatment. n = 3, mean and SEM are depicted. G) Colony survival was perfor-
med seeding 500 cells in triplicates per condition. Than cells were treated with IR in different dosages 
and colonies were fixed 8-9 days later. The graphs are representatives of 3 independent experiments.
sitol 3-kinase like serine/threonine kinase ATM, which phosphorylates tar-
get proteins on SQ/TQ motifs (38, 39). KHSRP was identified as a direct 
phosphorylation target of ATM (30), which resulted in the enhanced ma-
turation of specific microRNAs. We analyzed ATM activity by monitoring 
phosphorylation of ATM (S1981) and its target protein phosphorylation on 
SQ/TQ motifs before and after IR. Before IR, KHSRP depletion resulted 
in an induction of phosphorylated ATM foci (Fig. 2B). After IR, we obser-
ved a 3-fold increase of phosphorylated ATM foci in the absence of KHS-
RP (Fig. 2A + B), indicating that ATM is more active in the absence of 
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KHSRP. However, we observed a much smaller increase of SQ/TQ phosp-
horylation (Fig. 2A + C) or phosphorylation of ATM target protein CHK2 
(Fig. 2D). This indicates that KHSRP restricts ATM phosphorylation after 
IR, but does not alter ATM-dependent phosphorylation of target proteins. 
 Since ATM is activated by DSBs and an induction of phosphoryla-
ted ATM foci were observed already before irradiation, we analyzed γH2AX 
foci, which marks DSBs. Indeed, a modest, but significant 1.6 fold in-
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Figure 2: Activation of the DDR after KHSRP knockdown. A) Representative immunofluorescen-
ce images of siControl or siKHSRP treated U2OS cells stained with DAPI and for p-ATM (S1981) and 
p-SQ/TQ at t=0 and 1h after 5 Gy. Magnification 63× for left panel, the right panels are enlarged using 
ImageJ analysis software. B + C) Foci kinetics of p-ATM (S1981) and p-SQ/TQ over time after 5 Gy. 
The graph shows foci kinetics over time after 5 Gy. At least 50 cells were quantified per time point per 
experiment. The experiment was repeated three times. D) Western blot analysis of p53 and CHK2 at 1h 
after 1 and 5 Gy IR. A representative of 3 experiments is given. E) Absolute numbers of γH2AX foci per 
cell in non-radiated conditions were determined using ImageJ analysis software. F) Average number 
of γH2AX foci per cell was determined using ImageJ software. The graph shows foci kinetics over time 
after 5 Gy. At least 50 cells were quantified per time point per experiment. The experiment was repe-
ated three times. G) Representative immunofluorescence images at 0 G and 1h after 5 Gy of siControl 
or siKHSRP treated U2OS cells stained with DAPI and for γH2AX. Magnification 63× for left panel, the 
right panels are enlarged using ImageJ analysis software. Mean and SEM are depicted, Mann-Whit-
ney U test was performed to determine statistical significance. * p<0.05; ** p<0.01; *** p<0.001.
duction of γH2AX foci was observed after KHSRP depletion (Fig. 2E + G). 
Next, we analysed DSB repair kinetics by following clearance of γH2AX 
foci after IR. We observed a slightly reduced induction of γH2AX foci 1h 
after IR and a slightly reduced clearance of γH2AX foci (Fig. 2F + G). Sin-
ce γH2AX foci clearance kinetics are similar between control and KHSRP 
depleted cells, the overall DSB repair capacity is only modestly altered. 
KHSRP does not affect NHEJ, but is required for HR
 DSBs are repaired by non-homologous end joining (NHEJ) or homologous 
recombination (HR) (17). Since we observed a slight increase in γH2AX and 
phospho-ATM foci, we assessed both HR and NHEJ function via plasmid-ba-
sed assays. Interestingly, HR capacity after KHSRP depletion was markedly 
reduced (Fig. 3A), whereas NHEJ capacity was not altered (Fig. 3B). Next, 
we monitored 53BP1 foci formation, which direct DSB repair pathway choice 
towards NHEJ (40). Although at baseline more 53BP1 foci are present in the 
absence of KHSRP (Fig. 3C + D), 53BP1 foci kinetics after IR was not different 
between control and KHSRP depleted cells, suggesting normal functional NHEJ. 
KHSRP depletion results in HR phenotype.
 Next, we further dissected the apparent HR phenotype as obser-
ved in Fig. 3A. First, we monitored foci formation of essential HR proteins 
BRCA1 and RAD51. Since HR only takes place in the S- and G2-phase of 
the cell cycle when a sister chromatid is present, we co-stained for Gemi-
nin. Geminin is a cell cycle marker and is only expressed in the S/G2-phase 
(41). Interestingly, both the BRCA1 and RAD51 focus formation inducti-
on after IR was blunted in the absence of KHSRP (Fig. 4A – D), but is at 
control levels 24h after IR. These observations suggest a defect in HR.
 The reduced induction of BRCA1 by KHSRP silencing suggests that BRCA1 
loading on resected DNA ends is impaired. The replication protein A complex 
(RPA) covers single strand overhangs of the DSB, which is displaced by the 
BRCA1-PALB2-BRCA2 complex that leads to assembly of RAD51 nucleopro-
tein filaments (42-44). A defect in BRCA1 recruitment will lead to increased 
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numbers of RPA-coated DSBs, which can be monitored by the α-track assay 
(33). 53BP1 staining was used to locate DSB tracks (Supplementary Fig. 1A). 
In the absence of KHSRP, an increase in RPA+ 53BP1+ α-tracks were obser-
ved at DSB tracks (Fig. 4F), suggesting that KHSRP is involved in removal of 
RPA from the single strand overhangs of DSBs or efficient loading of BRCA1. 
HR phenotype in the absence of KHSRP is not due to inhibition of microR-
NA biogenesis
 KHSRP has several described functions, but microRNA maturation af-
ter DNA damage is the most prominently studied role in the DDR (30, 31, 
45). We assessed whether the observed HR phenotype by KHSRP depletion 
was induced by its microRNA biogenesis function. We transfected U2OS 
cells with a siRNA that targets DGCR8, one of the master regulators of mi-
croRNA biogenesis. DGCR8 inhibition inhibits microRNA biogenesis (46). 
First, the effect of DGCR8 knockdown was measured by qRT-PCR of three 
mature microRNAs (miR-30e, Let-7c and miR-26a), which resulted in a re-
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Figure 3: KHSRP is not involved in NHEJ, but is needed for HR. A) HR reporter assay was per-
formed as described in materials and methods. GFP signal induction is depicted relative to its own 
mock-transfected control. NHEJ assay was performed as described in the materials and methods. B) 
A representative image of 3 experiments is shown. The arrows indicate the size of the circular plasmid 
(top arrow with circle) and the digested plasmid (bottom arrow with incomplete circle). C) Average 
number of 53BP1 foci per cell at different time points after 5 Gy IR were counted using ImageJ analysis 
software. At least 50 cells were quantified per time point per experiment. The experiment was repe-
ated three times. D) Representative immunofluorescence images of non-irradiated and 1h after 5 Gy 
U2OS cells treated with siControl or siKHSRP and stained with DAPI and for 53BP1. For left panel mag-
nification is 63×, the right panels are enlarged using ImageJ analysis software. N = 3, mean and SEM 
are depicted, Mann-Whitney U test was performed to determine statistical significance, ** p<0.01.
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Figure 4: KHSRP knockdown affect HR-related proteins. A) Representative immunofluores-
cence images of non-irradiated and 1h after 5 Gy siControl or siKHSRP treated U2OS cells stained 
with DAPI and for BRCA1 (green) and geminin (red). Magnification 63× for left panel, the right pa-
nels are enlarged using ImageJ analysis software. B) Representative immunofluorescence images of 
non-irradiated and 1h after 5 Gy siControl or siKHSRP treated U2OS cells stained with DAPI and for 
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RAD51 (green) and geminin (red). Magnification 63× for left panel, the right panels are enlarged 
using ImageJ analysis software. C) Average number of BRCA1 foci per geminin positive cell were 
determined using ImageJ analysis software. Foci numbers were determined at different time points 
after 5 Gy IR. At least 50 cells were quantified per time point per experiment. The experiment was 
repeated three times. D) Average number of RAD51 foci per geminin positive cell were determined 
using ImageJ analysis software. Foci numbers were determined at different time points after 5 Gy 
IR. At least 50 cells were quantified per time point per experiment. The experiment was repeated 
three times. E) Quantification of 53BP1 and RPA positive tracks. N = 3, mean and SEM are depicted, 
Mann-Whitney U test was performed to determine statistical significance, * p<0.05; ** p<0.01.a
duction in mature microRNAs (Supp. Fig. 1B). Then, we analysed BRCA1 
and RAD51 foci formation 1h after 5 Gy IR, a time point in which we ob-
served the largest differences, and observed normal foci induction (Supple-
mentary Fig. 1C + D). In addition, HR function was also not affected in the 
absence of DGCR8 (Supplementary Fig. 1E), suggesting that the defect in 
HR by KHSRP depletion is independent of its microRNA biogenesis function. 
Discussion
 Here, we showed that KHSRP depletion resulted in increased activation 
of ATM and reduced HR as seen by blunted RAD51 and BRCA1 focus formation 
after IR. Interestingly, RPA coating of resected ends of DSBs was increased, 
which suggests that KHSRP is involved in proper displacement of RPA from 
the single strand overhangs or facilitates BRCA1 loading onto these single 
strand overhangs that also does not displace RPA. We propose a model in 
which KHSRP acts in during RPA displacement and BRCA1 loading (Fig. 5). 
 A commonly used assay to measure HR is the DR-GFP assay, which 
was used in this manuscript (35, 40). However, this assay is prone to arte-
facts and therefore other assays to measure HR should be performed, for 
instance the sister chromatin exchange assay (SCE assay) (40). Nevert-
heless, we can still speculate on how KHSRP is involved in HR. After DSB 
recognition by PARP, the MRN complex is recruited to and binds to DSBs 
and facilitated DSB repair by HR (47). Then, the MRN complex recruits 
CtIP, which together with exonucleases EXO1, BLM and DNA2 results in end 
resection (48, 49). RPA coats the single strand overhangs to stabilize sin-
gle strand DNA (50, 51). In the next step, RPA is displaced from the break 
by the BRCA1-BRCA2-PALB2 complex (42-44), which subsequently promo-
tes RAD51 filament formation. Therefore, it is conceivable that a defect in 
BRCA1 loading or a defect in RPA displacement from single strand over-
hangs by KHSRP depletion leads to reduced RAD51 foci formation as well. 
Although we did not study the role CtIP, BRCA2 and PALB2 after KHSRP 
depletion, it is conceivable that their recruitment to DSBs is also reduced. 
 It is currently not clear how KHSRP interacts with the HR machi-
nery. We performed a search in the Biogrid and Genemania databases, 
which list all known protein-protein interactions from literature and pro-
teome-wide screens (52, 53). Both databases did not predict a direct in-
teraction between BRCA1 and KHSRP, RAD51 and KHSRP, or KHSRP any 
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other HR factor. In some cases, an intermediary interaction was found, 
which is a common protein to which KHSRP and a HR protein both can 
bind (data not shown). It is conceivable that a direct interaction between 
BRCA1 and KHSRP is not yet identified or does not exist. Both BRCA1 and 
KHSRP can bind RNA species. BRCA1 was found to bind several types of 
RNA (21, 54, 55). After DNA damage, DDSR1, a long non-coding RNA 
(lncRNA), interacts with BRCA1 and the RBP hnRNPUL1, which preven-
ts unwanted DNA binding by BRCA1 and as a consequence fine-tunes HR 
(54). Furthermore, hnRNPUL1/2 associates with the MRN complex there-
by stimulating end resection, signalling and DNA repair via HR (29). The-
se data imply that KHSRP and BRCA1 could interact via a RNA compo-
nent, similarly as observed for the polycomb repressor complex 2 (56). 
 In conclusion, we have established a role for KHSRP in res-
tricting ATM activation and HR, in which KHSRP facilitates RPA dis-
placement or BRCA1 loading onto single strand overhangs. Futu-
re experiments should further dissect the role of KHSRP in the DDR. 
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Figure 5: Model. KHSRP promotes RPA displacement and/or BRCA1 loading followed by RAD51 
filament formation. DSBs are detected by the MRN complex and recruits CtIP. CtIP EXO1, DNA2 and 
BLM for end resection and RPA to coat single strand overhangs. The BRCA1 –PALB2 – BRCA2 com-
plex displaces RPA, promoting strand evasion and subsequent repair, via forming RAD51 filaments.
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Supplementary Figure 1: The effect on HR by KHSRP silencing is not regulated by mi-
croRNAs. A) A representative image of U2OS cells treated with 241americium source. Magnification 
of lest panel is 63×, right panels are enlarged using ImageJ analysis software. 53BP1 was used to 
locate DSB tracks (in between white arrow heads in red), next the track was scored for RPA stai-
ning (in between white arrow heads in green). The effect of DGCR8 knockdown was determined 
by qPCR of miR-30e, Let-7C and miR-26a. Mean and standard deviation are depicted. B + C) Im-
munofluorescence of BRCA1 (B) and RAD51 (C) was used to determine absolute number of foci per 
geminin positive cell. At least 50 cells were quantified per time point per experiment. N = 3, mean 
and SEM are depicted, Mann-Whitney U test was performed to determine statistical significance, 
*** p<0.001. D) HR reporter assay after DGCR8 knockdown. N = 3, mean and SEM are depicted.
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Discussion
 DNA damage can be deleterious to a cell if not properly repaired. 
Therefore an intricate network of DNA repair mechanisms and signalling 
pathways are present, which are called the DNA damage response (DDR). 
The DDR regulates different outcomes after DNA damage such as cell cy-
cle arrest, apoptosis or senescence. When not properly repaired, DNA da-
mage on its own can contribute to ageing or cancer development (1, 2). 
 Recently, the perspective on cancer changed from a one-dimensio-
nal disease to a disease that has a complex nature with a dynamic range 
of subtypes. However, all cancer types have common characteristics (3, 4) 
Chapter 1), which are currently exploited as treatment targets for cancer 
therapy. One characteristic most cancers have in common is genome insta-
bility caused by dysfunctional DNA repair machinery. Conventional cancer 
treatments, such as radiotherapy and chemotherapy, primarily target the 
DNA directly or the DNA repair machinery thereby killing the cancer cells. 
Although these types of treatments can be very effective, therapy resistan-
ce often occurs. Two types of resistance can be distinguished, intrinsic and 
acquired resistance. Intrinsic resistance is already present prior to treat-
ment, whereas acquired resistance develops during the course of treat-
ment (5). Since radiotherapy (RT) is a widely used treatment option, it is 
essential to understand the underlying mechanism of therapy resistance in 
order to overcome it. Several papers have already addressed the issue of 
acquired resistance (Chapter 1), however in each paper a different radia-
tion protocol was used to generate RT resistant cell lines and are therefo-
re difficult to compare with clinical cases. Therefore, this thesis describes 
the role of the DDR in acquired radiotherapy resistance induced by a clini-
cally relevant treatment protocol using ionizing radiation (IR) (6) and the 
differential regulation of double strand break (DSB) repair induced by IR. 
 The main conclusions from this thesis can be summarized as fol-
lows: Chapter 2 shows that long term DNA damage leads to adaptati-
on of the DDR and subsequent RT resistance. Acquired resistance cannot 
solely be attributed to one component only; often multiple processes are 
involved. That is why in Chapter 3 we used next generation sequencing 
to identify novel processes involved in acquired RT resistance. Indeed, 
we identified DDR pathways to be regulated in RT resistance. Interes-
tingly, alterations in energy metabolism also contributed to RT resistance 
in our model. IR causes a spectrum of DNA damage of which DSBs are 
the most lethal to the cell (7). Chapter 4 describes differences in tran-
scriptional responses after different genotoxic treatments in embryonic 
stem cells. Based on these results we were able to identify citrullination 
as a post-translational modification important for proper DSB repair by 
homologous recombination (HR) in cancer cells. Interestingly, in Chap-
ter 5 we implicate the RNA binding protein (RBP) KHSRP in HR after IR. 
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DSB repair and post-transcriptional regulation
 DSB repair is a tightly regulated process, which requires the involve-
ment of numerous proteins and post-translational modifications (PTM). In 
Chapter 5 we have identified a novel regulator in DSB repair and specifical-
ly in HR. Alternatively, DNA repair is not only regulated at the post-transla-
tional level, but also at the post-transcriptional level. Several mechanisms 
regulate RNA expression after DNA damage, of which microRNAs are well 
known. Another type of RNA regulation after DNA damage is by RNA bin-
ding proteins (RPBs) (reviewed in (8)). RBPs can, independently from their 
RNA-binding properties, regulate DSB repair by directly binding to core DSB 
recognition proteins (9), suggesting additional regulatory functions of these 
proteins in the DDR. Therefore in Chapter 5, we selected KHSRP, a RBP im-
plicated in the DDR, to investigate its role in DSB repair after IR and found 
that KHSRP regulates HR. It was already shown that DDR proteins could also 
act as RBPs themselves and thereby regulate the DNA damage response 
(8, 10, 11); prominent examples are Ku70/80, BRCA1 and 53BP1 (12-15). 
 The DDR proteins that were identified as RBPs often bind long non-co-
ding RNAs (lncRNA), which are also known to regulate genome organization 
by chromatin organization, modification and remodelling (16). Modifications 
of chromatin are important for DNA damage recognition and subsequent 
repair (17). Interestingly, histone modifiers important for DDR function, 
such as PRC2, Tip60 and KDM4D were also identified as RNA binding pro-
teins (18, 19). The exact mechanism by which the interaction of chroma-
tin modifiers and lncRNAs can regulate the DDR remains speculative, but 
one could argue that they are probably involved in chromatin remodelling; 
transcription silencing and DNA repair upon DNA damage (20). How KHS-
RP regulates HR is still unclear, but based on the above discussed roles 
of RBPs in DSB repair we can hypothesize that KHSRP may regulate HR 
by direct binding of HR proteins, however this hypothesis is unlikely since 
KHSRP is not recruited into DNA damage foci. A more feasible hypothesis is 
interaction of KHSRP with HR-related proteins or binding of KHSRP to RNAs 
involved in HR, thereby regulating chromatin condensation or transcription. 
DSB repair and post-translational modifications
 
 As mentioned previously, histone modifiers with important functions 
in the DDR were also identified as RBPs. Still their main function is to mo-
dify histones in response to DNA damage and thereby regulate DNA repair 
(17, 21, 22). The most well known PTMs upon DNA damage are phosp-
horylation, ubiquitylation, methylation and acetylation (23). A prominent 
example of a histone modification is the ATM-dependent phosphorylation 
of H2AX (γH2AX) upon DNA damage (24), which leads to recruitment of 
MDC1 to the DSB site (25). Subsequently, γH2AX spreads hundreds of kilo 
bases away from the break in an ATM-dependent manner (26). Further-
more, MDC1 recruits ubiquitin ligases RNF8 and RNF168, which ubiquity-
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late H2A and γH2AX and as a result 53BP1 and BRCA1 are recruited (27). 
Dependent on cell cycle stage at which the DSB occurred and other chro-
matin modifications, either non-homologous end joining (NHEJ) or HR ta-
kes place to repair the break. The major determinant is the recruitment 
of 53BP1 and the BRCA1-CtIP complex (28). Recently, it was shown that 
specific (chromatin) modifications are important in determining which type 
of DSB repair takes place (29-31). ASF1a, which is known as a histone 
chaperone of the H3-H4 heterodimers to promote nucleosome assembly 
after DNA repair (32), was shown to have a direct role in NHEJ (29). It 
was shown that ASF1a interacts with MDC1 and promotes its phosphoryla-
tion by ATM. Then MDC1 is able to recruit RNF8-RNF168, which ubiquity-
lates H2A and H2AX and facilitates recruitment of 53BP1 and BRCA1-RAP80 
(instead of BRCA1-CtIP) favouring NHEJ at the expense of HR. The data 
presented in this paper shows that, like RBPs, proteins with designated 
functions related to the DDR can also have direct, additional novel functi-
ons in DNA repair. Therefore we analysed the RNA response after DNA da-
mage, but also to identify novel functions of proteins involved in the DDR. 
 In Chapter 4 we show that citrullination is an important PTM in the 
regulation of HR and inhibition leads to defective HR in cancer cells. Inte-
restingly, autoantibodies against citrullinated proteins (ACPAs) have been 
implicated in the pathogenesis of rheumatoid arthritis (33). Furthermore, 
increased or decreased citrullination of proteins were shown to enhance or 
inhibit cancer development or progression via various mechanisms (34-37), 
indicating an important role for citrullination in different disease patholo-
gies. However, the role of citrullination in the DDR remains elusive. So far a 
few reports have been published linking one of the citrullination enzymes, 
PADI4, to p53 and HDAC2 in response to doxorubicin treatment (38-40). 
Whether these effects are due to the histone modifying enzyme activity of 
PADI4 or because of citrullination of non-histone targets is not known. Ho-
wever, we could speculate, based on published results by others, that citrul-
lination of non-histone targets can lead to the observed effects. For instance 
it was shown that the DNA methyltransferase DNMT3a is a target of PADI4 
and citrullination of DNMT3a is important for maintenance of p21 promo-
ter methylation (41). Previously we mentioned that increased citrullination 
is often found in cancer as well as hypermethylation of specific promoters 
(42). In part, the hypermethylation patterns observed in cancer cells could 
be explained by overexpression of PADI4 and thereby increased expression 
and stabilization of DNMT3a leading to hypermethylation of specific promo-
ters (41). In concert with the observed interaction of PADI4 with DNMT3a, 
PADI4 was also found to interact with histone deacetylase 2 (HDAC2) (39). 
Histone citrullination depended on the interaction of HDAC2 with PADI4; con-
versely acetylation of HDAC2 target protein p21 did not depend on PADI4. 
How HDAC2 influences PADI4 functioning is not known, but we could hypo-
thesize that HDAC2 deacetylates PADI4, which is then not able to citrullina-
te its target histones or proteins and thereby reduces repair via HR. In line 
with this hypothesis are our findings in Chapter 4 that citrullination inhibi-
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tion does not affect NHEJ and it was shown that HDAC2 promotes NHEJ by 
deacetylating histone 3 lysine 56 and histone 4 lysine 16 specifically (43). 
Regulation of DSB repair and mitochondrial metabolism upon DNA 
damage
 
 A central finding in this thesis is the involvement of mitochondrial 
energy metabolism in response to DNA damage and acquired RT resistan-
ce (Chapter 3; Chapter 4). In Chapter 2 we show that alterations in the 
DDR also contributed to acquired RT resistance, one of the effects we ob-
served was stalling of RT resistant cells (RR cells) in G2- and M-phase of the 
cell cycle. Transition from G2-phase to M-phase is promoted by the cyclin 
B1/CDK1 complex, which was also found to relocate to the mitochondria 
during G2/M transition and thereby to increase oxygen consumption rates 
(OCR) and ATP production to provide sufficient energy for G2/M transition 
(44, 45). Interestingly, upon DNA damage by IR CDK1 also re-localized to 
the mitochondria and increased OCR and ATP production to favour DNA 
repair by HR and cell survival (46). A possible mechanism by which the 
cyclin B1/CDK1 complex regulates mitochondrial energy production is via 
SIRT3 (47). Upon exposure to IR, SIRT3 is up regulated and re-localizes 
together with cyclin B1/CDK1 to the mitochondria, where it is phosphory-
lated by cyclin B1/CDK1. Subsequently, SIRT3 phosphorylation increased 
and deactetylation of mitochondrial proteins; leading to lower ROS levels 
and increased ATP production, promoting cell survival instead of apoptosis 
after IR (47). Results presented in Chapter 2 and Chapter 3 provide a ba-
sis for this phenomenon in RR cells, as they have increased OCR and seem 
to require increased amounts of ATP to recover from the DNA damage. 
 PTMs often require intermediates from metabolic pathways, such 
as acetyl-CoA for acetylation, as discussed later on (see DSB repair and 
post-translational modifications). Under normal conditions the metabolic in-
termediates remain constant, however after DNA damage the demand for 
intermediates is increased and as a consequence these intermediates need 
to be replenished to maintain homeostasis of mitochondrial metabolism, 
which is called anaplerosis (48). Although we did not observe increased 
acetyl-CoA or citrate concentrations in RR cells in Chapter 3, it does not 
rule out the possibility that other metabolic intermediates are involved.
 
Mitochondrial regulation of post-translational modifications
 As mentioned earlier Tip60 is an important chromatin modifier in 
the DDR. Tip60 is an acetyltransferase and upon a DSB it is recruited to 
the site of damage where it acetylates histones H2A, H4 and DDR pro-
teins such as ATM and p53 (49). As a consequence of H4 acetylation, the 
chromatin decondensates and is more accessible for DNA repair factors 
(50). Acetyl-CoA is the main donor for lysine-acetyl transferases, such 
as Tip60, and is present in both the cytosol and nucleus. In the nucleus 
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acetyl-CoA is produced by ATP-citrate lyase (ACLY) from citrate, which is 
produced in the tri-carboxylic acid cycle (TCA cycle) in the mitochondria. 
A recent study shows that ACLY-dependent histone acetylation by Tip60 
is an important determinant for HR in the S- and G2-phase of the cell 
cycle and prevention of acetylation leads to DSB repair via NHEJ (30). 
 Another example of how local metabolite production can contribute 
to DSB repair is shown by the TCA cycle enzyme fumarase (FH) (31). Upon 
exposure to IR FH is phosphorylated by DNA-pK and as a consequence FH 
binds H2A.Z and increases local production of fumarate from maltate. Sub-
sequently, fumarate inhibited the de-methylation of H3 lysine 36 by KDM2, 
which is an important histone modification in NHEJ. This promotes DSB re-
pair by NHEJ without affecting HR, indicating that this specific histone met-
hylation mark is essential for NHEJ primarily in the G1-phase of the cell cycle.
 All together these aforementioned examples show a complex wiring 
of DSB repair upon DNA damage. It also shows the importance of local 
metabolite production, which are normally produced in the mitochondria, 
to ensure substrate availability for histone modification enzymes. Interes-
tingly, the results presented in Chapter 2 and Chapter 3 show both invol-
vement of the DDR and mitochondrial respiration in the development of IR 
resistance, which leaves room for speculation about how these two path-
ways interact and how they together regulate modifications of histones and 
DDR proteins in IR resistance. Furthermore, it would be of interest to iden-
tify other non-histone targets of citrullination and to determine if the effect 
seen on HR is mainly due to histone citrullination or due to citrullination of 
for instance DDR proteins and how citrullination can contribute to acquired 
RT resistance. For RBPs it was already shown that they associate with can-
cer development and resistance to chemotherapy and radiotherapy (51-54). 
Future perspective
 
 Our findings, together with findings from others (55-62), have esta-
blished a role for the DDR and energy metabolism in RT resistance (Chap-
ter 2 and 3). However, the outcome of these studies is different, which 
suggest that characterization of individual tumours before and during treat-
ment can help predict whether or not a tumour will respond to RT and if the 
regimen should be adjusted. This highlights the importance of personalized 
medicine, which was also emphasized by studies on the effectiveness of tre-
atment on ex vivo breast cancer tumour slices (63, 64). A better understan-
ding of the DDR can contribute to gaining greater insight on the role of the 
DDR in acquired resistance. In Chapter 4 we used a NGS to identify novel 
players in the DDR and in Chapter 5 we show that KHSRP is also involved 
in HR. The major advantage of our genomic approach is the identification 
of many different RNA species in one run without prior selection (65). This 
allowed us to follow, unbiased, the total change in the RNA landscape over 
time after DNA damage and identify novel genes in the DDR (Chapter 4). 
This approach is also interesting to use when it comes to identifying factors 
General discussion
133
6
involved in acquired resistance. Using biopsies taken prior to and during RT 
treatment the RNA response can be monitored, and based on the results, 
RT treatment can be adjusted when necessary. Since RBP regulation direct-
ly affects RNA biogenesis in general and has a profound effect on DSB repair 
either via HR (Chapter 5) or NHEJ (51) in different tumour types, it is not 
only interesting to monitor the RNA response itself during RT treatment, 
but also the activity of related RBPs in the tumour that could be of interest. 
Overall, the regulation of DSB repair at different levels and by different 
PTMs as discussed above, show which different pathways that are con-
sidered to function as separate entities are actually tightly intertwin-
ed. Therefore, it is important for different fields of research to work to-
gether instead of focussing solely on their specific topic. In this way 
it might be possible in the future to find a cure for all cancer patients.
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Summary
 It is estimated that the incidence of cancer will increase from 13 mil-
lion to 22 million new cases each year worldwide. Cancer development is 
driven by changes in the DNA sequence such as mutations and chromo-
somal rearrangements, which occur as a consequence of DNA damage. To 
prevent cancer development it is important for the cell to counteract DNA 
damage. Thus, upon DNA damage the cell activates an adequate cellular 
response, which is called the DNA damage response (DDR). This response 
prevents cells from passing on faults in the DNA code, which, if kept, may 
turn into cancer cells. The DDR repairs the DNA using different repair me-
chanisms and DNA damage checkpoint activation, which result in different 
cellular outcomes such as cell death, temporary or permanent cell cycle 
arrest. As most, if not all cancer cells have one or more defects in the 
DDR, the higher sensitivity of cancer cells to DNA damage may be used 
to treat the cancer.  Cancer therapy, such as chemotherapy or radiothe-
rapy (RT), induces additional DNA damage that is very effective in cancer 
treatment. Although radiotherapy is a frequently used and effective tre-
atment option, development of radiotherapy resistance occurs regularly. 
 Two types of therapy resistance can be distinguished I) intrin-
sic resistance, in which the resistance is already present before treat-
ment and II) acquired resistance whereby the resistance is acquired 
in the course of treatment. Acquired resistance leads to recurrent and/
or metastasized tumours (tumours that have spread into other places in 
the body), which reduce the life expectancy of the patient. Currently, li-
mited data is available on the role of the DDR in acquired RT resistan-
ce. Therefore, we explored the role of the DDR in acquired RT resistance 
and the regulation of downstream processes in normal and cancer cells.
 In Chapter 2 and 3 we analysed the role of the DDR in acquired RT 
resistance in cancer cells and identified novel processes associated with ac-
quired resistance. We generated radio-resistant cancer cells (RR cells) using 
a clinically relevant treatment protocol. RR cells were sensitised to RT after 
a ‘RT holiday’, at which RR cells were cultured for a period of time after fina-
lizing the RT treatment (time re-sensitized RR cells). In Chapter 2, the DDR 
in RR cells was altered due to increased checkpoint activation and slower 
DNA repair. Interestingly, inhibition of checkpoint activation concomitantly 
with DNA repair sensitised RR cells to additional RT. Overall we show that the 
DDR in RR cells is altered and possibly contributes to the resistant phenotype.
 To identify novel processes that are associated with acquired RT re-
sistance we determined overall mRNA expression levels in RR cells and 
time re-sensitised RR cells in Chapter 3. As expected, we confirmed that 
the DDR is altered during RT resistance. Interestingly, energy metabolism 
was regulated during RT resistance in all populations tested. Verification 
of the mRNA data in RR cells indeed showed increased energy production 
by the mitochondria. Furthermore, forcing RT sensitive cancer cells to pro-
duce energy by the mitochondria induced resistance to RT. In conclusion, 
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using mRNA sequencing and verification with experiments we showed that 
energy metabolism is increased and contributes to acquired RT resistance.
 To clarify the role of the DDR in acquired RT resistance, it is impor-
tant to understand the factors in the DDR in healthy cells. In Chapter 4 we 
studied the DDR at different time points after introduction of DNA damage 
with different types of DNA damaging agents. DNA damage was induced 
by either ionizing radiation (IR), ultraviolet light (UV) or the chemothera-
peutic drug cisplatin. After treatment with these agents we analysed the 
overall RNA expression levels after 4, 8 and 12 hours of treatment. We 
observed a clear difference in mRNA and microRNA expression. MicroRNAs 
are small (± 22 nucleotides) non-coding RNAs that regulate gene expres-
sion by binding the target mRNA, thereby inducing mRNA degradation or 
translation inhibition. The mRNA response to DNA damage showed a clear 
DNA damage-dependent response, whereas the microRNAs showed a clear 
time-based distribution. The data indicate that mRNA and microRNA ex-
pression is tightly regulated upon DNA damage. Furthermore, we identified 
a novel modification, citrullination, in the DDR, especially in DNA repair. In 
summary, we made a transcriptional database with mRNA and microRNAs, 
which are regulated after different types of DNA damages. Additionally, 
citrullination was identified as a novel modification involved in the DDR.
 As was shown in Chapter 3 and 4, the RNA response is pivotal to DDR 
functioning. Not only gene regulation by RNAs, but also RNA regulation itself 
is important. RNA binding proteins (RBPs) regulate RNA biogenesis and these 
proteins were also found to be involved in the DDR. Therefore, in Chapter 5 
we focussed on the role of a specific RBP, KH-Type Splicing Regulatory Protein 
(KHSRP), in the DDR after IR. We found that KHSRP is an important protein 
involved in DNA damage repair after IR as without KHSRP DNA repair after 
IR is less functional. These observed effects were independent from KHSRPs 
function in microRNA biogenesis. In conclusion, we show a novel function 
of KHSRP in the DDR independent from its function in microRNA biogenesis.
In general, an elaborate knowledge of the DDR after IR is essential to un-
derstand the complicated nature of acquired RT resistance and the invol-
vement of the DDR in cancer. This knowledge can then be used to deve-
lop novel targeted therapies to overcome acquired RT resistance in cancer. 
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Samenvatting
 In de toekomst zal het aantal nieuwe gevallen van kanker wereldwijd 
per jaar toenemen tot 22 miljoen. Veranderingen in de nucleotidevolgor-
de van het DNA door bijvoorbeeld mutaties of veranderingen in het gehe-
le chromosoom kunnen lijden tot kankerontwikkeling. Deze veranderingen 
treden op als gevolg van DNA-schade. Om kankerontwikkeling te voorko-
men moet de cel DNA-schade tegengaan. Daarom activeert de cel in geval 
van DNA-schade de DNA-schaderesponse (DSR). Deze response voorkomt 
dat cellen fouten in de DNA-volgorde doorgeven aan de volgende generatie, 
welke, als ze niet gerepareerd worden, kunnen leiden tot de ontwikkeling 
van kankercellen. Door het gebruik van verschillende reparatiemechanis-
men en activatie van het DNA-schade checkpoint, wordt het DNA gerepa-
reerd via de DSR. Dit heeft verschillende gevolgen voor de cel, zoals cel-
dood of een tijdelijke of permanente stop van de celcyclus. De meeste, zo 
niet alle kankercellen hebben één of meerdere defecten in de DSR. Hierdoor 
hebben deze cellen een hogere gevoeligheid voor DNA-schade en kan deze 
hogere gevoeligheid worden gebruikt om kanker te behandelen. Kanker-
therapie, zoals chemotherapie of bestraling, is zeer effectief omdat ze extra 
DNA-schade veroorzaken. Hoewel bestraling zeer effectief is en vaak als be-
handelmethode wordt gebruikt, komt resistentie tegen bestraling vaak voor.
 Twee typen therapieresistentie kunnen worden onderscheiden: I) in-
trinsieke resistentie, waarbij de resistentie voor de behandeling op voor-
hand al aanwezig is en II) verkregen resistentie, waarbij de resistentie 
tijdens de behandeling optreedt. Verkregen resistentie leidt vaak tot te-
rugkeer of uitzaaiingen van de tumor, waardoor de levensverwachting van 
de patiënt daalt. Op dit moment is er beperkt data beschikbaar over de 
rol van de DSR in verkregen resistentie. Daarom onderzoeken wij in dit 
proefschrift wat de rol van de DSR in verkregen resistentie is en hoe de 
regulatie van de processen in de DSR verloopt in normale en kankercellen.
 In Hoofdstuk 2 en 3 hebben we de rol van de DSR in verkregen resis-
tentie in kankercellen onderzocht. Hierbij hebben we nieuwe processen ont-
dekt die betrokken zijn bij de ontwikkeling van verkregen resistentie. Door 
het gebruik van een klinisch relevant bestralingsprotocol hebben we bestra-
lingsresistente cellen (BR-cellen) gegenereerd. Door BR-cellen een ‘bestra-
lingsvakantie’ te geven waarbij BR-cellen voor een bepaalde periode niet 
bestraald werden na de laatste bestralingsdosis, werden deze cellen weer 
gevoelig voor bestraling. In Hoofdstuk 2 hebben we ontdekt dat de DSR 
veranderd is als gevolg van toegenomen checkpointactivatie en langzamer 
DNA-herstel. Interessant genoeg leidde remming van zowel checkpointac-
tivatie als DNA-herstel tot gevoeligheid van BR-cellen voor extra bestraling. 
Alles bij elkaar genomen laten we zien dat de DSR in BR-cellen veranderd 
is en mogelijk bijdraagt aan de ontwikkeling van verkregen resistentie.
 Om nieuwe processen te identificeren die mogelijk bijdragen 
aan de ontwikkeling van bestralingsresistentie, hebben we in Hoofd-
stuk 3 totale mRNA-expressieniveaus bepaald in BR-cellen en BR-cel-
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len die een ‘bestralingsvakantie’ gehad hebben. Zoals verwacht laten de 
data zien dat de DSR veranderd tijdens bestralingsresistentie. Een inte-
ressante bevinding is de betrokkenheid van het energiemetabolisme 
bij bestralingsresistentie in alle geteste samples. Verificatie van de data 
laat inderdaad zien dat de energieproductie door de mitochondriën ver-
hoogd is. Daarnaast, door bestralingsgevoelige kankercellen te dwingen 
energie te produceren door de mitochondriën, werden ze resistent voor 
bestraling. Alles samenvattend laten we zien dat het gebruik van mRNA 
sequencing en de daarop volgende verificatie van de data met experi-
menten het energiemetabolisme associëren met verkregen resistentie.
    Om de rol van de DSR in verkregen resistentie te verduidelijken, 
is het belangrijk om te begrijpen hoe de DSR werkt in gezonde cellen. 
Daarom hebben we in Hoofdstuk 4 de DSR bestudeerd op verschillen-
de tijdspunten na de introductie van DNA-schade door verschillende DNA 
beschadigende middelen. DNA-schade werd geïnduceerd door ioniserende 
straling, ultraviolet licht of het chemotherapeuticum cisplatine. Na behan-
deling met deze middelen hebben we de totale RNA-expressie niveaus vier, 
acht, en twaalf uur na behandeling geanalyseerd. We hebben een duidelijk 
verschil geobserveerd tussen mRNA- en microRNA-expressie. MicroRNAs 
zijn kleine (± 22 nucleotides groot) niet-coderende RNAs die genexpres-
sie reguleren door het binden van specifieke mRNAs. Als gevolg hiervan 
wordt het mRNA afgebroken of wordt de translatie geremd. De reactie van 
mRNA op DNA-schade laat een duidelijk DNA-schadeafhankelijk patroon 
zien, terwijl de microRNAs een duidelijk tijdsgebonden patroon laten zien. 
De data duiden op een strikte regulatie van zowel mRNA als microRNA na 
DNA schade in het algemeen. Daarnaast hebben we een nieuwe modifi-
catie in de DSR, citrullinatie genaamd, geïdentificeerd. In totaal hebben 
we een transcriptionele database met mRNAs en microRNAs gegenereerd, 
die beide worden gereguleerd na DNA-schade. Ook hebben we citrullina-
tie geïdentificeerd als een nieuwe modificatie die betrokken is bij de DSR.
 Zoals we al laten zien in Hoofdstuk 3 en 4 is de RNA-response es-
sentieel voor de DSR. Niet alleen worden genen gereguleerd door RNAs, 
ook de regulatie van RNAs zelf is belangrijk. RNA-bindende eiwitten (RBPs) 
reguleren RNA-biogenese en deze eiwitten zijn ook belangrijk in de DSR. 
Daarom hebben we in Hoofdstuk 5 gefocust op de rol van een specifiek 
RBP in de DSR na bestraling, KH-Type Splicing Regulatory Protein (KHSRP) 
genaamd. Wij hebben gevonden dat KHSRP een belangrijk eiwit is, dat be-
trokken is bij de DNA-reparatie na bestraling, sinds DNA-reparatie na be-
straling zonder KHSRP minder goed functioneert. Dit geobserveerde effect 
was onafhankelijk van de functie van KHSRP in microRNA biogenese. Ge-
baseerd op de data kunnen we concluderen dat KHSRP een nieuwe functie 
heeft in de DSR onafhankelijk van zijn functie in de microRNA biogenese.
 Om de gecompliceerde aard van verkregen resistentie en de betrok-
kenheid van de DSR daarbij te begrijpen, is uitgebreide kennis van de DSR 
onmisbaar. Deze kennis kan worden gebruikt bij de ontwikkeling van nieuwe 
specifieke therapieën om verkregen therapieresistentie in kanker te omzeilen.
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Name  Serena Tamara Bruens
PhD period 2012 – 2017 
Promotor  Jan Hoeijmakers
Co-promotor Joris Pothof
Courses                   Year Workload (ECTS)
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principles Part A       
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Biomedical English writing        2015   3
Workshops and Conferences       Year Workload (ECTS)
MGC PhD Workshop - Abstract       2013    30 hours
(Luxemburg, Luxemburg)
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(Ellecom, the Netherlands)
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(Copenhagen, Denmark)
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AACR Annual meeting - Poster presentation  2016    40 hours
(New Orleans, USA)
Radiotherapy Research day – Oral       2016      8 hours
presentation
(Rotterdam, the Netherlands)
Teaching           Year Workload (ECTS)
Werkcollege Bachelor Nanobiology         2012 - 2017   15 hours
HLO student            2013 - 2014   10 months
Master student          2015      6 months
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Dankwoord
Nou dat was het dan… Ein-de-lijk klaar! Na bloed, zweet en een heleboel tra-
nen ligt er dan een boekje. Deze periode heeft mij ontzettend veel geleerd. Er 
waren diepe dalen, maar ook hoge pieken. Uiteraard heb ik dit niet alleen voor 
elkaar gekregen, daarom wil ik via deze weg een aantal mensen bedanken.
Beste Jan, ik heb ontzettend veel bewondering voor je niet aflatende en-
thousiasme over ongeveer alles. Je bent altijd kritisch, maar met een po-
sitieve draai. Na besprekingen met jou en Joris had ik toch altijd weer het 
gevoel dat het allemaal goed zou komen. Ook in je drukke schema had je 
toch een gaatje om even bij te praten over de stand van zaken. Ik wil je 
bedanken dat je mij de kans hebt gegeven om mij te laten promoveren en 
ook dat je het vertrouwen in mij hebt om verder te gaan in en Postdoc.
Joris, hoe zal ik het zeggen… Ik ben inmiddels heel goed (maar misschien 
ook niet) in het managen van jou. Meer dan dat wil ik je bedanken voor het 
vertrouwen wat je in mij had en hebt om dit allemaal tot een goed einde te 
brengen. Ik waardeer onze gesprekken die altijd iets langer duurde dan de 
bedoeling was en ook altijd afweken van het eigenlijke onderwerp. Als ik 
het even niet meer zag zitten, iets met een kapotte gamma bron of zo, dan 
was je altijd in staat om het te relativeren en mij weer uit de put te krijgen.
Beste Roland, ontzettend bedankt voor je hulp tijdens de laatste periode van 
mijn promotie. Ik waardeer je Rotterdamse directheid, ook al was het af en 
toe even slikken. Dat je toch altijd even tijd vrijmaakte om iedereen in de 
goede richting te sturen (inclusief ondergetekende) heeft enorm geholpen.
Mijn paranimfen Sander en Renata, allereerst vind ik het een eer dat 
jullie mijn paranimf willen zijn. Lief en leed heb ik met jullie kun-
nen delen en het was en is nog steeds heel erg prettig dat, dat nog 
steeds kan. Met alle verandering is het fijn om een goede basis te heb-
ben en die kunnen jullie ook bieden. Ik hoop dat we met z’n drieën 
nog lang samen kunnen lachen en het over onze kinderen/katten kun-
nen hebben bij de koffie. O ja, en samen kunnen werken natuurlijk ;). 
Het Vermeulen lab, waar ik de eerste 2 jaar van mijn promotie door heb 
mogen brengen. Wim, Jurgen en Hannes, bedankt jullie bijdrage tijdens 
de eerste (en ook de laatste) 2 jaar van mijn promotie. Arjan, bedankt 
voor al je hulp met de celkweek en je slechte grappen kan ik wel waarde-
ren ;). Franzi, Yasemin, Christina, Barbara thanks for the nice time in the 
lab and during conferences. I wish you all the best in your future careers.
Karen, jij verdient een eigen alineaatje. Ik wil je bedanken voor onze 
gesprekken in de vroege ochtend als er (bijna) niemand aanwezig was. 
Het heeft mij geholpen om het allemaal in perspectief te plaatsen en 
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toch echt voor mijzelf te kiezen en niet iedereen tevreden te willen hou-
den. Als je kunt, sta je altijd klaar om te helpen en dat waardeer ik zeer. 
Imke en Mariangela! Onze uitstapjes en etentjes waren een leuke onder-
breking van het OIO bestaan. Mariangela, ik vind het zo knap dat je Ne-
derlands geleerd hebt. Blijven oefenen en dan schrijf je, je Nederlandse 
samenvatting straks zelf ;). Imke, ik vind het jammer dat je naar München 
verhuist bent, maar dat geeft wel een goede reden om je op te komen 
zoeken. Na 4 jaar kan ik oprecht zeggen dat ik er 2 vriendinnen bij heb.
De laaste 2-3 jaar van mijn promotie heb ik door mogen brengen in de 
ageing en clock groep, ook wel bekend als ‘de andere kant’. Bert, Wil-
bert, Peter, Ines, Maayke en Akos thank you for your input and conver-
sations during those years and I hope we will have many more in the fu-
ture. OIO-hok office mates Rana, Diana, Aida, Hester, Jiang, Astrid and 
Maria thank you for the great time and funny moments. I wish you all the 
best in obtaining your degree. Nicole, Sylvia, Yvette en Yvonne bedankt 
voor de gezellige tijd in het lab en aan de lunchtafel tijdens onze pauzes. 
Pier, Chiara and Maria, thank you for all your help during my PhD. It was nice to 
work with you and I hope we can do that more often in the future. All the regular 
chats we had when I came for Joris and he wasn’t there are highly appreciated. 
 
Ik mag uiteraard Buurman (a.k.a. Marjolein ;)) niet vergeten. Onze ge-
zamenlijke pogingen om experimenten te doen was niet altijd even suc-
cesvol, maar we konden er wel altijd om lachen. Het was fijn om ie-
mand te hebben die in dezelfde situatie zit/zat als ik. Altijd kon ik bij 
jou terecht om even te klagen of om gewoon even gezellig te praten. 
Een promotie doe je nooit alleen, zoals inmiddels wel duidelijk is en via deze 
weg wil ook graag de mensen van de “6e” bedanken. Nicole, Anja, Hanny, 
Nathalie, Dik, Kishan, Inger, Paula en Yanto. Bedankt voor alle gezellige 
praatjes en hulp als ik die nodig had (wat nog best vaak was eigenlijk ;)). 
Jasperina en Sonja, wat is de afdeling zonder jullie? Al-
tijd heerst er toch wel een lichte paniek als jullie er niet zijn. Be-
dankt voor jullie ondersteuning en hulp als ik het nodig had. 
Dan de IT mensen Nils, Ton en Sjozef, bedankt voor de ondersteuning die ik 
regelmatig nodig had omdat er ‘iets’ met mijn computer was. En nee Nils, er 
is nu niets mis met de microscoop en m’n computer doet het gewoon nog ;). 
De afdeling Moleculaire Genetica is groot en via deze weg wil ik 
alle andere mensen die ik niet bij naam genoemd heb, bedan-
ken voor hun hulp en bijdrage aan de gezellige sfeer op de afdeling. 
Appendix
150
A
Een deel van mijn onderzoek vond ook plaats in samenwerking met 
de afdeling Urologie. Guido, Wytske en Hanneke ik vond het heel pret-
tig om met jullie samen te werken. De besprekingen waren altijd open 
en jullie stonden altijd klaar met advies en goede ideeën om aan te wer-
ken. Ook als er geen besprekingen waren kon ik altijd even binnen lo-
pen met nieuwe data of als ik vastgelopen was en advies nodig had, be-
dankt daarvoor. Ook Wilma, Sigrun, Diana, Mirella en alle anderen die ik 
nu vergeet, jullie stonden en staan nog steeds altijd klaar voor hulp. Dat 
was erg prettig en maakte het ook fijn om met jullie samen te werken. 
Belangrijk zijn de mensen geweest die mij hebben geïntrodu-
ceerd in de wetenschap tijdens mijn HBO stages. Maikel, jij hebt 
mij enthousiast gemaakt voor het werken in het lab. Als be-
geleider was je prettig in omgang en je hebt mij veel geleerd. 
Joey! Ik heb zo ontzettend veel van jou geleerd. Maar het belang-
rijkste was, geef nooit op. Het was een eer om met jou te wer-
ken en om je paranimf te zijn. Helaas zit er nu een zee tussen ons, 
maar ik hoop nog veel te kunnen samenwerken in de toekomst.
Ondanks dat je zelf in opleiding bent, leid je zelf ook mensen op. Tijdens 
deze periode heb ik twee studenten gehad Aranka en Marjolijn. Ik heb ont-
zettend veel geluk met jullie beide gehad. Jullie waren snel zelfstandig en 
hebben daardoor een hoop werk kunnen verzetten. Ik heb ook veel van 
jullie geleerd en ik hoop jullie ook van mij. Het is ook goed om te weten 
dat jullie beiden goed terecht gekomen zijn en ik wens jullie veel succes. 
Ontspanning is eigenlijk iets wat niet in het woordenboek van een OIO voor-
komt, maar wat je toch wel nodig hebt. Ruby, Cynthia, Jantine, Chantal, 
Wenda, Tessa, Remco, Jacco, Jeffrey, Floris, Martijn, Freek, Doren, Ferdi, 
Anouk, Sander, Marit, Remco, Sjors, Dennie en Yin bedankt dat jullie heb-
ben gezorgd voor de af en toe broodnodige afleiding en ontspanning. Ik 
hoop dat we nog lang samen mogen korfballen, weekendjes weg gaan, naar 
de film gaan, uiteten gaan of gewoon op stap gaan. Ferdi, heel erg bedankt 
dat je mij geholpen hebt met het ontwerpen van de kaft van mijn boekje.
Dan de familie: ooms, tantes, neven en nichten. Wat wij hebben is heel 
uniek en ik hoop ook zo te houden voor zo ver het gaat. Bedankt voor jullie 
interesse de afgelopen jaren. Ondanks het wegvallen van opa en oma, zijn 
we bij elkaar gebleven en hebben we het met z’n allen gezellig gemaakt. 
Dat er nog vele uitjes, al dan niet met (klein)kinderen mogen volgen. 
Ook de schoonfamilie verdient een eervolle vermelding. Lizette, Dick, 
Ruby en Michiel en de rest van de familie. Het is een ontzettend warm 
bad waar je bij jullie in terecht komt en je graag even in blijft zitten. Als 
nieuweling (na bijna 10 jaar is dat natuurlijk niet echt het geval meer) 
wordt je met open armen ontvangen en is niets te gek. Er is een hoop 
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gebeurd in 10 jaar en het is heel fijn om te weten dat jullie er altijd zijn.
Het andere deel van de schoonfamilie Peter, Vera, Nikki, Nick, Jasper en Tim. 
Ook bij jullie werd ik gelijk in de familie opgenomen en dat was erg fijn. Jullie 
staan ook altijd klaar in goede en slechte tijden. We hebben tranen gehuild van 
verdriet, maar nog meer van het lachen en ik hoop dat, dat nog lang zo mag zijn.
Ik had dit niet kunnen doen zonder de onvoorwaardelijke steun van 
mijn ouders. Pap, mam bedankt dat jullie er voor gezorgd hebben dat 
er altijd een stabiele thuisbasis was en dat wij (ook Naomi en Den-
nis) ons nooit druk hebben hoeven maken of het überhaupt wel moge-
lijk was om te studeren. Ook al was het voor jullie onmogelijk om de 
naam van mijn opleiding te onthouden (iets met biologie toch?). Het 
ging al snel tot een onbegrijpelijk niveau en toch probeerde jullie altijd 
te helpen waar mogelijk. Ik kan nog steeds niet verklaren hoe het moge-
lijk is dat ik dit wel begrijp, maar niet weet hoe je krootjes moet koken. 
Lieve Ori, je weet dat ik niet goed ben met het in woorden uitdrukken 
hoe blij ik met je ben. Gelukkig weet je dat ik dat absoluut wel ben. Zon-
der jou had ik dit niet gered, je bent er altijd voor mij en je zorgt voor 
de stabiele basis die ik nodig heb. Voor zover je kon heb je mij gehol-
pen en je nuchtere kijk op dingen maakte het voor mij makkelijker om 
te relativeren. Nu snap je inmiddels hoe deze wereld in elkaar zit en 
dat je dus nooit huisvader kunt worden ;). Ik hoop echt dat we samen 
oud mogen worden en nog veel mooie momenten mee mogen maken.
Serena

